OAKLAND, CA–(Marketwire – July 19, 2010) –  The Center for Technology and Aging today announced grants to five organizations for remote patient monitoring (RPM) technology projects that will demonstrate how RPM improves the quality and efficiency of chronic disease management and post-acute care of older adults. Each project involves a coordinated effort among patients, families and caregivers.

“RPM technologies make a huge difference in the quality of life for those living with chronic conditions,” said David Lindeman, PhD, director of the Center for Technology and Aging. “These projects will underscore the need to reform reimbursement policies and make possible wider adoption of these technologies in public programs — Medicare and Medicaid — as well as among private insurers and health care systems.”

The U.S. health care system could reduce costs by nearly $200 billion during the next 25 years if RPM tools were utilized to care for patients with congestive heart failure (CHF), diabetes, chronic obstructive pulmonary disease (COPD), and chronic wounds or skin ulcers. Eight of 10 older Americans have one or more chronic diseases.

The Center’s RPM initiative goals are to demonstrate that these technologies can be used more widely because they reduce: the use of ER’s and hospitals by older adults, the need for those with chronic illness to move to intensive higher-cost care settings, and the burden on family and professional caregivers.

RPM includes a wide variety of technology, such as point-of-care monitoring devices — weight scales, glucometers, implantable cardioverter-defibrillators, and blood pressure monitors — which become part of a fully integrated health data collection, analysis, and reporting system between the devices, patients, and clinicians.

The grantees are:

• Sharp HealthCare Foundation (www.sharp.com/sharp-foundation) — Working with senior and home health agencies, this project will monitor patients who have five or more chronic conditions — which may include CHF, peripheral artery disease, COPD, atherosclerosis, hypertension, diabetes, and chronic kidney disease — with the goal of reducing unplanned hospital readmission rates.

• New England Healthcare Institute (www.nehi.net) — Using the Electronic House Call System (ExpressMD Solutions) and in collaboration with the Massachusetts Technology Collaborative, Atrius Health, and Blue Cross Blue Shield of Massachusetts, this Massachusetts-based project seeks to demonstrate clinical and financial benefits from the use of RPM technologies as evidenced by reducing hospital readmissions.

• Centura Health At Home (www.centurahealthathome.org) — In collaboration with an internal physician group, telehealth video technologies (inLife and Life View, made by American TeleCare) will be used to enhance 24/7/365 call center response for Centura Health at Home patients in Denver, Colorado. The goal is to reduce re-hospitalizations and to improve quality of life for patients who have diabetes, COPD, or CHF.

• AltaMed Health Services (www.altamed.org) and Stamford Hospital (www.stamfordhospital.org) — This project will expand use of RPM technology (HoneyWell’s HomMed device) with low-income seniors in East Los Angeles, California and Stamford, Connecticut who have CHF, diabetes, COPD, or hypertension. The goal is to promote better self-management habits and healthy behaviors while also establishing a new healthcare para-professional position, the “Telehealth Technician,” through community college training programs.

• California Association for Health Services at Home Foundation (www.cahsah.org) — In collaboration with several home care agencies, this project will use Intel’s Health Guide to monitor patients with chronic disease conditions or those needing post-acute care follow-up. The goal is to reduce avoidable 30-day readmissions, hospitalizations, and emergency department visits for Medi-Cal patients; and to inform public policy concerning RPM technology and Medi-Cal programs operating under federal waivers.

“One of the Center’s goals is to assure that funded projects aren’t ‘one and done,’ but are designed to be replicated,” said Lindeman. “Each grantee has identified ways to make sure their project can continue beyond the one?year grant period, can be broadly adopted by others, and is integrated within our long?term care system.”

The five $100,000 grants will be supplemented with a total of over $1,746,000 in matching funds. Individual project details and the Center’s RPM Position Paper are available at the Web site, www.techandaging.org.

The Center for Technology and Aging (www.techandaging.org) supports the rapid adoption and diffusion of technologies that enhance independence and improve home and community-based care for older adults. Through grants, research, and development of practical tools and best practice guidelines, the Center serves as an independent, non-profit resource for improving the quality and cost-effectiveness of long-term care services. The Center was established with funding from The SCAN Foundation (www.thescanfoundation.org) and is affiliated with the Public Health Institute (www.phi.org) in Oakland, CA.

Click here to see all recent news from this company

LOUISVILLE, KY–(Marketwire – July 19, 2010) –  This week at ICAD 2010, Neuronetrix for the first time publicly demonstrated their COGNISION™ System, an innovative platform which enables objective assessment of cognitive function. The demonstration focused on the COGNISION™ System’s ability, using a non-invasive technology called event-related potentials (ERP), to accurately measure the cognitive performance of a patient’s brain.

The demonstration was particularly important in light of a report presented by a select group of Alzheimer’s specialists from the National Institute on Aging (NIA) and the Alzheimer’s Association which proposed new diagnostic guidelines for Alzheimer’s disease. The report titled, “Redefining Alzheimer’s Disease,” proposes a new understanding of the disease which more closely matches clinical progression with a range of disease biomarkers. It also includes patients who meet clinical and cognitive criteria but who are negative for certain genetic, molecular, or structural biomarkers. “This is a tremendous opportunity for Neuronetrix as our test directly measures the electrical activity associated with cognition and is independent of biochemical pathways,” said Mauktik Kulkarni, Director of Research and Clinical Studies for Neuronetrix.

The new criteria also facilitates the tremendous drug development effort for disease modifying therapies for Alzheimer’s. Drug companies will now have a more reliable way of identifying those Alzheimer’s sufferers who might benefit from new drug therapies. The criteria also lays the groundwork for using positive changes in certain biomarkers as measures of drug effectiveness. “Because the COGNISION™ System could be used to measure progressive cognitive as well as drug response, we had tremendous interest from several of the large pharmaceutical companies at the conference,” said K.C. Fadem, Chief Operating Officer for Neuronetrix.

Neuronetrix previously completed a pilot clinical study with Alzheimer’s patients and healthy controls at the Sanders-Brown Alzheimer’s Disease Center at the University of Kentucky. The study validated the high data quality and ease-of-use of the COGNISION™ System in a clinical setting. Neuronetrix will soon be initiating a large multi-center clinical study which will validate their ERP biomarkers as an accurate and reliable measure of cognitive impairment. The company is planning a longitudinal follow up study which will validate their ERP biomarkers as a measure of progressive cognitive decline. “Because of the low cost, ease of use, and measurement potential of the COGNISION™ test, ERP testing could become a standard of care for those patients who develop cognitive disorders such as Alzheimer’s disease,” said K.C. Fadem.

About Alzheimer’s Disease
Alzheimer’s disease is a chronic neurodegenerative disease of the brain which eventually leads to death. Today, Alzheimer’s disease affects over five million Americans with 500,000 new cases reported each year. Medicare/Medicaid spending exceeds $100 billion on beneficiaries with Alzheimer’s and other dementias.

About Neuronetrix
Neuronetrix is an emerging med-tech company focused on revolutionizing the diagnosis of patients with neurologic disorders by providing accurate and meaningful diagnostic information to physicians early in the disease process.

Information about Neuronetrix is available at http://www.neuronetrix.com or by contacting K.C. Fadem at [email protected] or (502) 561-9040.

CLARKSTON, MI–(Marketwire – July 19, 2010) –  RDM Associates, a specialized accounting and business consulting firm based in Clarkston, Mich., has announced the appointment of Cynthia Sikina to the newly-created position of CEO, according to company president and founder Rick Miller.

“We’re thrilled to have Cindy joining RDM Associates,” said Miller. “She brings well-rounded senior management talent and experience which are an exceptional fit with our goals and strategies. We’ve had the opportunity to work with Cindy in the past and we’ve been very impressed with her executive skills. Our accounting services model is non-traditional and technology intensive — concepts she relates to. I know that she will be a great asset to our firm as we work together to manage the next phase of our growth and expand our range of client services.”

Ms. Sikina’s responsibilities encompass the overall management of the firm’s business, including overseeing strategic planning, client services, new business and staff development. 

Since 2007, Ms. Sikina served as senior vice president and chief financial officer for Detroit’s Karmanos Cancer Institute & Center, where she was responsible for all aspects of fiscal management. Previous management positions have included COO/CFO for Wayne State University’s Physician Group from 2001-2007; director of financial services for the University of Michigan Medical School and other positions since 1992; and prior various financial planning and accounting roles for industrial companies beginning in 1981.

Prior to her role as CFO at KCI, Ms. Sikina served as a member of the KCI Board of Directors and its Finance and Executive committees for 6 years. She has also served as a member of the Karmanos-Crittenton Health Services Board of Directors.

She received an MBA with distinction from the University of Michigan Graduate School Of Business Administration in 1989 and is a member of the Beta Gamma Sigma Honor Society for high scholastic achievement. She earned a BBA degree with distinction from U of M in 1981 and received the CPA Certificate of Examination.

Ms. Sikina lives with her husband, Mark Sikina, in Novi.

DALLAS, TEXAS–(Marketwire – July 19, 2010) – The following corrects and replaces the release sent on July 19, 2010 at 6:00 am ET. The phone number stated in the contact information and last paragraph of the release should have read “(214) 613-3133” instead of “(806) 553-6166”.

Odyssey and VistaCare Hospice in Texas can help you learn more about the type of care required in the final stages of life. 

“People appreciate the care hospice provides,” said Dr. Luis Gonzales, M.D., a National Medical Director for Odyssey Hospice and VistaCare Hospice. “Over 98% of family members tell us they would recommend hospice in Texas to others, and oftentimes our patients and families tell us they wish they’d been told about hospice in Texas sooner. Despite this, there are a lot of misconceptions among people who have not experienced the support hospice in Texas provides.”

One of the major misconceptions is that hospice is a location where one goes to live out the very last days of their life.

But in fact, hospice in Texas is a philosophy of care, and not a specific location at which to receive it. According to the National Hospice and Palliative Care Organization (NHPCO), 69% of hospice patients receive care in what they consider their home. The remainder are cared for in a hospice inpatient facility or hospital. Odyssey Hospice and VistaCare Hospice in Texas provide care wherever the patient’s home may be – a house, assisted living community, nursing home, or even during a brief hospital stay.

“The reality is that most people – medical professionals or otherwise – often equate hospice with death, but the truth is that hospice in Texas is about life” said Dr. Gonzales. “This lack of understanding can lead to a large number of people who are served by hospice in Texas for only a few days. Unfortunately, in these cases the patient and their loved ones don’t receive all of the benefits hospice offers.” Hospice is designed by Medicare to be a 6 month benefit, with the ability to provide care beyond that time for persons who remain eligible. Hospice in Texas is about quality of life.

Hospice in Texas provides compassionate, patient-centered care that offers medical expertise, comfort and support for those nearing the end of life, while also offering assistance for their loved ones. Hospice in Texas is delivered by a team of professionals who are experienced and committed to providing specialized care to persons seeking comfort, relief from symptoms, and gentle guidance.

Odyssey Hospice and VistaCare Hospice provide personalized care based on the needs of each patient and family. As one of the most experienced providers of hospice in Texas and throughout the United States, Odyssey and VistaCare offers CareBeyond, clinical programs for persons coping with specific illnesses. Developed by multidisciplinary team members, Odyssey and VistaCare hospice in Texas recognizes that patients with lung disease, for example, are treated differently, and have very different needs from, dementia patients. Using evidence based clinical practices, CareBeyond offers additional, specialized care to meet unique needs. 

Those who are approaching the end of life typically fear dying in pain, dying alone and are concerned about their loved ones. Hospice in Texas helps with each of these concerns. At Odyssey Hospice and VistaCare Hospice in Texas, our team of professionals is committed to serving patient and caregiver needs, whether they are physical, emotional or spiritual. Hospice is there when care and support are needed most.

With the early involvement of hospice, pain and symptoms are managed quickly so that people are comfortable. Only then can they work on other important aspects of their life. When chosen earlier, hospice in Texas provides greater benefits that are received for a longer period of time, including the opportunity for reflection and closure.

Hospice in Texas also provides bereavement care for up to 13-months for surviving family members. Care may include phone calls, newsletters, memorial services, connection to community resources and support. 

If you would like to receive more detailed, local information about hospice in Texas, please click here for information pertaining to hospice in Houston, or here for more information regarding hospice in Dallas. Odyssey & VistaCare also have hospice locations, providing in-home and/or inpatient treatment, throughout Texas. 

To learn more about hospice in Texas, please visit http://local.odsyhealth.com, or call (214) 613-3133.

MUNDELEIN, IL–(Marketwire – July 19, 2010) –  A new VHA case study whitepaper released today by Medline Industries, Inc. details how the company used observational studies and context-based design to build human factors and social behaviors into its redesigned Foley Catheter Management tray.

The whitepaper, Social Practice and Clinicians’ Meaning of Urinary Catheter Insertions, showed that the redesigned tray significantly influenced the clinician’s ability to provide high quality care by creating a greater focus on providing patient comfort, maintaining sterile technique and decreasing the time of the entire insertion process. The observational study was comprised of three separate three-day observations of clinicians conducting catheterizations in the emergency department, medical/surgical floors and operating rooms at Providence Sacred Heart Medical Center and Children’s Hospital, Spokane, WA.

“Health care manufacturers are often overlooked when clinicians redesign clinical practices. Yet, the design of a product can be key to helping clinicians improve clinical performance and patient education,” said Trent Haywood, MD, JD, Senior Vice President of Clinical Performance and Chief Medical Officer for VHA and lead investigator. “For example, Medline chose to redesign the urinary catheter tray based upon the observational data uncovered in the clinical setting. Such design emphasis shows how manufacturers can be a key partner in quality and safety.” 

The unique partnership between Medline and the VHA research team highlights how industry vendors can partner with healthcare providers to develop a comprehensive system that incorporates proper procedures and social behaviors that are easy to adopt in everyday practice.

Medline launched its ERASE CAUTI program, which is based on the same criteria the CDC used in developing their new CAUTI prevention guidelines, last fall. Soon after the tray’s introduction, Medline met with the VHA Clinical Performance team to discuss studying the tray and how it’s used in actual clinical practice. Emphasis was put on understanding the objectives of catheter insertions from the clinician’s perspective, clarifying the actual practice that unfolds and identifying areas where the catheter management system aided the clinician or failed to aid the clinician based upon the clinician’s perspective on the practice.

Findings summarized in a case study whitepaper showed that clinicians preferred the benefits of the single layer tray which did not require steps related to maneuvering and positioning with a two layer tray. They also preferred the change to swab sticks that decreased the number of steps in the prepping and cleansing of the perineum. Clinicians retained the patent-pending patient education card for the patient or placed it in location where the patient might review it — a departure from previously observed behavior where the education was discarded without much attention. Clinicians also used the full-colored photography packaging to better explain the procedure to patients.

“Chief Nursing Officers (CNOs) want to help their staff reduce variability in the procedures that are done so that the potential to make an error decreases,” said Connie Yuska, Medline’s Vice President of Clinical Services and a former CNO. “We redesigned the tray taking into account the interaction between the patient and the clinician and facilitate learning — things that challenge nursing leaders every day.”

The VHA whitepaper, as well as additional information on the ERASE CAUTI program, is available for download on Medline’s website at www.medline.com/erase.

About Medline Industries, Inc. 

Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

TAMPA, FL–(Marketwire – July 19, 2010) – Sage North America Healthcare Division, providing practice management software and services to more than 80,000 physicians in North America, today announced several tools it is providing to practices, clients and members of the healthcare community to help them navigate the final Stage 1 meaningful use rules recently announced under the 2009 HITECH Act.

The final rule details the requirements physicians must satisfy to be eligible for financial incentives for the adoption and meaningful use of healthcare information technology under the HITECH Act.

“With the Stage 1 finalized rules, time is of the essence as healthcare providers race against the clock to prepare for and comply with the criteria,” said Betty Otter-Nickerson, President of Sage Healthcare. “With more than three decades of experience in this industry, we continue to be a knowledgeable and trusted source of information for our clients.”

The Health Information Technology for Economic and Clinical Health (HITECH) Act was created to promote the adoption and meaningful use of health information technology and includes more than $20 billion to aid in the development of a robust IT infrastructure for healthcare and to assist providers and other entities in adopting and using health IT.

Along with the Stage 1 meaningful use rules, a separate final rule was published establishing comprehensive guidelines that vendors’ products must meet for functionality, interoperability and security. Along with a third final rule released in June establishing a temporary certification program for testing and certification of vendor systems, the critical pieces are all in place to implement Stage 1 of the three-stage federal EHR incentive program designed to improve healthcare outcomes and patient care.

Tools of Success: Sage Meaningful Use White Paper, e-Consults and Webinar
Otter-Nickerson said she and Sage are aware of the confusion and questions surrounding meaningful use, the financial incentives, and how EHRs will drive efficiency and cost savings in today’s healthcare economy. To that end, Sage has developed several tools to help physicians and practices navigate the meaningful use landscape.

“We are dedicated to serving physicians and their practices, and we remain true to our mission of helping small and midsized ambulatory physician practices fulfill their ambitions, both with regard to using technology and to succeeding in a changing healthcare economy,” said Otter-Nickerson.

For physicians and practices seeking information about meaningful use rules, Sage North America Healthcare Division will host a one-hour public webinar on meaningful use and the final rule, featuring a 30-minute question and answer session. This free event, “Understanding Meaningful Use,” will take place Aug. 10, 2010, from noon to 1 p.m. EST. For more information or to register, visit www.SageHealth.com/MUFinalRule.

Webinar speakers will include Betty Otter-Nickerson, President, Sage Healthcare Division; Michael Burger, Sage Senior Director of Clinical Product Management; and Brenda Pawlak, Senior Manager of Health Policy at Manatt Health Solutions.

In addition, Sage is making a free white paper available to anyone interested in meaningful use. The white paper details how meaningful use may or may not affect practices differently and includes information about incentives and what it means to meaningfully use EHRs in the current healthsphere. The white paper will be available at the Sage Meaningful Use webinar.

Sage will also host several “e-consults” — web-based informational sessions for practice managers and physicians interested in learning more about meaningful use, the rules, and technology and electronic records in the practice space. For more information, please visit www.sagenorthamerica.com

“Now that the final rule has been released, we will continue to support and offer guidance in response to the needs of our clients and physicians while offering the market’s most competitive products,” said Otter-Nickerson.

Meaningful Use Webinar details:
Date: Tuesday, August 10
Time: Noon to 1 pm EST
Title: Understanding the “Meaningful Use” Final Rule
Cost: Free of charge
Registration URL: www.SageHealth.com/MUFinalRule
Moderator: Elizabeth W. Woodcock, MBA, FACMPE, CPC
Speakers:
Betty Otter-Nickerson, President, Sage Healthcare Division
Michael Burger, Sage Senior Director of Clinical Product Management
Brenda Pawlak, Manatt Health Solutions, Senior Manager of Health Policy

View Sage Healthcare Division YouTube interviews.

View Sage Healthcare Division information.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers including more than 80,000 physicians. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, Sage Software, Sage logos and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

LONG ISLAND, NY–(Marketwire – July 19, 2010) –  SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today announces to its shareholders that its negotiations are progressing well towards a definitive agreement with Genesis Biopharma, Inc. (“Genesis”) to acquire an exclusive worldwide sublicense for a new compound in development for the treatment of Painful Diabetic Neuropathy (PDN).

The Company expects the definitive agreement and subsequent closing to be finalized in a reasonably short period of time.

Dr. Jan Stahl, CEO of TRDX, commented: “We are pleased to be nearing completion of negotiations with Genesis. Additionally, plans for funding the development of Genesis’ PDN solution are progressing. We look forward to the successful completion of these key milestones in the near future.”

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell of every living thing on Earth. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called “amide bonds”).

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company’s business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

TIBURON, CA–(Marketwire – July 19, 2010) –  NovaVision, Inc., headquartered in Boca Raton, Fla., filed for Chapter 7 Bankruptcy in the State of Florida (Case #10-21343-PGH) on April 28, 2010 after more than seven years of continuous operation. The bankruptcy trustee has engaged The Magnum Group, Inc., to solicit offers for NovaVision’s assets which include the NovaVision Visual Restoration Therapy (VRT) system, a neuroplacticity platform that has been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of stroke, traumatic brain injury, amblyopia (“lazy eye”) and optic nerve damage. 

NovaVision has received a total investment of $49,200,000 since its founding in 2003 and has generated revenues of approximately $1,000,000 each year for the past three years. The company’s non-invasive computer-based neuroplacticity products have treated more than 3,000 patients worldwide. NovaVision estimates the total market opportunity for its portfolio of products to exceed 300,000 units in U.S. optometry, ophthalmology, neurology, and primary care practices as well as rehabilitation centers. 

“NovaVision was the first company to commercialize a non-invasive, computer-based therapeutic model to help the large population of patients that have lost visual functionality and independence due to stroke or brain injury,” said Holger Weis, former Chief Financial Officer for NovaVision. “While it is extremely unfortunate that NovaVision has fallen victim to the current economic environment, there remains huge market potential to keep these treatments alive in the marketplace while continuing to commercialize the numerous patents and discoveries that NovaVision has invested nearly fifty million dollars to advance.”

NovaVision was founded in 2003 by Bernhard Sabel, PhD, who led the original research team that published a double-blind placebo controlled clinical study in Nature Medicine in 1998. This landmark study, as well as many subsequent studies, has validated VRT as a clinically proven treatment to restore lost vision resulting from stroke, traumatic brain injury, or other acquired brain injuries. In 2003, NovaVison’s Visual Restoration Therapy was granted 510(k) clearance by the U.S. FDA for the diagnosis and treatment of these conditions.

VRT treatment has been offered at leading neurological, eye and rehabilitation centers throughout the U.S. and Europe and it can be prescribed by eye doctors, neurologists or physiatrists. Data from a recent retrospective study showed that more than 70 percent of U.S. patients who underwent a six-month treatment protocol with NovaVision VRT showed significant improvement in their vision. 

“Visual field defects are common after brain insults such as stroke and traumatic brain injury and they cause significant disability,” said neurologist Jose G. Romano, MD, FAHA, Associate Professor of Clinical Neurology, Director, Cerebrovascular Division, University of Miami Miller School of Medicine. “In my experience, VRT has positively impacted the majority of patients treated with improvements in reading, mobility and avoidance of injuries. Techniques such as VRT are an important addition to the limited rehabilitation options available to these patients.”

The Company has also developed devices that aid in the diagnosis of visual field deficits, including an Inpatient Device for assessment and therapeutic use in rehabilitation centers and the Head Mounted Perimeter, a portable and ADA-compliant instrument to aid in the assessment of visual field deficits. Additional indications for VRT include age-related macular degeneration, glaucoma, diabetic retinopathy and attention deficit disorder/attention deficit hyperactivity disorder. 

“VRT is the only restorative therapy available for patients suffering from visual field loss following stroke or trauma,” said Michael Rosenberg, MD, Director of Neurology and Neuro-ophthalmology, New Jersey Neuroscience Institute at JFK Medical Center in Edison, New Jersey. “I have been providing VRT to my patients for more than five years with results similar to published research in which 70 percent of patients achieved marked improvements in visual function. It is my sincere hope that I will again be able to offer VRT as a treatment option very soon.”

NovaVision maintains a strong and broad based portfolio of patent protection on its methods and apparatus in the form of issued patents and applications, both domestically and internationally. In the U.S., the Company has a total of five issued patents and 12 pending applications. The international patent portfolio includes one issued patent and more than 30 pending applications. NovaVision’s wholly-owned European subsidiary, NovaVision AG, located in Magdeburg, Germany is also available for sale. 

To learn more about NovaVison’s assets and patents, please contact Randy McDonald, Managing Director and President of The Magnum Group, Inc. at [email protected] or (415) 435-5550.

About The Magnum Group

Founded in the San Francisco Bay Area in 1980, The Magnum Group, Inc. is the largest business development firm serving the ophthalmic (vision care) industry. Specializing in acquisition and financing agreements, strategic alliances, joint venture, licensing and distribution contracts, The Magnum Group represents both Buyers and Sellers and has managed more than $250 million in transactions since 1995. For more information, please visit http://www.themagnumgroup.com/

Click here to see all recent news from this company

MARKHAM, ONTARIO–(Marketwire – July 19, 2010) – Extendicare Real Estate Investment Trust (“Extendicare REIT” or “Extendicare”) (TSX:EXE.UN) today announced it will hold a conference call and live audio webcast on Friday, August 6, 2010, at 10:00 a.m. (ET) to discuss financial results for the second quarter ended June 30, 2010.

Following the issuance of the news release on August 5, 2010, Extendicare will post a copy, along with an update of the supplemental information package, on its website www.extendicare.com under the investors/financial reports section.

The call will be hosted by Tim Lukenda, President and Chief Executive Officer; Doug Harris, Senior Vice President and Chief Financial Officer, and Paul Tuttle, President of Canadian Operations. Following management’s presentation, there will be a question and answer session for analysts and institutional investors.

To participate in the August 6, 2010, conference call, please dial 1-888-789-9572 or 416-695-7806 followed by the passcode 7354234#. The conference call will also be accessible via webcast at www.extendicare.com under the investors/presentations & webcasts section. A replay of the call will be available approximately two hours after completion of the live call until midnight on August 20, 2010. To access the rebroadcast dial 1-800-408-3053 or 416-695-5800, followed by the passcode 3683111#.

About Us

Extendicare REIT is a leading North American provider of long-term and short-term senior care services through its network of owned and operated health care centers. We employ 37,700 qualified and experienced individuals dedicated to helping people live better through a commitment to quality service that includes post-acute care, rehabilitative therapies and home health care services. Our 258 senior care centers in North America have capacity for approximately 28,900 residents. Extendicare REIT is a specified investment flow-through trust (SIFT) that has been subject to the SIFT tax since January 1, 2007.

VICTORIA, BRITISH COLUMBIA–(Marketwire – July 16, 2010) – Vigil Health Solutions Inc. (TSX VENTURE:VGL)(“Vigil”) today announced that it has entered into an aggregate $200,000 loan agreement with British Columbia Discovery Fund (VCC) Inc. and GrowthPoint Capital Corp. The loan is secured by all of Vigil’s property and is due and payable on December 31, 2010. The loan is convertible at the option of the lenders into Vigil’s common shares at a rate of one common share for each $0.10 of indebtedness ($0.20 if Vigil’s proposed consolidation announced below occurs). Any common shares issued on conversion of the loan will be subject to a four month hold period from today’s date. The obligations of Vigil and the lenders under the loan agreement are conditional upon receipt of acceptance by the TSX Venture Exchange of the loan.

Vigil will seek shareholder approval at its Annual General and Special Meeting of shareholders to be held on August 24, 2010, to consolidate its common shares at a ratio of one new share for each twenty outstanding common shares. In order to be effective, the consolidation resolution must be approved by at least three-quarters of the shareholder votes cast at the meeting and be accepted by the TSX Venture Exchange. The purpose of the share consolidation is to facilitate future financings and strategic initiatives by Vigil. Vigil currently has 100,046,135 common shares outstanding. If the consolidation is approved, Vigil will have approximately 5,002,306 common shares outstanding. Vigil’s name will not be changed in connection with the proposed consolidation.

MUNDELEIN, IL–(Marketwire – July 16, 2010) – Medline Industries, Inc., the company who produced the original Pink Glove Dance, is looking for breast cancer survivors in the San Francisco area who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating almost 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves.

When and where will it be?
Filming will take place Saturday, July 24^th at 3:00 p.m. in the big field just east of Fort Point Pier, with the Golden Gate Bridge in the background.

What are the qualifications to participate?
Participants need to be breast cancer survivors and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com/sign-up.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Details of the day, and any weather updates, will be posted on www.pinkglovedance.com.

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country called to see if they could be part of the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

MADISON, WI–(Marketwire – July 16, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO) maker of advanced, integrated radiation therapy solutions for cancer care, today announced that James Cook University Hospital (JCUH) in Middlesbrough, England began treating cancer patients with the TomoTherapy^® Hi·Art^® treatment system last month. The TomoTherapy treatment system, which enables delivery of state-of-the-art CT image-guided intensity modulated radiotherapy (IG-IMRT), reinforces the hospital’s leadership in cancer care for the people of the North East of England. 

Among the first people to be treated was a 55-year-old female patient from Middlesbrough with breast cancer and an unusual chest anatomy. “We could not have treated this woman on a conventional linear accelerator treatment machine, nor with surgery, so it’s extremely satisfying to know we can now offer this quality of treatment to a wider range of patients,” said Karen Pilling, the superintendent radiographer in charge of the TomoTherapy system at JCUH. “The start-up from training through to treating our first patients has been very smooth and easy, and we are benefiting from the reduced set-up time required by the TomoTherapy treatment system. With integrated CT image guidance we are able to see the treatment plan with isodose contours overlaid onto the daily CT images, giving us extra reassurance that the treatment is the most accurate possible.” 

The TomoTherapy treatment system delivers radiation therapy in continuous helical rotations around the patient’s body. By enabling precise IMRT, the system allows clinicians to conform treatment to the shape of the tumor while helping to reduce radiation exposure to surrounding healthy tissue and critical structures. In addition, TomoTherapy technology allows the radiotherapy staff to directly CT image the soft tissues and tumour immediately prior to treatment, and make any necessary adjustments, thereby ensuring greater accuracy for high precision techniques where internal anatomy might change throughout the course of treatment.

Dr. Peter Dunlop, clinical oncologist and clinical director of the James Cook oncology service, outlining his reasons for choosing the TomoTherapy platform stated, “We felt it was extremely important to have fully integrated image guidance and intensity modulation, and we believe TomoTherapy provides that most effectively. It produces the best conformality available. The design of the system is such that there are no junctions, no matching fields, minimized risk of dose calculation mistakes, no uncontrolled hotspots, no gantry collisions and no more electron mode errors. For patients, the megavoltage CT (MVCT) set-ups ensure that we are accurately targeting their tumours. We have found the operation is smooth and treatments are comfortable for patients because they are often quicker than with conventional IMRT, especially in complex head and neck cases.”

Christopher Walker, head of Radiotherapy Physics at James Cook, responsible for all technical and medical physics aspects of this advanced technology, stated, “Procurement of the TomoTherapy system has provided Middlesbrough with an ‘off the shelf’ technical solution to the challenges faced in delivering high quality radiotherapy. The TomoTherapy solution has allowed us to leapfrog to a position of excellence in cancer care in the U.K. The system has a small physical footprint coupled with a reduced radiation shielding requirement compared to conventional machines. We were able to install it in a pre-existing treatment room, which was considered obsolete by present day conventional radiotherapy standards. As a result, TomoTherapy technology has allowed us to provide additional treatment capacity without the need for an expensive new build whilst maximising the efficiency of the existing facility. Installation and acceptance testing passed quickly and seamlessly allowing the physics team to concentrate on the clinical commissioning process. This process was reduced to a relatively simple validation exercise as all the beam data required for patient treatment planning was already pre-loaded in to the dedicated planning computer. The collaborative approach presented by TomoTherapy has allowed us to rapidly introduce advanced treatment methodologies in a safe and controlled way. The whole process was greatly enhanced by the support and training offered to us both by TomoTherapy and Oncology Systems Limited.”

James Cook University Hospital, as a publicly funded National Health Service hospital, has firmly embraced this radiotherapy technology as the most advanced treatment in its arsenal and as a cost-effective approach for treating technically complex cases.

“At an extremely difficult economic time, particularly within the public sector, James Cook has above all, upheld its belief in the unsurpassed quality of treatment brought by TomoTherapy,” says Julie Mead, director and clinical advisor at Oncology Systems Ltd. “The whole oncology team, with support from the Trust Management, has worked hard to secure this new technology for the people of the North East of England. Now with its TomoTherapy system in place, James Cook has become a leader in the UK NHS with the ability to offer world class radiotherapy for its patients.”

TomoTherapy technology is developed and manufactured by TomoTherapy Inc. and is supplied in the U.K. by Oncology Systems Limited, based in Shrewsbury, England.

About James Cook University Hospital 
Based in the north east of England, JCUH is an NHS Foundation Trust and large district general hospital. The hospital was opened in October 2003 and has a capacity of 1,007 beds. It incorporates the full range of all acute and elective medical and surgical specialties including cardiac surgery, cardiology, renal medicine / haemodialysis, neurosurgery, vascular surgery and the regional spinal injuries unit. The radiotherapy and oncology service delivers an integrated service to a population of approximately one million, extending through Teesside, South Durham and North Yorkshire.

About Oncology Systems Limited 
Oncology Systems Limited (OSL), is a privately owned limited company based in Shrewsbury, England. OSL is an exclusive supplier of radiation therapy technology to the UK and Ireland. It distributes TomoTherapy^® cancer treatment technology to the UK’s NHS and private radiotherapy facilities, and to both public and private providers in the Republic of Ireland.

About TomoTherapy Incorporated 
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

BEVERLY HILLS, CA–(Marketwire – July 16, 2010) –  After the completion of one quarter since the acquisition of the Bella Vita Clinic in the Greater Toronto Area (GTA), Therma-Med Inc. (PINKSHEETS: THRA) is pleased with the steady progress that has been evident throughout the transition period and are optimistic about the continued growth of the clinic. The clinic is picking up steam as we move into the second quarter of ownership, it has been established that the Bella Vita clinic is a revenue generating acquisition, and is an active contributor to Therma-Med Inc.’s overall growth plan. The clinic is actively in the process of hiring an additional Chiropractor, Massage Therapist and Naturopathic Doctor to its existing staff, in order to position themselves at the forefront of wellness centers in the area. The additional support will allow the clinic to operate at extended hours, conveniently catering to all patients, and the added services available will certainly attract patients that are searching for a “1 stop wellness retreat.”

The Therma-Med Inc. business model of implementing support services and making key revenue producing acquisitions is without question showing results on a small scale as is demonstrated with the Bella Vita Clinic. While taking these steps to grow operations at this recently acquired clinic, plans continue to move forward in accordance with the company’s business plan of targeting, researching, and implementing Thermal Imaging, medical support services and nutraceutical sales at additional key revenue generating clinics across North America.

About Therma-Med Inc.:
Therma-Med Inc. provides alternative medicinal procedures, premium nutritional supplements, medicinal products and current medical support services by making them available to patients through their clinics and online through e-commerce purchasing applications. Therma-Med Inc., through highly specialized Thermal Imaging and breakthrough alternative procedure clinics, is poised to become a healthcare industry leading company, providing the alternative medicine approach to good health, as well as providing patients with an adjunctive diagnostic procedure that effectively pursues and exposes the benefits of early detection and prevention of various medical conditions. Therma-Med Inc. utilizes thermal imaging systems that incorporate state-of-the-art infrared technologies and proprietary software to accurately and cost-effectively measure physiological changes in the human body, allowing patients of all walks of life access to a proactive form of maintaining good health and quality of life through early detection and prevention.

Cautionary Statement Regarding Forward-Looking Information:
Except for statements of historical fact relating to the Corporation, certain information contained herein constitutes forward-looking statements. Forward-looking statements are frequently characterized by words such as “potential,” “estimate,” “plan,” “expect,” “project,” “intend,” “believe,” “anticipate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change. The reader is cautioned not to place undue reliance on forward-looking statements.

IRVINE, CA–(Marketwire – July 15, 2010) –  Sun Healthcare Group, Inc. (NASDAQ: SUNH) invites investors to listen to a conference call with Sun’s senior management on Thursday, July 29, 2010, at 10 a.m. Pacific / 1 p.m. Eastern to discuss the Company’s earnings for the second quarter of 2010.

To listen to the conference call, dial (888) 437-9315 and refer to Sun Healthcare Group. A recording of the call will be available from 4 p.m. Eastern on July 29, 2010, until midnight Eastern on Aug. 30, 2010, by calling (888) 203-1112 and using access code 1833674.

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At March 31, 2010, SunBridge centers had 23,205 licensed beds located in 25 states, of which 22,423 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary.

COLUMBIA, SC–(Marketwire – July 15, 2010) –  BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, announced that, in spite of the uncertainty of the nation’s current economic climate, Sales Revenues continued to rise during the first two (2) fiscal quarters of 2010. This expansion of business represented an increase of fifteen percent (15%) above that for the same period in 2009 and exceeded the company’s forecasted growth for the first six (6) months of the year. The Specialty Biopharmaceutical class of products, primarily in the clinical areas of Oncology and Infectious Disease, served as the primary driver for Sales Revenue during this period. Also notable were gains within the Protein Biotherapeutics class, specific to the Hemophilia and Hyper-Immune product lines.

In addition, BDI Pharma realized significant growth in staffing through new hires during Q2 2010. Over the past ninety (90) days, the size of the company’s Biopharmaceutical Sales Staff grew by twenty percent (20%). The company also experienced growth within the BDI Promotions Division (the company’s Advertising and Promotional Division), as well as the Corporate Customer Service Division and established a new specialty sales division during the past quarter.

“Growth, at BDI Pharma, is not just an objective, it is an expectation and, as such, it is something for which we plan and prepare,” said William A. Shirey, III, Executive VP. “The key to BDI Pharma’s growth can be found in our commitment to incorporate a relatively simple matter — the strategic allocation of corporate resources — and to merge it with something far more difficult — the actual expense of those resources in a conscientious manner. Many companies adopt the former, but ultimately bend in response to market pressure and lose their will to integrate the latter. At BDI Pharma, we apply both with equal veracity as we strive to supply substantial, quantifiable value to our customers and manufacturing trade partners, alike.”

About BDI Pharma, Inc.

Since 1995, BDI Pharma, Inc. (formerly known as Blood Diagnostics, Inc.) has built an exceptional reputation as the industry trusted source for products and service. The company has exhibited an exemplary track record providing an unparalleled level of customer service, market data and product integrity to both its customer base and trade partners. Such commitment to the product channel has earned BDI recognition as “ADR,” or Authorized Distributor of Record, for the manufacturers it represents. BDI’s specialty pharmaceutical focus is evident in its commitment to biotherapeutics, chemotherapies, vaccines and plasma protein therapies, including albumin, IVIG, coagulation factors, high-titer immune globulins, and injectables. 

BDI Pharma defines its customer-centric approach to serving the nation’s healthcare community through innovative inventory supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent need delivery. An open-access resource for reference material, educational literature, market data and online ordering, BDI Pharma’s home web page www.bdipharma.com has become an industry renowned point of reference. Proprietary programs for product consignment (www.consignadvantage.com), influenza vaccine pre-booking (www.securiflu.com), vaccine ordering (www.securivax.com) and purchasing/reward programs (www.qoreprogram.com and www.securigam.com) round out a family of solutions tailored to the needs of the healthcare community at large.

SAN FRANCISCO, CA–(Marketwire – July 15, 2010) –  With the innovative use of several emerging technologies, San Francisco-based digital healthcare agency Eveo made a big impression at the 2010 ASCO trade show. The 46th Annual meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, June 4-8, 2010, where more than 30,000 oncology specialists from around the world gathered to discuss the latest innovations in research, quality, practice and technology in cancer. Eveo (www.eveo.com) partnered with marketers to create customized, engaging programs that improved the overall quality of customer interactions and led to a dramatic increase in booth traffic.

Eveo’s Stereoscopic 3D Animation Video was viewed by over 1,000 participants at ASCO. In addition, the multi-touch technology and “Build a Patient” program were showstoppers as they deepened customer engagement and improved retention. Eveo also released several new applications for the iPhone and iPad that enabled health care providers to stay connected with their customers in a whole new way. “We knew the technologies we had in place were going to be a hit at ASCO,” says Eveo CEO and founder Olivier Zitoun, “but we didn’t expect the reaction to be as big as it was. The traffic in the booths was remarkable.”

Ensuring success at trade shows is no easy task. To maximize the potential for success, Eveo recommends following these simple best practices:

1. Start planning for the launch of new technologies early in the booth planning process. The more time you spend up front, the more smoothly everything will go.
2. Perform live technology testing for new programs as part of the booth planning and set up process. This is often overlooked, but an important key to success.
3. Train reps and booth personnel on new technologies prior to the show. Reps should be focused on demonstrating exciting new technologies, not learning them as they go.
4. Optimize booth staffing by utilizing reporting and tracking for all show displays.
5. Send post-conference surveys to customers and corporate participants to learn about what worked and what didn’t.
6. Make sure there are clear signs and directions for each display, especially if it is a new technology.
7. To maximize ROI, develop programs that reps can use in the field after the show or health care providers can access digitally and/or via mobile devices. 

To enlist Eveo’s help in your next tradeshow, contact [email protected]. For a full list of Eveo’s services, visit http://eveo.com/what-we-do/.

ABOUT EVEO
For innovative e-marketing strategies and powerful digital solutions, many of the world’s leading pharmaceutical, biotech and medical device companies depend on Eveo, a full-service independent digital healthcare agency headquartered in San Francisco. Founded in1999, Eveo is led by CEO Olivier Zitoun and a seasoned management team with extensive backgrounds in healthcare and interactive. Eveo’s core capabilities encompass all facets of digital marketing, as well as non-traditional web solutions, video production, 3D animation, tradeshow solutions, mobile applications, multi-touch experiences and more. The agency has a staff of over 150, with field offices in Chicago, New York, New Jersey and Philadelphia. Over the course of its ten years in business, Eveo has collected over 70 industry awards and in 2010 was named the #1 Independent Digital Healthcare Agency in the U.S. (based on 2010 Agency List ranking agencies by revenue). Eveo is redefining the e in e-marketing. Visit: www.eveo.com

ORLANDO, FL–(Marketwire – July 15, 2010) –  WellCity, Inc. (http://www.WellCity.com), a wellness-related social network and subsidiary of WellTek, Inc. (OTCBB: WTKN), today announced a strategic partnership with XOOMA Worldwide (http://www.XoomaWorldwide.com), a global network marketing company, in which the two companies have collaborated to bring more than 200,000 new users, cutting edge wellness products, a robust infrastructure and a major distribution system into WellCity. The agreement serves as a catalyst for both companies to carry out its rapid expansion plans.

As part of the relationship, XOOMA will provide exclusive support with product distribution and logistics, one of XOOMA’s strongest assets. The two companies also agreed to work on future product development together.

“Our collaboration with WellCity is about joining our global mission of Changing the Health of a Generation with a true innovator in social networking,” said Ron Howell, President and CEO of XOOMA Worldwide. “We believe that the combination of WellCity and XOOMA’s strengths will be incredibly attractive to our distributors as well as WellCity ‘residents.'”

Randy Lubinsky, Chairman and CEO of WellTek, noted, “XOOMA provides WellCity with an immediate global platform and 200,000 new ‘residents,’ exposing us to a much larger audience. It’s a global brand that people already recognize.” Lubinsky continued, “The superiority of XOOMA products is consistent with the Gold Standard of our other brands. Partnering with XOOMA is a natural progression to our tactical expansion initiative and integrates well into WellTek’s growing portfolio of trusted health, fitness and wellness brands.”

About XOOMA Worldwide
XOOMA Worldwide is a global network marketing company distributing cutting edge health and wellness products: including vitamins and minerals, functional health beverages and weight loss and skin care products to over 60 countries around the world. XOOMA’s Scientific Advisory Board provides education and guidance on health related topics and peer-reviewed scientifically supported nutritional applications for prevention and optimal health support.

About WellCity Incorporated
WellCity is a social utility where health- and wellness-minded ‘residents’ can closely commune with one another; receive support, information and encouragement from their ‘neighbors’ and from a league of leading professional experts; shop for health and wellness-oriented product and services; compete in WellCity’s proprietary 90-Day Wellness Challenge; and even enjoy income opportunities by leveraging their personal network. For more information on the Company, please visit www.WellCity.com.

About WellTek Incorporated
WellTek is a global health, fitness and wellness company that provides proven solutions to help address some of the world’s most pressing and costly health and wellness challenges. The Company owns and operates WellCity, Inc., a premiere wellness-related social utility that helps ‘residents’ live longer, feel better, look younger and enjoy life more as they age. The Company’s subsidiary, MedX Limited, manufactures, markets and distributes the most advanced medical exercise equipment to the medical and fitness markets. Through its wholly owned subsidiary Pure HealthyBack, Inc., WellTek is redefining healthcare delivery by providing health plans, self-insured employer groups, and consumers with a viable non-surgical, lower cost treatment for patients who are seeking lasting relief from chronic neck and back pain. For more information on the Company, please visit www.WellTekinc.com. 

Certain statements contained in this press release, which are not based on historical facts, are forward-looking statements as the term is defined in the Private Securities Litigation Reform Act of 1995, and are subject to substantial uncertainties and risks in part detailed in the respective Company’s Securities and Exchange Commission filings, that may cause actual results to materially differ from projections. Although the Company believes that its expectations are reasonable assumptions within the bounds of its knowledge of its businesses, expectations, representations and operations, there can be no assurance that actual results will not differ materially from their expectations. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include the Company’s ability to execute properly its business model, to raise additional capital to implement its continuing business model, the ability to attract and retain personnel — including highly qualified executives, management and operational personnel, ability to negotiate favorable future debt facilities and capital raises, and the inherent risk associated with a diversified business to achieve and maintain positive cash flow and net profitability. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will, in fact, occur. 

SAUNDERSTOWN, RI–(Marketwire – July 15, 2010) –  The Federal government issued new rules Tuesday that will reward doctors and hospitals for the “meaningful use” of electronic health records, a top goal of President Obama. The rules significantly scale back proposed requirements that the health care industry had denounced as unrealistic.

What: subject matter expert: impact of new government standards for EHRs on small physician practices

Why: Doctors and hospitals could receive as much as $27 billion over the next 10 years to buy equipment to computerize patients’ medical records. A doctor can receive up to $44,000 under Medicare and $63,750 under Medicaid, while a hospital can receive millions of dollars, depending on its size

Who: Amazing Charts founder and CEO Dr. Jonathan Bertman, one of the nation’s leading experts on EHR/EMR systems and issues/trends impacting small and medium-sized physician practices.

Amazing Charts, due to its industry-leading usability and satisfaction ratings in multiple studies and $995 price tag is the EHR-of-choice for small practices (used by more than 3600 practices in the U.S. alone)

Click here to see all recent news from this company

BETHESDA, MD–(Marketwire – July 15, 2010) –  

*MEDIA NOTE: Study will be presented at the Washington State Convention Center on Saturday, July 17, at 7:30am.

Essential foot care by a podiatrist has now been statistically proven to reduce hospitalization and amputation in adults with diabetes, according to a first of its kind study conducted by Thomson Reuters. The study will be presented by Vickie R. Driver, MS, DPM, during the American Podiatric Medical Association’s (APMA) 98th Annual Scientific Meeting in Seattle, July 15-18, 2010. The presentation will highlight the dramatic impact that as few as one visit to a podiatrist can have on patients with diabetes.

The study, which was sponsored by APMA, examined records for more than 32,000 patients with diabetes, ages 18-64, and compared health and risk factors for those who had podiatry visits to those who did not. Researchers found that care by a podiatric physician (defined as at least one preventative, pre-ulcer visit) was associated with a nearly 29 percent lower risk of amputation and 24 percent lower risk of hospitalization. Diabetic foot complications are the leading cause of non-traumatic lower limb amputation in the U.S. 

“The results of this study undeniably support visits to a podiatrist being critical to a diabetes patient’s health and well being,” said APMA member Dr. Driver. “No longer can care by a podiatrist be considered optional for those with diabetes, and the earlier a podiatrist is included in the diabetes management team, the better quality of life for the patient and greater health-care cost savings for all involved. This study clearly allows us to understand both the clinical and economic value of a podiatrist, in the team approach to saving diabetic patients’ feet.”

The study was conducted using Thomson Reuters’ MarketScan Research Databases, which house fully integrated, de-identified health-care claims data extensively used by researchers to understand health economics and outcomes. Studies based on MarketScan data have been published in more than 130 peer-reviewed articles in the past five years.

Lead researcher Teresa Gibson, PhD, director of health outcomes research at Thomson Reuters said, “Using the MarketScan Databases, we statistically matched patients with diabetes and foot ulcers who had visited a podiatrist with like patients who had not. The analysis of the data indicates that patients who had seen a podiatrist in the year prior to the onset of a foot ulcer had significantly lower rates of any amputation and hospitalization than those who had not.”

For additional information on the study, visit www.apma.org/diabetesstudy.

Media interested in attending the presentation during the APMA 98^th Annual Scientific Meeting should contact Angela Berard at [email protected] or 301-861-9342.

Founded in 1912, the American Podiatric Medical Association (APMA) is the nation’s leading and recognized professional organization for doctors of podiatric medicine (DPMs). DPMs are podiatric physicians and surgeons, also known as podiatrists, qualified by their education, training and experience to diagnose and treat conditions affecting the foot, ankle and structures of the leg. The medical education and training of a DPM includes four years of undergraduate education, four years of graduate education at an accredited podiatric medical college and two or three years of hospital residency training. APMA has 53 state component locations across the United States and its territories, with a membership of close to 12,000 podiatrists. All practicing APMA members are licensed by the state in which they practice podiatric medicine. For more information, visit www.apma.org.

Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.

Click here to see all recent news from this company

SALT LAKE CITY, UT–(Marketwire – July 15, 2010) –   When Patrick Treend was a member of the Florida Marlins organization, he faced some pretty stiff competition as an up-and-coming pitcher. Now, he’s making a pitch to become the voice of our nation’s Child Care and Early Education insurance industry.

Treend, President of Security Planning & Insurance Corporation, which for more than 30 years has been one of the nation’s most-trusted insurance Agencies, has quickly become one of the most highly respected advocates in the child care industry. He oversees the day-to-day operations of the parent company’s two primary entities, Child Care Insurance Professionals and Charter School Insurance Professionals, the preferred choice for insurance in early education and child care.

“My general philosophy is to work as our client’s voice, their advocate,” says Treend. “We strive to get the most competitive rates and coverage without any allegiance to any one carrier. Generally speaking, child care and early education has very little competition, little to no national resources and no voice as it relates to insurance services. In most cases, people are taken advantage of because of the lack of competition and overall lack of insurance professionals that focus on this market.”

Due to his vast insight and expertise on the current trends within the child care industry, Treend is asked to speak at all of the regional conferences for the prestigious National Child Care Association (NCCA). He was recently in Atlanta to address his constituents on the state of the health care industry.

On the new legislation for Health Care Reform: “Under the new Health Care Reform Law, small businesses will find major changes to how they must provide health coverage and how much they must pay for it,” claims Treend. “I remain concerned that any advances under the new reform bill will be eroded by the unchecked rise of health care costs that were not adequately addressed in the legislation.”

Added Treend, “As it relates to Child Care and small businesses in general, it will have a huge impact for the smaller centers. The majority of the smaller centers cannot afford a traditional group plan and, if they could, the employee base cannot afford their employee portion. The only thing that the reform bill will do in the near future is make the process more confusing and costly.”

For Treend to be asked to voice his opinions has not been uncommon since making his pitch to the insurance industry in 2002. After quickly rising in ranks at Liberty Mutual Group and Zion’s Insurance Agency, Treend set his strike zone on child care and early education, revamping Security Planning & Insurance Corporation by making it the first insurance Agency of its kind to focus exclusively on providing packaged insurance to private and independent Charter Schools and Child Care Centers nationwide.

Child Care Insurance Professionals and, more recently, Charter School Insurance Professionals, are already considered ahead of their time and are the preferred choice for child care and charter schools looking for cost savings, favorable terms, targeted service and exceptional follow-through.

“Child Care and Charter Schools now have the convenience of dealing with one insurance Agency that handles all their policies, creating a significant cost savings. Our firm’s business model of targeted insurance programs and packages, particularly in the commercial child care industry, has taught us the value of market specificity. We believe focusing on a specific market niche enables us to provide targeted service and benefits that an individual school or an independent provider would not be able to access,” said Treend. 

For more information on Child Care Insurance Professionals and Charter School Insurance Professionals, visit their respective sites at www.ChildCareInsuranceProfessionals.com and www.CharterSchoolInsurancePros.com or call (888) 812-9992.

Click here to see all recent news from this company

DUERLE, BELGIUM–(Marketwire – July 15, 2010) – Remedent, Inc. (OTCBB: REMI), an
international company specializing in research, development, and
manufacturing of oral care and cosmetic dentistry products, reported
results for the final quarter and for the year ended March 31, 2010 (in US
Dollars).

Net sales in the fourth quarter decreased 27% to $2.5 million from $3.4
million in the same year ago quarter. The decrease in sales was due to non
recurring license fees of approx $1 million received from Denmat in the
fourth quarter ended March 31, 2009.

Loss from operations in the fourth quarter was a loss of $111,138 $(0.01)
per share as opposed to a loss of $1,079,063 $(0.05) in the same year-ago
quarter, based upon 20 million weighted average basic shares outstanding.

Net loss for the year ended March 31, 2010 was $2.4 million or $(0.12) per
share, as compared with a loss of $3.0 million or $(0.15) per share for the
year ended March 31, 2009.

Cash and cash equivalents totaled $614,000 at March 31, 2010 as opposed to
$1.8 million at March 31, 2009.

Management Commentary

“Our sales strategy of shifting from our previous wholesale sales (B2B)
model via a distributor to a direct retail model (B2C) is beginning to take
shape. Included in our net loss of $111,000 for the fourth and final
quarter ended March 31, 2010, was a loss of $550,000 directly attributable
to our subsidiary Sylphar. The improved results are attributable to the
inclusion for the first time of our Asian operations into our consolidated
financial statements together with the gain realized from the sale of First
Fit. Sales at all our Spa locations, namely in Beijing, Hong Kong, Taiwan
and in Europe continue to exceed our expectations as sales continue to
climb during the first quarter of the next financial year,” said Guy De
Vresse the CEO of Remedent.

Conference Call Information

Remedent will host a conference call on July 20, 2010 at 11:00 a.m. Eastern
Standard time (8:00 a.m. Pacific time) to discuss these results and its
strategic plans for the future. A question and answer session will follow
management’s presentation. To participate in the call, dial the appropriate
number 5-10 minutes prior to the start time.

Date: Tuesday,  July 20,2010
Time 11:00 a.m. Eastern time (8:00 a.m. Pacific time).
Dial in number: 1-888-677-8749
International: 1-913-312-1482

A simultaneous web cast and replay of the call will be available through
July 31, 2010. The replay pass code is 8101477.

About Remedent

Remedent, Inc. specializes in the research, development, manufacturing and
marketing of oral care and cosmetic dentistry products. The company serves
professional dental industry with breakthrough technology for dental
veneers. These products are supported by a line of professional veneer
whitening and teeth sensitivity solutions. Headquartered in Belgium,
Remedent distributes its products to more than 35 countries worldwide. For
more information, go to www.remedent.com.

Statement under the Private Securities Litigation Reform Act of 1995

Statements in this press release that are “forward-looking statements” are
based on current expectations and assumptions that are subject to risks and
uncertainties. Such forward-looking statements involve known and unknown
risks, uncertainties and other unknown factors that could cause Remedent’s
actual operating results to be materially different from any historical
results or from any future results expressed or implied by such
forward-looking statements. In addition to statements that explicitly
describe these risks and uncertainties, readers are urged to consider
statements that contain terms such as “believes,” “belief,” “expects,”
“expect,” “intends,” “intend,” “anticipate,” “anticipates,” “plans,”
“plan,” “projects,” “project,” to be uncertain and forward-looking. Actual
results could differ materially because of factors such as Remedent’s
ability to achieve the synergies and value creation contemplated by the
proposed transaction. For further information regarding risks and
uncertainties associated with Remedent’s business, please refer to the risk
factors described in Remedent’s filings with the Securities and Exchange
Commission, including, but not limited to, its annual report on Form 10-K
and quarterly reports on Form 10-Q.

                      REMEDENT, INC. AND SUBSIDIARIES
                  CONSOLIDATED STATEMENTS OF OPERATIONS
                                (unaudited)



                           Three months ended            Year ended
                                March 31,                 March 31,
                            2010         2009         2010         2009
                        -----------  -----------  -----------  -----------
Net sales               $ 2,472,815  $ 3,390,355  $ 8,247,940  $14,639,541
Cost of sales               952,189    1,650,315    4,322,680    6,614,723
                        -----------  -----------  -----------  -----------
  Gross profit            1,520,626    1,740,040    3,925,260    8,024,818
                        -----------  -----------  -----------  -----------
Operating Expenses
Research and development     39,850       24,273      271,195      248,652
Sales and marketing         461,078      370,042    1,352,260    2,793,970
General and
 administrative           1,313,812    1,639,656    4,524,324    5,312,192
Depreciation and
 amortization               168,218      173,903      726,499      615,674
                        -----------  -----------  -----------  -----------
TOTAL OPERATING
 EXPENSES                 1,982,958    2,207,874    6,874,278    8,970,488
                        -----------  -----------  -----------  -----------
  OPERATING LOSS           (462,332)    (467,834)  (2,949,018)    (945,670)
                        -----------  -----------  -----------  -----------
NON-OPERATING (EXPENSE)
 INCOME 
Warrants issued pursuant
 to Distribution Agreement       --           --     (168,238)  (4,323,207)
Gain on disposition of OTC       --           --           --    2,830,953
IMDS provision                   --     (300,000)          --     (300,000)
Interest expense/other
 deductions                 (50,596)    (166,972)    (171,364)    (417,147)
Interest income/other
 income                      54,907        1,884      170,244      348,997
Other income                     --           --     (169,358)          --
                        -----------  -----------  -----------  -----------
TOTAL OTHER INCOME
 (EXPENSES)                   4,311     (465,088)    (168,238)  (1,860,404)
                        -----------  -----------  -----------  -----------

LOSS FROM CONTINUING
 OPERATIONS BEFORE
 INCOME TAXES              (458,021)    (932,922)  (3,118,376)  (2,806,074)
Income tax expense          (14,242)     (32,633)     (14,242)     (32,633)
                        -----------  -----------  -----------  -----------

NET LOSS FROM CONTINUING
 OPERATIONS BEFORE
 MINORITY INTEREST         (472,263)    (965,555)  (3,132,618)  (2,838,707)
NET (LOSS) INCOME
 ATTRIBUTABLE TO
 NON-CONTROLLING
 INTERESTS                 (346,683)     114,208     (782,703)     114,208
                        -----------  -----------  -----------  -----------

NET LOSS FROM CONTINUING
 OPERATIONS, ATTRIBUTABLE
 TO REMEDENT INC. COMMON
 STOCKHOLDERS           $  (111,138) $(1,079,763) $(2,349,915) $(2,952,915)
                        ===========  ===========  ===========  ===========

LOSS PER SHARE
Basic and fully diluted $     (0.01) $     (0.06) $     (0.12) $     (0.15)
                        ===========  ===========  ===========  ===========
WEIGHTED AVERAGE
 SHARES OUTSTANDING
Basic and fully
 diluted                 19,995,969   19,995,969   19,995,969   19,559,653
                        ===========  ===========  ===========  ===========

OTHER COMPREHENSIVE
 INCOME (LOSS):
Net loss attributable
 to Remedent, Inc.
 common stockholders    $  (111,138) $(1,079,763) $(2,349,915) $(2,952,915)
Foreign currency
 translation adjustment    (102,949)     (45,371)      (9,464)    (668,245)
                        -----------  -----------  -----------  -----------
Total other comprehensive
 loss                      (214,287)  (1,125,134)  (2,359,379)  (3,621,160)
Less: comprehensive
 (loss) income
 attributable to
 non-controlling
 interest                   (42,623)     (54,700)       7,130      (54,700)
                        -----------  -----------  -----------  -----------
COMPREHENSIVE LOSS
 ATTRIBUTABLE TO
 REMEDENT INC.,
 COMMON STOCKHOLDERS    $  (171,664) $(1,070,434) $(2,366,509) $(3,566,460)
                        ===========  ===========  ===========  ===========




                      REMEDENT, INC. AND SUBSIDIARIES
                        CONSOLIDATED BALANCE SHEETS


                                              March 31,2010  March 31,2009
                                              -------------  -------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents                     $     613,466  $   1,807,271
Accounts receivable, net of allowance for
 doubtful accounts of $65,845 at March 31,
 2010 and $33,966 at March 31, 2009                 806,931      3,208,120
Inventories, net                                  2,161,692      1,937,946
Prepaid expense                                     920,487      1,310,900
                                              -------------  -------------
Total current assets                              4,502,576      8,264,237
                                              -------------  -------------
PROPERTY AND EQUIPMENT, NET                       1,735,719      1,024,999
OTHER ASSETS
Long term investments and advances                  750,000        750,000
Patents, net                                        246,992        163,106
Goodwill                                            699,635             --
                                              -------------  -------------
Total assets                                  $   7,934,922  $  10,202,342
                                              =============  =============
LIABILITIES AND STOCKHOLDERS' EQUITY
 (DEFICIT)
CURRENT LIABILITIES:
Current portion, long term debt               $     215,489  $      78,798
Line of Credit                                      674,600        660,200
Accounts payable                                  1,932,684      1,398,420
Accrued liabilities                                 491,536      1,590,360
Due to related parties                              268,484             --
Income taxes payable                                     --         39,339
                                              -------------  -------------
Total current liabilities                         3,582,793      3,767,117
  Long term debt less current portion               425,882        100,542
                                              -------------  -------------
Total liabilities                                 4,008,675      3,867,659
                                              -------------  -------------

EQUITY:
Preferred Stock $0.001 par value (10,000,000
 shares authorized, none issued and
 outstanding)                                           --            --
Common stock, $0.001 par value; (50,000,000
 shares authorized, 19,995,969 shares issued
 and outstanding at March 31, 2010 and
 19,995,969 shares issued and outstanding at
 March 31, 2009)                                     19,996         19,996
Treasury stock, at cost; 723,000 and 723,000
 shares at March 31, 2010 and March 31, 2009
 respectively                                      (831,450)      (831,450)
  Additional paid-in capital                     24,742,201     24,106,055
Accumulated deficit                             (19,565,943)   (17,216,028)
Accumulated other comprehensive income (loss)
 (foreign currency translation adjustment)         (650,059)      (640,595)
Obligation to issue shares                           97,500             --
                                              -------------  -------------
Total Remedent, Inc. stockholders' equity         3,812,245      5,437,978
                                              -------------  -------------
Non-controlling interest                            114,002        896,705
                                              -------------  -------------
Total stockholders' equity                        3,926,247      6,334,683
                                              -------------  -------------
Total liabilities and equity                  $   7,934,922  $  10,202,342
                                              =============  =============

SPRING, TX–(Marketwire – July 15, 2010) –  Dallas-based developer The LaSalle Group, Inc. is breaking ground on its third specialized Alzheimer’s and Memory Care Assisted Living Community in the Houston area, Autumn Leaves of Cypresswood, in Spring, TX. Company leadership, principal investors and other key partners will gather to see the newest addition to the Autumn Leaves family at official ground breaking ceremonies Tuesday, July 20 beginning at 11:00 a.m. Ceremonies will take place at the Cypresswood site located at 6327 Cypresswood Drive in Spring, TX. Local media and Spring area officials are invited to attend as well. 

Research of the Houston area has continued to show a demand for dedicated Alzheimer’s beds that exceeds the current supply. “We will continue to develop in the Houston market,” said Mitchell Warren, President of The LaSalle Group. “Our partners and investors recognize the pent-up need for our dedicated services that cater to this specific population and based on our in-depth market research results, we are committed to continuing our growth pattern in this market.” Autumn Leaves of Cypresswood will be the 15th property developed by LaSalle over the past ten years. Currently, The LaSalle Group has nine Autumn Leaves communities operating successfully in the Dallas/Fort Worth market and three in the greater Chicago area. The first Houston property to open, Autumn Leaves of The Woodlands, is set to accept their first residents in August; construction on the second Houston property, Autumn Leaves of Riverstone, is underway in Missouri City and scheduled to be completed in early Spring 2011. The company plans to continue their current expansion into the Houston market opening new communities in the area over the next three years.

Autumn Leaves of Cypresswood is scheduled to be completed and accepting residents by late Spring 2011. The property will feature 38 units and accommodate approximately 46 residents. For more information on this or other LaSalle Group projects, contact the home office at (214) 239-8400.

Construction and Management
Lake Superior Contracting, LaSalle’s in-house, full-service construction division, will coordinate and manage the design and construction of the new property ensuring the distinctive, research-based structural design attributed to all of LaSalle’s Autumn Leaves communities is in place. Sister firm Constant Care Management Company will manage and oversee all of the day-to-day operations once the community opens.

About The LaSalle Group, Inc. 
Family-owned and operated, The LaSalle Group (with its subsidiaries and affiliates) develops, builds, manages and owns specialized assisted living residences for people with Alzheimer’s and other forms of memory impairment, as well as other specialized real estate properties throughout the United States. For more information about our business, companies and current projects visit http://www.LaSalleGroup.com or call 1-800-452-7255. “Our Family Caring For Your Family”

About Alzheimer’s Disease
Alzheimer’s disease is a fatal and progressive brain disease that affects over 5.3 million Americans. Currently there is no cure and medications do not stop or reverse the disease. As the most common form of dementia, it accounts for more than approximately 60% of dementia cases.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 15, 2010) –  Healthnostics, Inc. (PINKSHEETS: HNSS), a medical manufacturing and biotechnology analytics company, has sold an interest in MedBioWeb, Corp., in exchange for 150 million shares of its common stock, thereby reducing the actual issued and outstanding shares of Healthnostics, Inc., to 155,857,509.

As the Company refocuses its business, it is contemplating the possibility of a sale of its remaining interest in MedBioWeb Corp. MedBioWeb Corp. may more readily achieve its profit goals as an independent company and Healthnostics, through its recent acquisition, may be more able to show a substantial increase in per share earnings due to the near halving of outstanding shares.

The Company will continue to pursue acquisitions that are both compatible and synergistic.

“The Company is witnessing dramatic changes, all of which we believe bode well for our stockholders. We are focusing on profitability and earnings per share, factors that will enhance our ability to thrive and grow,” said Alan Grofe, president.

About Healthnostics
Healthnostics, Inc. is a medical and biotechnology analytics company that provides comprehensive patient clinical monitoring and risk management systems to acute care hospitals and utilizes its Internet portals to deliver medical and biotechnology resource information to industry professionals as well as to the general public. Healthnostics’ major products include: Worldwide Wipes Co., a manufacturer and distributor of medical and other wipes, MedGuardian, a patient care monitoring and risk management system for hospitals that is fully Web-based; and through the MedBioWeb subsidiary, MedBioWorld™, one of the largest professional medical and biotechnology directory resource and reference portal sites on the Internet, and FamilyMedicalNet, a companion consumer healthcare information portal.
For further information please visit Healthnostics www.healthnostics.com, and Worldwide Wipes Co. www.wipesco.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com.

And visit us on Facebook at www.facebook.com/Healthnostics.

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

TUSTIN, CA–(Marketwire – July 15, 2010) –   Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has launched a new investor video channel on its corporate website (www.radient-pharma.com) to deliver regularly scheduled, dynamic video content to Wall Street and the investing community. The videos are also available at: http://radient.investorcandy.com/radient/RD#videos.

Investor communications through RPC’s new investor video channel will be delivered on a regular basis and will cover a broad range of topics and information, including personalized messages from RPC’s executive team, breaking company news, and in-depth updates on the Company’s business and product commercialization strategy, execution, timeline and progress. RPC also plans to leverage its online video channel as a medium to communicate to other key audiences beginning in the third quarter of 2010. Targeted audiences include distributors, strategic partners, oncologists, general practice physicians and cancer patients who may have used or are considering using RPC’s Onko-Sure in vitro diagnostic cancer test. 

“Video is becoming increasingly important as a way of reaching investors and business partners with valuable information,” commented RPC’s Chairman and CEO Mr. Douglas MacLellan. “RPC’s new Investor Video Channel is an excellent complement to our just launched corporate website and an excellent channel to communicate business activities that are of material importance our investing community.”

Updates on the availability of new content will be broadly communicated through the issuance of press releases. For additional information on RPC visit the Company’s website located at www.radient-pharma.com or contact RPC Investor Relations at 206.310.5323 or [email protected].

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic and therapeutic products, including the company’s Onko-Sure in vitro diagnostic (IVD) cancer test — a simple, non-invasive, patent-pending and regulatory-approved test used for the detection, screening, and monitoring of various types of cancer. Onko-Sure is approved by: the US FDA for the monitoring of colorectal cancer; Health Canada as a lung cancer screen and as a cancer monitoring tool; and as a cancer monitoring or cancer screening test in the European Union, India, Korea, and Taiwan. Visit www.Radient-Pharma.com for additional information.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 15, 2010) –  (PINKSHEETS: SREH) — SREH CEO, Tony Dibiase, announces the official launch of the company’s website, www.SREHoldings.com, “toward overall branding, marketability, transparency and developing a strong corporate identity as a publicly traded holdings company. The site has been designed to provide easy access to information about SREH’s subsidiary companies, Mobile2Earth (www.mobile2earth.com) and Scientific News International (www.scientificnewsroom.com) both with a rich base of intellectual property as well as IP development internally and for clients,” states Dibiase.

www.SREHoldings.com is a clean interface for a user-friendly experience featuring company overviews, news, progress and updates. “The new website exemplifies the dynamism and scope of SREH and its subsidiaries. Serving as a home base, the website provides both existing and prospective clients and shareholders timely, quality information about SREH and its subsidiaries with links to each individual company’s website therein. Mobile2Earth and SNI are not exactly sexy companies, per se,” states Dibiase. “But therein lies a trademarked and 13 year industry tested news service, subscription based social networking, exclusive non-biased content for medical professionals, iPhone and iPad apps as members of the Apple Developer Connection, to start. They both feature highly unique, marketable IP that can lead to sexy growth and corporate expansion. The SREH website helps exhibit all that we do in an easily digestible form, with the individual company sites available for customers, clients and the like with branding in place, accordingly. Both companies feature robust capabilities and the new holdings page simplifies this and strengthens our brand all the while.”

The company has submitted current disclosure and financial documents with OTCMarkets and will announce an update in tier status once reflected on the site.

CUTTING EDGE MEDICAL MEETING NEWS EXCLUSIVELY AT Scientific News International! (www.scientificnewsroom.com) is SREH’s premiere all-in-one platform for medical conference and news information focusing on Cardiology, Gastroenterology, Hematology, Nephrology, Oncology, Primary Care, Rheumatology and Urology. The site is the web’s only online resource for medical professionals with access to the latest, cutting edge data presented at major medical meetings worldwide. Staffed by global medical writers, SNI reports the most current research and therapy findings directly. The site’s profitability is IP and subscription based without bias from any medical or pharmaceutical provider. 

In the beginning, there was…Fishing, Manga, global tide reports and more! Get your iphoneMobile2Earth (www.mobile2earth.com) app now. Choose from the iphone King James Bible, fishing reports worldwide, Japanese e-books and comics and so much more as Mobile2Earth unleashes phase 1 of its iphone app releases for mass consumption. 

Safe Harbor: This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

SOUTH SAN FRANCISCO, CA–(Marketwire – July 15, 2010) –   Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the European Patent Office (EPO) has granted a European patent covering combinations of the Company’s lead drug candidate, voreloxin, with cytarabine. Cytarabine is the standard-of-care treatment for Acute Myeloid Leukemia (AML), and the therapy used in combination with voreloxin in a fully enrolled Phase 2 trial in patients with relapsed and/or refractory AML. Sunesis has also announced plans to initiate a multinational, randomized, double-blind, placebo-controlled, pivotal Phase 3 clinical trial of voreloxin in combination with cytarabine in a relapsed/refractory AML patient population in the second half of this year. European Patent No. 1 729 770 B1, titled “SNS-595 [voreloxin] and Methods of Using the Same,” following completion of the patent validation process, will provide patent coverage for such combination products in 30 member states of the European Patent Convention, including the major European markets, through 2025. Corresponding patent applications are pending in major markets throughout the world including Australia, Canada, Japan and the United States. 

“This patent is an important new addition to our intellectual property estate, as it covers the combination of voreloxin and cytarabine, the contemplated initial market application,” stated Daniel Swisher, Chief Executive Officer of Sunesis. “We are pursuing a sophisticated and deliberate strategy to provide exclusive coverage in the voreloxin patent estate out to 2030. Beyond our granted patents, we have filed patent applications covering formulations, combination uses, dosing, manufacturing processes and composition of matter claims. We look forward to the successful prosecution of these patent applications in multiple territories around the world.”

About Voreloxin

Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a fully enrolled single agent Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a fully enrolled Phase 2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. A Phase 2 single agent clinical trial in platinum-resistant ovarian cancer has also completed enrollment. Sunesis plans to initiate a multinational, randomized, double-blind, placebo-controlled, pivotal Phase 3 clinical trial of voreloxin in combination with cytarabine in a relapsed/refractory AML patient population in the second half of this year.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The National Cancer Institute estimated that nearly 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. in 2009. Additionally, it is estimated that prevalence of AML is approximately 25,000 in the U.S. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

This press release contains forward-looking statements, including without limitation statements related to the prosecution of patent applications and Sunesis’ plans to initiate a pivotal Phase 3 clinical trial of voreloxin in the second half of this year. Words such as “evaluate,” “planned,” “will,” “look forward” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis’ current expectations. Forward-looking statements involve risks and uncertainties. Sunesis’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include without limitation, risks related to Sunesis’ need for additional funding to fully finance the planned voreloxin pivotal trial, the risk that Sunesis’ development activities for voreloxin could be halted or significantly delayed for various reasons, the risk that Sunesis’ clinical studies for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that data to date and trends may not be predictive of future data or results, the risk that Sunesis’ nonclinical studies and clinical studies may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis’ clinical trials, risks related to the manufacturing of voreloxin, and the risk that Sunesis’ proprietary rights may not adequately protect voreloxin. These and other risk factors are discussed under “Risk Factors” and elsewhere in Sunesis’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

MARKHAM, ONTARIO–(Marketwire – July 15, 2010) – Extendicare Real Estate Investment Trust (“Extendicare REIT” or the “REIT”) (TSX:EXE.UN) today announced that it has declared a cash distribution of C$0.07 per unit of the REIT (the “REIT Units”) for the month of July 2010, which is payable to unitholders of record at the close of business on July 30, 2010, and will be paid on August 16, 2010.

Extendicare Limited Partnership (the “Partnership”) also announced that it has declared a cash distribution of C$0.07 per Class B limited partnership unit (the “Exchangeable LP Units”) for the month of July 2010, which is payable to unitholders of record at the close of business on July 30, 2010, and will be paid on August 16, 2010.

The current annualized distribution rate of the REIT and Partnership is C$0.84 per unit, payable in monthly distributions of C$0.07 per unit. In accordance with the distribution policy of both the REIT and the Partnership, unitholders of record at the close of business on the last business day of each calendar month will be paid a distribution on or about the 15^th day of the following month.

Management estimates that approximately 70% of the 2010 distributions of the REIT and Partnership will be characterized as tax-deferred returns of capital for Canadian residents. To the extent the remaining 30% of distributions of the REIT and Extendicare LP to be made in 2010 are taxed as dividends, those paid to Canadian residents are eligible dividends as per the Income Tax Act (Canada). The REIT is not required to, and does not, calculate its “earnings and profits” pursuant to the United States Internal Revenue Code of 1986, as amended, and therefore no portion of its distributions represent qualified dividend income for U.S. tax purposes.

The REIT has a Distribution Reinvestment Plan, which provides Canadian resident holders of REIT Units and Exchangeable LP Units with the opportunity to increase their respective investments at a 3% discount to the volume weighted average trading price of the REIT Units on the TSX for the five trading days immediately preceding the distribution payment date. A copy of the Plan package is available under the investors section of the REIT’s website.

About Us

Extendicare REIT is a leading North American provider of long-term and short-term senior care services through its network of owned and operated health care centers. We employ 37,700 qualified and experienced individuals dedicated to helping people live better through a commitment to quality service that includes post-acute care, rehabilitative therapies and home health care services. Our 258 senior care centers in North America have capacity for approximately 28,900 residents. Extendicare REIT is a specified investment flow-through trust (SIFT) that has been subject to the SIFT tax since January 1, 2007.

Forward-looking Statements

Information provided by Extendicare REIT from time to time, including this release, contains or may contain forward-looking statements concerning anticipated financial events, results, circumstances, economic performance or expectations with respect to the REIT and its subsidiaries, including its business operations, business strategy, and financial condition. Forward-looking statements can be identified because they generally contain the words “expect”, “intend”, “anticipate”, “believe”, “estimate”, “project”, “plan” or “objective” or other similar expressions or the negative thereof. Forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available, and the REIT assumes no obligation to update or revise any forward- looking statement, except as required by applicable securities laws. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the REIT to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on the REIT’s forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare REIT with the securities regulatory authorities, available at www.sedar.com and on the REIT’s website at www.extendicare.com.

CAMBRIDGE, MA–(Marketwire – July 15, 2010) –  PharmaPros, a technical consulting and solutions provider specializing in data and workflow management for clinical trials, today announced that Medelis, a single-source provider for oncology drug development services, has selected PharmaPros’ recently launched eClinical OnDemand™ solution, a unique Software as a Service (SaaS) subscription model for data and technology management.

With eClinical OnDemand™, PharmaPros acts as an outsourced technology department providing all of the technology implementation, management, and support for an end-to-end eClinical suite, as a managed service accessible by the study, program, or as a functionally outsourced department. With this solution, small to mid-sized organizations gain the advantage of a seasoned technology team and best-in-class clinical technology suite delivered with the added value of Dataflow Manager, PharmaPros’ first-in-class study management solution. With Dataflow Manager as the solution’s central interface, study teams can collaborate on study management operations using real-time data intelligence, across systems, sources, and vendors.

“We are excited to have been selected by Medelis to provide this solution. PharmaPros has a unique domain expertise at the intersection of data and technology. This enables us to not only deliver the highest quality services, but to enable specialty service providers to focus on their core competencies and deliver innovative solutions,” said PharmaPros CEO, Peg Regan.

PharmaPros will provide additional services to support both EDC and paper based studies using their proprietary methodology: electronic Data Lifecycle Management (eDLM) in conjunction with Dataflow Manager. With the advantage of an integrated study workflow and access to in-stream study progress, Medelis and PharmaPros will work seamlessly throughout the trial to ensure the expected data lifecycle, trial milestones, and data availability are managed to expectation.

“We are pleased to have found this unique solution to extend our own service offerings. eClinical OnDemand™ has enabled us meet client requirements for progressive technology, in-stream study status and integrated data extracts on-demand, providing us a competitive advantage we would not have with other, more traditional outsourced solutions,” said Bob Bosserman, CEO of Medelis Inc.

PharmaPros’ eClinical OnDemand™ is the first solution of its kind in the industry. Providing small to midsize companies a fully integrated eClinical technology suite, supported by mission critical services to ensure data is managed and available on a continuum from start-up to analysis. Integrated data from all sources including sites, labs, and imaging centers are delivered through PharmaPros study management application Dataflow Manager, providing study teams an unparalleled view of study progress.

About PharmaPros Corporation
PharmaPros Corporation is a technical consulting and solutions provider specializing in data and technology for clinical trials. The company’s innovative approach and deep industry expertise, has resulted in the commercialization of a revolutionary solution that is redefining clinical trials management. The company’s premiere solution — Dataflow Manager™ — provides the ability to manage clinical trials using the most accurate and up-to-date information available, enabling trial sponsors and managers to make more rapid, and better-informed decisions during a trial. PharmaPros was formed in 1996, with headquarters in Cambridge, MA.

PORT ST. LUCIE, FL–(Marketwire – July 15, 2010) –  RightSmile, Inc. (PINKSHEETS: RIGH) (www.RightSmile.com), the leader in Cosmetic Laser Teeth Whitening, continues to add more SmileShoppes across the country, while adding monthly reoccurring revenue at the same time. Furthermore, the Company will be reducing the current amount of shares outstanding by nearly 500 million shares within the coming days.

RIGH has been adding more SmileShoppes from the efforts of the independent rep groups recently signed up. Each SmileShoppe delivers monthly reoccurring revenue to the Company of approximately $500 per month, by just adding 10 new SmileShoppes per month at the end of a year the Company will have added $60,000 a month in additional revenue. The Company also has its first full time, in-house sales person, working from the corporate office in FL, and has been making good headway into the South Florida market.

The Officers of RIGH have decided to exchange their shares of Common stock for Preferred stock to ease investors’ minds that they may be selling their shares into the market. “Management is focused on building strong shareholder value and letting the shareholders know we are in it for the long haul,” stated Gene Caiazzo, President.

This reduction will reduce the Outstanding shares of the company’s Common stock to 550,000,000 from currently over 1 billion.

The Company has been working diligently on compiling and delivering all the information asked for by the audit team and looks forward to posting the audited financials on PinkSheets.

Once the financials are complete the company will hold its Annual Shareholders meeting this August in Fort Lauderdale, FL. As previously announced, all shareholders who attend the meeting can get their teeth whitened for free.

About RightSmile®:

Based in Port St. Lucie, Florida, RightSmile, Inc. engages in the distribution of branded and private label Cosmetic Laser Teeth Whitening products. Through Revodent, RIGH became a manufacturer of teeth whitening products. Revodent supplies numerous manufacturers/manu-packagers with components for teeth whitening solutions; in addition, they also supply final products designed for use in the dental, salon/retail and internet markets.

The Company believes all remarks made in the release to be accurate to the best of its knowledge.

The foregoing press announcement contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Click here to see all recent news from this company

ONTARIO, CA–(Marketwire – July 15, 2010) – Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products is pleased to announce they are in the process of adding an additional prescription drug to their product line. This drug known as Fortex is used for the relief of pain and inflammation of musculoskeletal conditions such as arthritis and muscle soreness.

Fortex will be prescribed by orthopedic surgeons, rheumatologists, general practitioners and pharmacists throughout Canada. Under the terms of the exclusive license agreement, Axxess Pharma will have sole rights to manufacture and market the prescription drug in Canada. The Company anticipates this prescription drug will provide a significant source of residual revenue due to the continued increase of senior citizens and overworked population.

For more information, please contact Investor Relations at (973) 351-3868.

About Axxess Pharma, Inc.:

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Safe Harbor

Statements about the Company’s future expectations and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words “anticipate,” “estimate,” “expect,” “intend,” “plans,” “projects,” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.

ALEXANDRIA, VA–(Marketwire – July 14, 2010) –  On Wednesday, July 14, the Obama Administration joined medical professionals and leaders from the health community to announce preventive health care coverage made available under the Affordable Care Act. Under this act, new insurance plans are required to provide preventive care without cost-sharing, which will remove financial barriers for many Americans for preventive services that can help alleviate disease and reduce costs. 

The American Diabetes Association believes that while this is laudatory, relying exclusively on the United States Preventive Services Task Force (USPSTF) “A and B” recommendations, will not lead to adequate screening of patients at risk for diabetes. Blood glucose screening is one of the most essential tools for detecting diabetes and something that should be part of a basic package of benefits and services. 

Under the new rule, asymptomatic adults with sustained high blood pressure will have access to diabetes screening and adults and children will have access to obesity screening and counseling through their clinician at no cost. Ensuring that patients with other risk factors, such as a family history of diabetes or who are obese, also have access to preventive screenings at low or no cost will allow for earlier diagnosis and subsequent prevention of dangerous and costly complications. 

Through implementation of the Affordable Care Act we must ensure that patients at high risk of diabetes are screened for the disease when they see their primary care physician. Nearly 6 million of the 24 million Americans living with diabetes have not been diagnosed. There is an additional 57 million Americans with pre-diabetes, and nearly 93 percent do not know it. If left untreated, diabetes leads to costly and dangerous complications such as blindness, amputation, heart disease, and kidney disease. Relying solely on the USPSTF recommendation, which gives an “I” statement to blood glucose screening for any asymptomatic patient not experiencing high blood pressure, will continue to leave millions of Americans undiagnosed and in danger of facing otherwise avoidable health complications such as blindness, amputation, heart disease, and kidney disease.

We are supportive of the provisions that cover obesity screening and other diabetes-related prevention services. We look forward to working with the Obama Administration and Congress to ensure that people have access to diabetes screenings, as well as to the preventive services that help to manage the disease and prevent complications following diagnosis.

American Diabetes Association guidelines (below) recommend screening for individuals who meet the common risk factors for diabetes. These criteria are consistent with those used in scientific studies of diabetes prevention.

• All adults who are overweight and have additional risk factors:
  • Physical inactivity
  • First degree relative with diabetes
  • Women diagnosed with gestational diabetes or who delivered a baby weighing > 9 lb.
  • Hypertension (high blood pressure) or cholesterol abnormality
  • Other clinical conditions associated with resistance to the effects of insulin
• In the absence of the above criteria, testing should begin at age 45 years
• If results are normal, testing should be repeated at least at 3 year intervals, with consideration of more frequent testing depending on initial results and risk status.

The American Diabetes Association believes that targeted diabetes screening as outlined by the our recommendations and supported by the National Institute of Diabetes and Digestive and Kidney Diseases, and are in line with risk factors recommended by the Centers for Disease Control and Prevention must be considered a covered preventive service. Doing so will meet the dual goals of the Affordable Care Act, that is emphasizing prevention and reining in healthcare costs.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

SAN FRANCISCO, CA–(Marketwire – July 6, 2010) –  New decorative contact lenses called circle lenses are an emerging and potentially dangerous trend among teenagers and young adults. In response to this, the American Academy of Ophthalmology (Academy) would like to alert consumers to the hazards of buying any decorative lenses, including circle lenses, without a prescription. Any type of contact lens is a medical device that requires a prescription, proper fitting by an eye care professional and a commitment to proper care by the consumer.

Inflammation and pain can occur from improperly fitted, over-the-counter lenses and lead to more serious problems including corneal abrasions and blinding infections.

Although over-the-counter sales of nonprescription “plano” cosmetic lenses have been illegal in the United States since 2005, they are still widely available without prescription in retail stores and on the Internet. In 2005, an Academy-backed federal law classified all contact lenses as medical devices and restricted their distribution to licensed eye care professionals.

To protect your eyes, all contact lenses must be fitted by an eye care professional. If you have any pain, burning, redness, tearing or sensitivity to light while wearing any type of contact lenses, see your ophthalmologist, an Eye M.D. For more information about contact lenses, go to www.geteyesmart.org.

Media: Spokespeople are available to comment.

About the American Academy of Ophthalmology
The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons — Eye M.D.s — with more than 29,000 members worldwide. Eye health care is provided by the three “O’s” — opticians, optometrists and ophthalmologists. It is the ophthalmologist, or Eye M.D., who can treat it all: eye diseases and injuries, and perform eye surgery. To find an Eye M.D. in your area, visit the Academy’s Web site at www.aao.org.

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – July 6, 2010) –  The Cystinosis Research Foundation of Irvine, Calif., announced it has awarded $988,759 in grants to seven specialized research studies in the United States, France, Belgium and Ireland that are focused on finding a cure for cystinosis and improving understanding of the rare, deadly metabolic and genetic disease. Cystinosis afflicts about 500 children and young adults in the U.S. and 2,000 worldwide.

“The $11.8 million in cystinosis research grants awarded to date has resulted in an important milestone. The CRF’s mission to find a better treatment for cystinosis has been realized with the final Phase 3 clinical trial of Delayed-Release Cysteamine currently under way at Emory University and soon to be at several other sites in the U.S. and Europe. Without the concerted effort of CRF, we would not be where we are today. We are very close to unlocking the mysteries of this terrible disease,” said Nancy Stack, CRF Trustee and President.

The CRF is the leading funding source for bench and clinical investigations of cystinosis worldwide.

The foundation’s latest round of funding follows the recent formation of the CRF Cystinosis Gene Therapy Consortium. The consortium’s goal is to advance progress on the most promising current findings, including moving novel therapeutic modalities into human patients as quickly as possible. Work is now under way at The Scripps Research Institute in La Jolla, Calif., to develop the necessary preclinical animal model data and translate these results into an FDA-approved clinical trial.

The CRF is launching the Cure Cystinosis International Registry (CCIR), whose purpose is to consolidate information about cystinosis patients into a single data repository which will help advance research and clinical trials leading to future treatments and cures.

The CRF awards research grants in the spring and fall of each year. The latest round of funding awards were presented to researchers at the University of California campuses at Irvine and San Diego; Massachusetts General Hospital; State University of New York at Buffalo; University Hospital, Leuven, Belgium; University College, Cork, Ireland; and a team from the Institut de Biologie Physico-Chimique, Paris; and the University Medical Center, Mainz, Germany.

Cystinosis is a metabolic disease that slowly destroys every organ in the body, including the liver, kidneys, eyes, muscles, thyroid and brain. There is a medicine that prolongs the children’s lives, but there is no cure. Most cystinosis sufferers succumb to the disease or its complications by age 40.

In patients with cystinosis, the amino acid cystine accumulates in the tissue due to the inability of the body to transport cystine out of the cell. This causes development of crystals, resulting in early cell death.

“The advancements achieved thus far are the result of CRF’s focused efforts and targeted approaches to research. We are dedicated to bringing the first stem cell and gene therapy clinical trial for cystinosis to reality. We hope that, if all goes well, there will be a clinical trial for a cure within the next two to three years,” she said. The CRF currently is funding 48 research studies, including 13 research fellows worldwide.

Nancy Stack and her husband, Geoffrey, a managing director of the SARES•REGIS Group, an Irvine real estate company, have a daughter, Natalie, 19, with cystinosis.

Every dollar raised by the CRF is committed for medical research. Administrative costs are privately underwritten. All grants are awarded based on evaluations by the CRF’s Scientific Review Board, which is comprised of leading doctors and research scientists in the field.

SPRING 2010 RESEARCH GRANTS FUNDED

Total: $988,759

Alan Davidson, PhD, Principal Investigator
Massachusetts General Hospital, Boston, Massachusetts
“Characterization and Rescue of CTNS-iPS Cells”
$129,557 – 1 year grant

Bruno Gasnier, PhD, Principal Investigator
Institut de Biologie Physico-Chimique, Paris, France
Ellen Closs, PhD, Co-Investigator
University Medical Center, Mainz, Germany
“Molecular Study of Lysosomal Transporters Involved in the Cystine-depleting Effect of Cysteamine”
$169,384 – 2 year grant

Patrick Harrison, PhD, Mentor and Ciaran Lee, Research Fellow
University College, Cork, Ireland
“Cystinosis Gene Repair”
$146,258 – 2 year grant

Elena Levtchenko, MD, PhD, Mentor and Joost Schoeber, PhD, Research Fellow
University Hospital, Leuven, Belgium
“Studying Podocyte Function in Nephropathic Cystinosis”
$150,000 – 2 year grant

Miriam Britt Sach, MD, PhD, Principal Investigator
University of California, San Diego
“In Vivo ATP Metabolism in Cystinosis Patients as Assessed by MR Spectroscopy”
$109,493 – 1 year grant

Jennifer Simpson, MD, Principal Investigator
James Jester, PhD, Co-Investigator
University of California, Irvine
“Novel Treatment Modalities for Corneal Cystinosis”
$180,000 – 2 year grant

Mary Taub, PhD, Principal Investigator
State University of New York at Buffalo
“Mechanisms Underlying the Fanconi Syndrome in Cystinosis”
$104,067 – 1 year grant

The Cystinosis Research Foundation is the largest non-profit provider of funds for cystinosis research in the world. For more information, call Zoe Solsby at (949) 223-7610 or visit www.cystinosisresearch.org.

LOS ANGELES, CA–(Marketwire – July 6, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mymedicalrecords.com) today announced that Jeff Holtmeier, MMR’s representative to China, will be in Zhengzhou, China next week for meetings with the Company’s China JV partner Unis-TongHe (“Unis-TH”), Hewlett-Packard China and other strategic partners regarding the planned launch of Zhengzhou City’s Electronic Medical Record (“EMR”) project. These will consist of plans to include a customized version of MMR’s proprietary Personal Health Record (“PHR”) services and professional document imaging solutions led by MMRPro, (www.mmrpro.com) and the MMRPro/Kodak Scan Station Solution. MMRGlobal has a 10-Year Joint Venture Agreement with Unis-TH in China.

“Our Joint Venture operations with Unis-TH in China are in addition to our contract with Chartis International, which has plans to begin offering MyMedicalRecords and MyEsafeDepositBox to Chartis policyholders worldwide including China,” said Robert H. Lorsch, MMRGlobal Chairman and Chief Executive Officer.

Representatives of the Unis-TongHe MMR Medical Information Technology Service Group Joint Venture (“JV”) will be formalizing plans to commence the Zhengzhou City medical records project, which includes MMR’s Personal Health Records services and other related products (www.mmrtheatre.com). Initial programs call for the provision of a variety of EMR services to China. The initial project will include deployment to one-third of Zhengzhou’s population of nearly seven (7) million and, ultimately, the JV could deploy services to the majority of Zhengzhou’s 1410 municipal health institutions. These institutions include 164 hospitals, 43 community health centers, 134 community health stations, 14 women and children health maintenance centers, 17 disease prevention and control centers and seven health supervision stations.

The first phase of the project includes two administrative regions of Zhengzhou City with more than 2.3 million residents. During the phase one trial period, the solution is expected to cover 42,231 healthcare professionals that include 16,389 assistant doctors and 16,432 registered nurses.

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheatre.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. MMRGlobal, Inc. disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on the reasonable expectations of MMRGlobal, Inc. as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to the Unis-TongHe/MMR JV, both the Company’s and the JV’s business prospects, results of operations or financial condition, national and international government regulations and the risks associated with doing business across borders and territories, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

UTICA, NY–(Marketwire – July 6, 2010) –  CONMED Corporation (NASDAQ: CNMD) announced today that it expects to report second quarter 2010 financial results before the market opens on Thursday, July 29, 2010, and will also hold a conference call live over the Internet at 10:00 a.m. Eastern Time that same day. This webcast can be accessed from CONMED’s web site at www.conmed.com. Replays of the call will be made available through August 6, 2010.

The Company anticipates that forward-looking information and additional material details related to second quarter 2010 earnings and the Company’s expectations on a prospective basis may be discussed during the call. Such forward-looking information may involve risks and uncertainties such as those described in the Company’s SEC filings.

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use our medical devices. Headquartered in Utica, New York, the Company’s 3,400 employees distribute its products worldwide from several manufacturing locations.

SCOTTSDALE, AZ–(Marketwire – July 6, 2010) –  Today the recreational athlete has access to quality sports care and rehabilitation. With a foundation of chiropractic, the prevention and maintenance of sports related injuries is moving to higher levels. Practitioners offer a variety of techniques to assist the individual as a complete physical system, rather than trying to fix an isolated condition.

Dr. Wendy Weisflog, D.C., C.C.S.P., chosen as a “Top Doctor of 2009” by Phoenix Magazine, operates the Arizona Sports & Rehabilitation Center in Scottsdale, Arizona. She takes an advanced approach by introducing a variety of treatment options. “We don’t stop with the traditional chiropractic approach,” claims Dr. Weisflog. “We work with the complete individual, providing the right combination of treatments and focused lifestyle guidance. We help our patients not only deal with nagging physical problems, but set them up for long-term success.”

Chiropractic deals with the structure of the body, with an emphasis on the spine. Manipulation or “adjustment” of the spine and skeletal structure is used to realign and relieve nerve interference or other malfunction. Spinal and joint alignment is the essential building block of resolving chronic injury.

Chiropractic is accepted as a viable approach, especially in sports medicine. In a 2002 study, 31% of NFL teams use chiropractors in an official capacity as part of their staffs, with trainer referrals to chiropractors approaching 77%.

Following chiropractic treatment, a prescribed course of activity allows the body to return to normal movement without causing further damage. Various forms of massage relax muscles and soft-tissue, allowing skeletal adjustments to be sustained. Length of treatment depends on severity of the injury and the patient’s condition. At the appropriate time, exercise and strength training may be introduced to help the individual return to normal activity.

At Arizona Sports & Rehabilitation Center, the patient is encouraged to make lifestyle changes to avoid continuing aggravation. The recreational athlete benefits from the professionals that treat them, because the pros demand the best. Dr. Weisflog states, “We use a variety of programs depending on the attitude, commitment and needs of our clients. Some find acupuncture helpful, while others respond to E-Stim therapy, which involves mild electrical stimulation. Also, we give them a maintenance program which usually involves stretching and age-appropriate exercise, so they won’t need a long-term rehabilitation period.” 

Today’s amateur athlete has a wide range of top level options, all geared to getting back in the game, quickly and easily. For more information: www.azsportsrehab.com

Click here to see all recent news from this company

BURLINGTON, VT–(Marketwire – June 30, 2010) –  Marathon Health today announced that Averitt Express, a leading provider of freight transportation and supply chain management, will offer onsite health services to its associates at its corporate campus in Cookeville, TN. 

The Averitt clinic is scheduled to open in early October 2010.

Marathon Health will implement and manage the onsite health clinic for Averitt associates, spouses, and dependents over the age of six. Available services include acute and primary care, wellness and health promotion, health coaching, disease management, medication dispensing, and the Marathon eHealth Portal technology to support the delivery of care and coaching.

The opening of an onsite health clinic is a logical next step for Averitt’s health benefit strategy according to Averitt consultant Jeff Lynch, Summit Financial Group. “Over the past five years, we have systematically introduced wellness/prevention into the medical plan design, workplace policies, and employment policies. Balancing the cost pressures related to healthcare with a sincere desire to provide high-quality health benefits is a challenge for Averitt. The answer is providing Averitt associates with access to a full range of health services at work; this is a win-win for Averitt and its associates.”

“Our associates’ overall health is very important to us, and we strive to provide the appropriate tools to help them achieve the best health possible,” said Scott Wolf, Averitt vice president, corporate services. “We are very excited about how the onsite clinic will contribute to the overall health and wellbeing of our team.”

The foundation for Marathon Health services is health risk identification and mitigation. This total population health risk management approach addresses the health needs of the entire population, helping the healthy maintain good health, and helping those with costly and debilitating chronic disease to manage conditions.

“We are proud to partner with Averitt and to contribute to their vision of health and wellbeing for Averitt associates and their families,” said Jeff Shea, Marathon Health vice president.

About Averitt Express

Established in 1971, Averitt Express is a leading provider of freight transportation and supply chain management with international reach to more than 100 countries. The company specializes in delivering customized solutions with a single source of accountability for service offerings that include cross border/domestic offshore, dedicated, expedited, intermodal, international ocean/air, local customization, less-than-truckload, PortSide™, transportation management, truckload (dry van, flatbed, refrigerated, brokerage), warehousing and value-added services, including a centralized call center, strict performance metrics and an ongoing focus on green/sustainability efforts. Averitt’s technology offerings include a full suite of web-based shipping tools, electronic data interchange (EDI) and transportation and operations management systems. For more information, please call 1-800-AVERITT (283-7488) or visit http://www.averittexpress.com.

About Marathon Health

Marathon Health of Colchester, VT, offers a proven solution for helping employers reduce the total cost of healthcare. The Marathon Health approach integrates the best practices of onsite primary care, health assessment with risk identification, coaching and advocacy, and disease management for high cost chronic conditions. Marathon Health supports its unique model with an eHealth Portal delivering medical content, interactive diet and fitness tools, a personal health record, and an electronic medical record to manage care. For more information, please visit www.marathon-health.com.

NEW YORK, NY–(Marketwire – June 30, 2010) –  Healthnostics, Inc. (PINKSHEETS: HNSS), a medical and biotechnology analytics company, announced that in addition to its recent investment in a medical manufacturing company, it has invested in the repurchase of 90 million shares of its common stock in a private transaction, thereby reducing the actual issued and outstanding shares to 305,857,509. Of this total, the approximately 39 million shares which are not closely held are traded in the public market. These shares constitute the public float.

Both the investment in an ongoing acquisition and the investment in the repurchase of shares will have the immediate effect of increasing shareholder equity through significantly enhanced earnings per share.

About Healthnostics

Healthnostics, Inc. is a medical and biotechnology analytics company that provides comprehensive patient clinical monitoring and risk management systems to acute care hospitals and utilizes its Internet portals to deliver medical and biotechnology resource information to industry professionals as well as to the general public. Healthnostics’ major products include: MedGuardian, a patient care monitoring and risk management system for hospitals that is fully Web-based; and through the MedBioWeb subsidiary, MedBioWorld™, one of the largest professional medical and biotechnology directory resource and reference portal sites on the Internet, and FamilyMedicalNet, a companion consumer healthcare information portal.

For further information please visit Healthnostics www.healthnostics.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com.

And visit us on Facebook at www.facebook.com/Healthnostics.

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

CALGARY, AB–(Marketwire – June 30, 2010) –  Celebrities are accustomed to getting the latest and greatest products from Gifting Services. Sometimes it is a clever gadget or a miracle skin cream. Sometimes they are amused, impressed or even shocked. On occasion they are left in awe of an innovative product that is becomes an instant “must have.” This season’s newest must have item is the Advanced Whitening Toothbrush from World White Smiles. When celebs think of tooth whitening they imagine the bright LED lights from the dentist’s office. World White Smiles took those lights and put them into a toothbrush! This is the James Bond of toothbrush technology. “How did they do this?” asked Nicole Scherzinger. Celebs had a consistently similar response to Debi Mazar who said, “This is genius.” A few of the other celebs who received the products were Jodi Sweetin, AnnaLynne McCord, Patti Labelle, Snooki and Chris Bauer.

Perfect white teeth are the soul of your smile. This patented LED Light Toothbrush is a revolutionary dental care system that not only cleans the teeth but also prevents many forms of gum disease.

Features/Benefits

• Reduces bleeding gums
• Leaves teeth feeling smoother longer
• Scientifically proven to kill the photosensitive bacteria of the mouth and gums — the bacteria that causes gingivitis and other more severe forms of periodontal disease, and even kills thrush on contact
• Whitens naturally — Does not utilize harsh chemicals to whiten teeth
• Enhances the whitening capabilities of any whitening toothpaste
• Increases saliva production — Which protects teeth and gums from periodontal disease by keeping the mouth more alkaline
• Prevents halitosis

Some bacteria are photosensitive and when activated by visible light, induce a photodynamic reaction that kills them within seconds.

Deeply cleaning
Photodynamic energy can activate active oxygen ion in toothpaste and rapidly spread to teeth surrounding and every inch of space and edge where the common tooth brush is hard to reach. Clean and whiten each tooth completely. The innovative manual toothbrush is similar in outward appearance to conventional toothbrushes but that’s where the similarity ends. No toothbrush currently on the market can stand up to the superior performance of the LED Light Toothbrush. Electric toothbrushes can only brush the plaque off the tooth surface and nothing more. You can benefit from using this innovative technology today by brushing with this revolutionary toothbrush.

Natural design
Round-head brush is grinded by adopting advanced technology to nurse your teeth and gums. The handle designed by using Ergonomics can be held comfortably and controlled freely.

Battery
One AAA battery. It can be used for three months if teeth are brushed twice each day and for three minutes each time. It is safe and reliable. Photodynamic energy belongs to low energy light that is safe for gums or oral.

Affordable
We offer free Teeth Whitening Toothpaste while supplies last, you pay only a small shipping and handling fee as needed. Dentists recommend changing your toothbrush every 3-6 months.

BETHESDA, MD and FORT WAYNE, IN–(Marketwire – June 30, 2010) –  GetWellNetwork, Inc. today announced a successful collaboration with EXTENSION, INC. to enable patients at Norton Brownsboro Hospital in Louisville, Ky. to send messages directly to their attending nurse as well as to automate new patient care workflows that enable the hospital to provide better service and care more efficiently. Norton Brownsboro is one of five hospitals in the Norton Healthcare system, the Louisville area’s leading health provider.

The integration to EXTENSION® keeps the GetWellNetwork system connected to the right nurse and staff member, enabling nursing workflows that keep nurses informed and connected to their patients at all times — via the Cisco wireless device. The integration is accomplished through a new systems interface developed by GetWellNetwork using the HL7 protocol. 

EXTENSION specializes in solutions that turn Cisco Unified Communications into a clinical workflow tool by automating notifications using text messages, phone calls, and emails. It also allows nurses to acknowledge the notification directly from his/her phone and escalate the issue when needed. Through this integration effort, the GetWellNetwork system now sends alerts that inform nurses when patients have not completed important education videos or other service requests.

“The GetWellNetwork system provides us with valuable input from our patients but we needed an automated way for that information to be delivered to the handheld Cisco phones that are assigned to each of our staff on a given day,” said Doug Winkelhake, President, Norton Brownsboro Hospital. “We appreciate how quickly GetWellNetwork and EXTENSION came together to help us make patient experience and quality of care much better and more efficient.”

“By working with EXTENSION, we’re able to send actionable patient information right to the attending nurse and staff at Norton Brownsboro Hospital,” said Robin Cavanaugh, CTO, GetWellNetwork, Inc. “This integration effort is also noteworthy because it is standards-based, which means that we can implement this for any of our client hospitals who want to take the next level of patient engagement.”

“This solution was created in a way that leverages the existing process for how nurses and other staff members receive and react to other types of alerts sent by EXTENSION,” said Josh Mahler, COO, EXTENSION, INC. “By incorporating these new alerts into the existing process, minimal training was required.”

About EXTENSION, INC.
EXTENSION, INC. is based in Fort Wayne, IN and is the developer of the EXTENSION® Solution Suite (ESS). EXTENSION tightly integrates any HL7-based or web services-based medical application with Cisco Advanced Unified Communications, using standards-based protocols. EXTENSION recently earned the ‘Cisco Collaboration Partner of the Year for the US/Canada’ award at the 2010 Cisco Partner Summit. For more on EXTENSION visit www.OpenTheRedBox.com.

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

Click here to see all recent news from this company

SANTA ANA, CA–(Marketwire – June 30, 2010) –  SixLog Corporation, an Astro Pak company providing on-site biological decontamination and sterilization services, today announced it will be demonstrating its revolutionary iHP™ (ionized Hydrogen Peroxide) room disinfection/sterilization technology at the annual conference for APIC (Association for Professionals in Infection Control), July 12-14 at booth #2235 at the New Orleans Convention Center in New Orleans, Louisiana.

SixLog’s featured system uses iHP™ technology, the next-generation of hydrogen peroxide fogging systems. It is faster, more effective, and safer than alternatives. Originally developed for the US Department of Defense to combat biological warfare, this breakthrough technology is now available for commercial use. iHP™ has proven efficacy in a multitude of industries including Life Sciences and Pharmaceutical, and SixLog now offers its service to the healthcare industry to address the ongoing challenges resulting from a nationwide goal of preventing healthcare-associated infections (HAIs).

“I am very excited to be able to offer our room disinfection/sterilization service to the healthcare industry,” says Vanessa Valdez, general manager of SixLog. “iHP™ is a proven sterilant that not only kills all microorganisms, but their spores as well, eradicating any possible reproduction of pathogenic organisms leading to nosocomial infections. We offer fully integrated, customized solutions to meet infection prevention needs at an affordable price. iHP™ can easily augment any hospital’s terminal cleaning protocol to provide a more robust result.”

SixLog’s room disinfection/sterilization service utilizing iHP™ technology solves critical infection control challenges in the healthcare industry and is particularly effective against common “super bugs” such as MRSA, C. difficile, VRE and multi-drug resistant (MDR) Acinetobacter. iHP™ does not damage sensitive electronics and dissolves into just water and oxygen making it safe for staff, patients and visitors as well as the environment. A few examples of iHP™ room disinfection/sterilization applications include:

• Emergency and patient rooms
• Intensive care units
• Surgical suites
• Tissue culture labs
• Bone marrow transplant suites
• Blood banks
• Sputum induction areas

For more information about SixLog’s iHP™ technology or to view it in action, please visit SixLog at booth #2235 at APIC 2010 July 12-14 at the New Orleans Convention Center, or contact us at [email protected] or 877-4SIXLOG (474-9564).

About SixLog Corporation

SixLog provides on-site biological decontamination for equipment, rooms, entire buildings, and modes of transportation such as ambulances, trains, and cruise ships. Its proprietary iHP™ (ionized Hydrogen Peroxide) decontamination technology is utilized across a variety of industries including Life Sciences, Pharmaceutical, Healthcare, First Responders, Transportation, and Public Facilities. SixLog is privately held with headquarters in Santa Ana, CA. For more information, please visit www.sixlogcorp.com.

Click here to see all recent news from this company

WINNIPEG, MANITOBA–(Marketwire – June 30, 2010) – DiaMedica Inc. (TSX VENTURE:DMA) (“DiaMedica” or the “Company”), is pleased to announce the completion today of its $2.26 million short form prospectus offering of units (the “Offering”) and its previously announced acquisition (the “Acquisition”) of Sanomune Inc., a privately held biopharmaceutical company focused on neurological disorders (“Sanomune”). 

The Offering

Pursuant to the completion of the Offering, DiaMedica has issued a total of 5,650,000 units (each a “Unit“) at a price of $0.40 per Unit for aggregate gross proceeds of $2.26 million. Each Unit is comprised of one common share in the capital of the Company (each a “Common Share“) and one Common Share purchase warrant (each a “Warrant“), with each Warrant entitling the holder thereof to acquire a further Common Share until the second anniversary of the closing of the Offering. The expiry date of the Warrants is subject to acceleration if the volume-weighted average trading price of the Common Shares on the TSX Venture Exchange (the “TSX-V“) exceeds $0.75 per share for a period of 10 consecutive trading days. 

The Offering was led by Bolder Investment Partners, Ltd., as agent (“Bolder”). In connection with the completion of the Offering, Bolder exercised its agent’s option to increase the size of the Offering by 13%, or 650,000 Units. 

The net proceeds of the Offering will be used to fund DiaMedica’s ongoing research and development programs, including planned pre-clinical trials for our lead products, and for general working capital purposes. 

As compensation for its services as agent, Bolder received a cash commission of $226,000, and received broker warrants to acquire up to 565,000 Common Shares exercisable at the price of $0.40 per share at any time on or prior to June 30, 2011.

The Acquisition

Pursuant to the completion of the Sanomune Acquisition, DiaMedica has issued a total of 12,807,377 Common Shares to Sanomune shareholders as consideration for all of the issued and outstanding shares of Sanomune.

“With the completion of this financing and the strategic acquisition of Sanomune, we have brought together two of Canada’s Top 10™ Life Sciences Companies,” stated Mr. Rick Pauls, President and Chief Executive Officer of DiaMedica. “This acquisition allows us to take advantage of a unique opportunity to strengthen our patent portfolio and expand into neurological and autoimmune disorders targeted by our lead program, DM-99/199, which has demonstrated neural protection (protects brain cells) and neural cell proliferation (creates brain cells)”.

As a result of the Acquisition, in addition to Sanomune’s lead compound, SAN-61, DiaMedica also acquires a panel of monoclonal antibodies that trigger the inhibition of glycogen synthase kinase 3 beta (GSK-3ß). GSK-3ß plays an important role as a regulatory switch for numerous cell-signaling pathways and has been linked to diabetes, cancer, infectious diseases and a variety of neurological disorders. It is anticipated that the monoclonal antibody program will compliment DiaMedica’s DM-99/199 program, which has also been shown to have GSK-3ß inhibiting properties.

As announced in its April 20, 2010 press release, DiaMedica obtained the required minority shareholder approval (the “Minority Approval”) for the Acquisition under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”), by securing written consents to the transaction from shareholders representing approximately 65% of the Common Shares held by parties eligible to vote for approval of the transaction under Part 8 of MI 61-101. This is in excess of the simple majority requirement (i.e., 50%+1) set out in MI 61-101 for such Minority Approval. 

In addition to the related parties described in DiaMedica’s February 18, 2010 press release regarding the Acquisition (each a “Related Party” and collectively, the “Related Parties”), Common Shares held by two investment funds, Manitoba Science & Technology Fund (“MST”) and Crocus Investment Fund (“CIF”) were also excluded for the purposes of obtaining Minority Approval for the Acquisition. MST and CIF each hold approximately 24.75% of the voting common shares of Genesys Ventures Inc., a Related Party, and are therefore each “a related party of an interested party” as described in MI 61-101. Immediately prior to the completion of the Acquisition and the Offering, the Related Parties, in the aggregate, beneficially owned, or exercised control or direction over, a total of 5,493,523 Common Shares, or 28.60% of the total issued and outstanding Common Shares. To the knowledge of the Company, based on public filings by each of MST and CIF, immediately prior to the completion of the Acquisition and the Offering, MST and CIF held, in the aggregate, a total of 3,065,764 Common Shares, or 15.96% of the total issued and outstanding Common Shares.

Management Changes

DiaMedica further announces the appointment of Mr. Pauls to the full-time position of President and Chief Executive Officer and the appointment of Dr. Mark Williams to Vice-President, Research. Dr. Stephen Waters has resigned from his interim role as Executive Vice-President and Interim Chief Scientific Officer.

Mr. Pauls, who has been an active board member since 2005, and is currently the Chairman of the Board of DiaMedica, has served as the acting President and Chief Executive Officer of the Company since July 2009. Mr. Pauls was previously the Managing Director of CentreStone Ventures Inc., a life sciences venture capital fund which he was involved with from inception. While with CentreStone, Mr. Pauls led investments in Orasi Medical Inc., winner of the Red Herring Global 100; LED Medical Inc., winner of Red Herring Canada 50 award in the Health category; as well as DiaMedica and Sanomune, both named among Canada’s Top 10™ Life Sciences Companies. Prior to his role with CentreStone, Mr. Pauls was employed by Centara Corporation, another early stage venture capital fund.

“We would like to express our gratitude to Dr. Stephen Waters for his valuable contributions to our strategic planning efforts and we look forward to working with him as a consultant,” continued Mr. Pauls. “The Board of Directors of DiaMedica joins me in thanking Dr. Waters for his efforts, and we wish him continued success in his future endeavors”.

In conjunction with these management changes, the Board of Directors has approved a grant of 457,500 stock options to certain directors, executives and employees under the terms of the Company’s stock option plan. The options have an exercise price of $0.42 per share and are exercisable for a period of 5 years. This grant of such options is subject to acceptance by the TSX-V.

Please visit DiaMedica’s new company website at www.diamedica.com.

About DiaMedica and Sanomune

DiaMedica is a biopharmaceutical company, focused on developing novel treatments for diabetes and neurological disorders. The Company’s diabetes program is based on a critical liver nerve signaling mechanism involved in enhancing insulin sensitivity after meal consumption. Two of DiaMedica’s products have demonstrated human efficacy in lowering blood sugar levels in diabetics based on this novel nerve signaling mechanism.

As a result of the Sanomune Acquisition, DiaMedica plans to expand its DM-199 program into neurological and autoimmune disorders. Sanomune has demonstrated that its lead compound, SAN-61, a naturally occurring protein, confers neural protection (protects brain cells) and triggers neural stem cell proliferation (creates brain cells) for the treatment of numerous neurological disorders including Alzheimer’s disease. DiaMedica has also acquired from Sanomune a panel of monoclonal antibodies targeting diabetes, neurological disorders and cancers through the inhibition of GSK-3ß.

Both DiaMedica and Sanomune were recognized as one of Canada’s Top 10™ Life Sciences Companies in 2008/2009. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”.

For further information please visit www.diamedica.com.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations.
These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our acquisition of Sanomune may be found in our press releases dated February 18, 2010 and April 20, 2010.

MADISON, WI–(Marketwire – June 30, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of highly integrated radiation therapy solutions, announced today that Peking Union Medical College Hospital has selected the TomoTherapy^® treatment system to advance its cancer care capabilities. Located in Beijing, the teaching hospital is one of the most prestigious healthcare facilities in China and a leader in radiation oncology that treats more than 200 patients per day. Peking Union will become the first Ministry of Health system-based general hospital in Beijing to offer TomoTherapy technology.

“After comparing a number of radiation therapy options, we chose a TomoTherapy treatment system in order to provide the most integrated, advanced treatment platform in the world,” said Dr. Fuquan Zhang, chairman of Radiation Oncology at Peking Union Medical College Hospital. “We expect that TomoTherapy will provide advantages compared to traditional delivery methodologies, and that the simple operational platform will help increase throughput for many complex cases, while helping reduce the chance for mistakes. In other words, TomoTherapy is an efficient and advanced system that meets our demanding clinical environment.”

The TomoTherapy treatment system will be used to treat the hospital’s most challenging cases, starting with head, neck and gynecological cancers. The system’s unique helical IMRT capability enables clinicians to deliver highly conformal dose distributions to complex tumors. Additionally, the integrated CT image guidance offered by the TomoTherapy platform allows for precise patient positioning based on internal anatomy at time of treatment. This feature helps increase treatment delivery accuracy and ensure that radiation exposure to surrounding organs and tissue is minimized.

“Peking Union Medical College Hospital has a strong reputation throughout China for its radiation oncology services. With the addition of the TomoTherapy platform, clinicians there can advance their treatment capabilities with IG-IMRT, allowing them to better address more complex cases,” said Paul Baumgart, general manager of TomoTherapy’s Asia-Pacific Operations. “The introduction of TomoTherapy technology at Peking Union will provide a great showcase of the platform’s capabilities for the Chinese market, and is evidence of the growing demand for our solution in Asia.”

The TomoTherapy treatment system was sold to Peking Union Medical College Hospital by the company’s Chinese distributor TomoKnife. The system is expected to be installed later this year.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements
Statements in this release regarding future products or product capabilities, events, expectations and other similar matters, including but not limited to statements using the terms “expect,” “expected,” “should” or “will” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company’s control, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TomoMobile, TomoHD, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

SPRINGFIELD, OH–(Marketwire – June 30, 2010) –  AdCare Health Systems, Inc. (NYSE Amex: ADK), an Ohio-based long-term care, home care and management company, has priced a public offering of 1,714,286 shares of its common stock at $3.50 per share. AdCare expects to receive net proceeds of approximately $5.5 million from the sale of the common stock. AdCare has granted a 30-day option to the underwriter to purchase up to an additional 15% or 257,143 shares to cover over-allotments. The offering is subject to customary closing conditions and is expected to close on Friday, July 2, 2010.

AdCare plans to use the net proceeds of the offering for acquisition purposes, working capital and general corporate purposes. C.K. Cooper & Company is acting as the sole manager for the public offering.

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission (SEC) on May 4, 2010, which became effective on June 23, 2010. The offering will be made by a prospectus supplement and accompanying base prospectus, copies of which have been filed with the SEC.

Copies of the prospectus supplement and accompanying base prospectus may be obtained from the SEC’s website at www.sec.gov or from C.K. Cooper & Company, 18300 Von Karman Avenue, Suite 700, Irvine, California 92612, Attention: Hue Lapham/Syndicate Department, or [email protected], or via fax +1-949-477-9211.

This press release does not constitute an offer to sell or solicitation of an offer to buy any securities. Any such offer may be made only pursuant to the company’s prospectus supplement and accompanying base prospectus for the offering and only in states in which the offering is registered or exempt from registration and by broker-dealers authorized to do so. The securities offered by the prospectus involve a high degree of risk.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) develops, owns and manages assisted living facilities, nursing homes and retirement communities and provides home healthcare services. Prior to becoming a publicly traded company in November of 2006, AdCare operated as a private company for 18 years. AdCare’s 900 employees provide high-quality care, management services and other services for patients and residents residing in 19 facilities, seven of which are assisted living facilities, 11 skilled nursing centers and one independent senior living community. The company owns eight of those facilities. In the ever-expanding marketplace of long-term care, AdCare’s mission is to provide quality healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Safe Harbor Statement
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law. Such forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available to management, and involve known and unknown risks, results, performance or achievements of the company which may differ materially from those expressed or implied in such statements. Such factors are identified in the public filings made by the company with the Securities and Exchange Commission and include the company’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements.

LOS ANGELES, CA–(Marketwire – June 30, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) today gave guidance in the form of projected sales, portions of which may be recognized as deferred revenue (“Sales”). For the 12 months ending December 31, 2010 the Company expects Sales of $2.7 million or 350 percent over 2009. Based on the knowledge of management today, the Company also projects Sales of $28 million for the 12 months ending December 31, 2011 or an increase of over 800 percent. Sales for the first six months of 2010 are expected to exceed the first six months of 2009 by more than 20 percent not including any revenues from International Licensing in 2010. This demonstrates that the Company’s core Sales are growing at a pace of over 100 percent after excluding the licensing revenues the Company reported last year. These projections do not include revenues from Chartis in 2010 which may occur, or any revenues from new affinity sales, China, India, integration to wireless devices, clinical trials, biotech assets or revenue that may be recognized through acquisitions.

According to Ingrid Safranek, Chief Financial Officer, “With the launch of MMRPro, the Company is taking the proactive step of early-adopting Accounting Standards Update (“ASU”) 2009-13, Revenue Recognition (Topic 605) Multiple-Deliverable Revenue Arrangements. This allows the Company to consistently record revenue on these sales up to and through the Company’s mandatory adoption date of January 1, 2011. Additionally, this new ASU is closer to the FASB’s proposed alignment with International Financial Reporting Standards. Adoption of this new standard results in revenue being reported earlier than under the old accounting rules.”

“Management has taken what we believe to be a cautious approach to our guidance by carefully evaluating our sales and marketing agreements, distribution channels and long lead times for time-to-market, which the Company has experienced in the past,” added Safranek.

The Company has modeled patient upgrades internally as follows: Patient upgrades will come from MMRPatientView through MMRPro sales from resellers and distributors, and National Payment Providers (“NPP”). The Company projects that the average MMRPro user will have 2.5 physicians, each with 2,000 active patient charts, or 5,000 patients per MMRPro placement. The Company projects that doctors will upgrade an average of two patients per month to MMRPatientView (www.mmrpatientvideos.com ),which should continue to increase year-over-year as the public becomes more aware of the importance of having a personal health record (“PHR”) and the government mandates the use of PHRs in healthcare reform. Physicians receive 35 percent of all revenue from patient upgrades, which the Company believes can result in substantially more income to doctors than the $44,000 in government stimulus programs. Kodak distributors and resellers and NPP receive an additional 15 percent as long as their MMRPro sale is active which should be no less than three years.

According to Robert H. Lorsch, Chairman and Chief Executive Officer of MMRGlobal, “In addition to the Company’s core business, we foresee incremental growth from the effects of an acquisition strategy by adding business units that sell complementary products and services to MMRPro customers, and from our targeted expansion into the Pacific Rim with Kodak, and India with Nihilent. As part of the acquisition strategy, the Company could introduce a full-blown Electronic Medical Records product after meaningful use criteria are finalized. We continue to work with GRSworldwide on opportunities to introduce the Company’s products and services to the clinical trials market. Also, it is impossible to predict revenues, if any, which could come from the Company’s pre-merger Favrille biotech assets. While the Company continues to explore opportunities involving those assets, we remain focused on our core business, which is the development and marketing of professional and consumer-based health information technology products and services.”

Last Sunday, on June 27^th, the Company ran a 30-second commercial during the 37th Annual Daytime Emmy Awards primetime television special. The Company converted more than 20 percent of all visitors to its website to an e-mail address and more than 5 percent to paid accounts despite a 30-day free trial. MMR will continue to exploit its commercial advertising on the Web and in direct marketing materials through its agreement with E-Mail Frequency.

The Company is in the process of translating its consumer websites into seven foreign languages in support of its Chartis agreement and believes that once completed, this could result in additional licensing and/or direct international marketing opportunities. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com, www.mmrpro.com and view our product videos at www.mmrtheater.com.

About MMRGlobal, Inc.
MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, the risk the Company’s products are not adopted or viewed favorably by the healthcare community, risks related to the current uncertainty and instability in financial and lending markets, timing and volume of sales and installations, length of sales cycles and the installation process, market acceptance of new product introductions, ability to establish and maintain strategic relationships, ability to identify and integrate acquisitions, relationships with licensees, competitive product offerings and promotions, compliance with and changes in government laws and regulations and future changes and initiatives in the healthcare industry, undetected errors in our products, risks related to third party vendors, risks related to obtaining and integrating third-party licensed technology, acceptance of the Company’s marketing and promotional campaigns, risks related to a security breach by third parties, maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets, uncertainties associated with doing business internationally across borders and territories, and additional risks discussed in the Company’s filings with the Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. 

Click here to see all recent news from this company

SPRINGFIELD, OH–(Marketwire – June 29, 2010) –  AdCare Health Systems, Inc. (NYSE Amex: ADK), an Ohio-based long-term care, home care and management company, intends to offer shares of its common stock in an underwritten public offering. C.K. Cooper & Company is acting as the sole manager for the public offering.

AdCare plans to use the net proceeds of the offering for acquisition purposes, working capital and general corporate purposes.

AdCare previously filed a registration statement, together with the accompanying base prospectus, with the Securities and Exchange Commission (SEC) on May 4, 2010, which became effective on June 23, 2010. Investors are advised to carefully consider the investment objectives, risks and expenses of AdCare before investing. The base prospectus contains certain information about AdCare and should be read carefully before investing. A prospectus supplement describing the particular terms of the offering will be filed with the SEC and will form a part of the effective registration statement. When available, copies of the prospectus supplement and accompanying base prospectus may be obtained from the SEC’s website at www.sec.gov or from C.K. Cooper & Company, 18300 Von Karman Avenue, Suite 700, Irvine, California 92612, Attention: Hue Lapham/Syndicate Department, or [email protected], or via fax +1-949-477-9211.

This press release does not constitute an offer to sell or solicitation of an offer to buy any securities. Any such offer may be made only pursuant to the company’s prospectus for the offering and only in states in which the offering is registered or exempt from registration and by broker-dealers authorized to do so. The securities offered by the prospectus involve a high degree of risk.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) develops, owns and manages assisted living facilities, nursing homes and retirement communities and provides home healthcare services. Prior to becoming a publicly traded company in November of 2006, AdCare operated as a private company for 18 years. AdCare’s 900 employees provide high-quality care, management services and other services for patients and residents residing in 19 facilities, seven of which are assisted living facilities, 11 skilled nursing centers and one independent senior living community. The company owns eight of those facilities. In the ever-expanding marketplace of long-term care, AdCare’s mission is to provide quality healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Safe Harbor Statement
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law. Such forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available to management, and involve known and unknown risks, results, performance or achievements of the company which may differ materially from those expressed or implied in such statements. Such factors are identified in the public filings made by the company with the Securities and Exchange Commission and include the company’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements.

MADISON, WI–(Marketwire – June 29, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, announced today that it has signed an equipment supply group purchasing agreement with Premier Purchasing Partners, L.P., the group purchasing unit of Premier, Inc. The agreement provides TomoTherapy greater reach into Premier’s not-for-profit hospitals and health centers, which includes 2,300 U.S. hospitals and more than 67,000 other healthcare facilities, while enabling Premier members to access special pricing and terms for innovative radiation oncology solutions and establishing a streamlined purchasing solution for them.

TomoTherapy’s radiation therapy solutions enable high treatment quality for a broad patient population, with capabilities to treat cancers throughout the body.

“We are pleased to be partnering with Premier, the leading group purchasing organization serving not-for-profit healthcare institutions,” said Fred Robertson, TomoTherapy CEO. “In addition to providing TomoTherapy expanded reach through Premier’s network, this agreement will offer Premier’s members better access to highly precise cancer treatment solutions.”

About Premier Healthcare Alliance
Premier is a performance improvement alliance of more than 2,300 U.S. hospitals and 67,000-plus other healthcare sites working together to achieve high quality, cost-effective care. Owned by not-for-profit hospitals, Premier maintains the nation’s most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier works with the Centers for Medicare & Medicaid Services and the United Kingdom’s National Health Service North West to improve hospital performance. Headquartered in Charlotte, N.C., Premier also has offices in San Diego, Philadelphia and Washington. http://www.premierinc.com.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

NEW YORK, NY–(Marketwire – June 29, 2010) –  Neostem (NYSE Amex: NBS) was cleared for manufacturing penicillin and cephalosporin powder for injection at its new manufacturing facility by China’s State Food and Drug Administration. The news helped convince WBB Securities to upgrade the company from ‘sell’ to ‘hold’.

WBB Securities initially extended coverage on Neostem on June 3, 2010 with a ‘sell’ recommendation, however, it should be noted that the investment banking firm began touting four other stem cell companies in late April. The fact that Neostem raised $5 million in cash through a placement in late June had no bearing on the investment banker’s outlook, however, after the Chinese State Food and Drug Administration cleared the way to begin selling drugs manufactured at Neostem’s new, state-of-the-art facility in China, WBB Securities analysts had second thoughts and upgraded the company’s shares.

Neostem announced Tuesday morning that two of its manufacturing lines were up and running at its China pharmaceutical manufacturing unit which would increase production capacity by more than 50%. With that country’s State FDA giving the green light to manufacture penicillin and cephalosporin powder for injection, sales forecasts are expected to show substantial gains.

Based on sales results for 2009 and the new manufacturing plant’s increased capacity, sales could increase by more than $20 million.

Neostem founder and CEO, Dr. Robin Smith, noted that Eyre was one step closer to becoming “one of the largest antibiotic producers in Eastern China.”

Note to Editors: “News Features” are stories provided to publishers copyright-free for print or online display at no charge. All we ask is that publishers include our byline (AXcess News) as the source, or if online, link to our Web Site: http://www.axcessnews.com. If you are interested in displaying our news on a regular basis, please contact our editorial department at: 775-461-0362 or by email at: [email protected].

Click here to see all recent news from this company

LAS VEGAS, NV–(Marketwire – June 29, 2010) –  VisualMED Clinical Solutions Corp. (The “Company”) (PINKSHEETS: VMCS) (FRANKFURT: VA6) announces that it has received in the past three weeks firm orders for its Clinical Information System from independent private medical facilities worth an aggregate amount of 2.6 million.

The deals are multi-year rental agreements that will see the deployment of the Company’s signature smart Electronic Health Record, with full CPOE, decision support and medical alerts, over the next 3 months. A significant part of the implementation support and help desk will be outsourced for greater speed and efficiency.

Starting in April the Company has been receiving increasing requests for quotes as medical facilities seek to meet the 2011 deadline for the first and largest disbursement to physicians under ARRA provisions. The key for physicians to secure these payments is meeting the meaningful use criteria which can only be demonstrated by using a true intelligent CPOE such as the ones VisualMED has been offering for many years.

“Thanks to the new reforms our time has come,” says Chairman Gerard Dab. “We are now becoming a mainstream product line that helps physicians meet new regulatory standards. Providers have only five years to implement systems that offer meaningful use before they face punitive measures, and there is a shortage of expertise in the marketplace to do so.” 

VisualMED appears to be benefiting from the new regulatory environment created by the Healthcare Information Technology provisions of the American Recovery and Reinvestment Act (ARRA), which has earmarked close to $40 Billion to promote the widespread adoption of systems that correspond to federal norms of meaningful use, such as those owned and marketed by the Company since 2006.

Medical institutions are under increasing pressure to adopt such technologies. There is an industry-wide rush to identify systems that can help physicians qualify for federal ARRA reimbursement grants. This has led to an increased demand for products and services from companies that can deliver the rich medical content and suitable interoperability required.

The Company continues to work with its network of licensees and will seek to expand its network of strategic alliances. It expects to be profitable for a second consecutive year and has continued to contain operating costs.

ABOUT VISUALMED

VisualMED markets smart EHR with Clinical Information Systems (CIS) and Computerized Physician Order Entry that meet the new regulatory environment ushered in by the American Recovery and Reinvestment Act of 2009 and the Health Reform Act of 2010.

We offer a powerful technology platform both scalable and interoperable, developed at a cost of some forty million dollars and tested over many years in tertiary care and ambulatory environments.

Our solutions help medical facilities reduce mortality and morbidity due to medical errors, increase provider efficiency and bring down operating costs. Their key clinical components are a core solution in the new agenda to promote greater patient safety and reduce risks due to medication errors.

Detailed information on our company and its products is available on our web site at www.visualmedsolutions.com

FORWARD-LOOKING STATEMENTS

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of the Company. These statements are based on suppositions and uncertainties as well as on management’s best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for the Company’s products and services, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

WEST HARTFORD, CT–(Marketwire – June 29, 2010) –  ORLive, the vision of improving health, presents a personalized partial knee replacement surgery. Presented by ConforMIS, the surgery will be broadcast live from University of Wuerzburg Orthopedic Center for Musculoskeletal Research.

This week ORLive also invites you take part in the latest installment of the Virtual Brain Tumor Board, and to watch and learn from our library of spine surgery videos.

NEW ON ORLIVE

LIVE SURGERY — German Language Broadcast to Europe, Featuring ConforMIS iUni^® G2 Patient Specific Partial Knee Replacement System
Live June 29, 2010, 11:00 AM EDT

Live from the University of Wuerzburg Orthopedic Center for Musculoskeletal Research, a live partial knee replacement surgery using the ConforMIS iUni^® G2 system. The broadcast will feature Dr. Wolfgang Fitz of Brigham and Women’s Hospital, Dr. Ulrich Nöth and Dr. Maximilian Rudert, both of the University of Wuerzburg Orthopedic Center for Musculoskeletal Research, presenting and performing the surgery. Learn more about this broadcast, presented entirely in German, at http://www.orlive.com/conformis-inc-/videos/n-chste-generation-patienten-spezifischer-knieoberfl-chenersatz-mit-conformis-iuni-sup-/sup-g2-17-00-uhr-mez-1.

Viewers will be able to interact and ask questions via the ORLive website. Learn more about this program, and request a reminder on ORLive.com.

ORLIVE REFERRALS — Week of June 28, 2010
Each week ORLive highlights on-demand videos for our membership and visitors.

Spine Health Referral: XLIF^® Procedure from Tampa General Hospital

CME Referral: Complex Cases in Cardiovascular Anesthesiology

Viewer’s Referral: Revision Knee Surgery Featuring the Zimmer^® NexGen^® LCCK System, from Zimmer

HIGHLIGHTS

NOW ON-DEMAND — Advances in Treating Pediatric Epilepsy
Now Available On-Demand

If a child’s seizures can’t be controlled with medications, surgery may be the solution. See how the Neurosurgical team at NewYork-Presbyterian Phyllis & David Komansky Center for Children’s Health is making advancements in epilepsy. Hosted by Philip Stieg, MD, PhD, and featuring Jeffrey Greenfield, MD, PhD, Samual Weinstein, MD, and Theodore Schwartz, MD, this program goes in depth into the latest surgical advancements and options for patients.

Viewers of this video are invited to interact with the surgeons via the ORLive website, and to join the community and receive regular updates from the NewYork-Presbyterian Phyllis & David Komansky Center for Children’s Health on pediatric epilepsy.

LIVE PROGRAM: Minimally Invasive Heart Surgery: Robot Assisted Mitral Valve Repair
Now Available On-Demand

Baptist Health South Florida will take center stage when viewers watch as cardiac surgeon Dr. Lynn Seto uses the da Vinci Robotic Surgical System to perform a mitral valve repair.

The webcast will be moderated by television personality Diane Magnum. She will moderate commentary by Dr. Seto and cardiologists Dr. Paul Seigel and Dr. Romeo Majano, who will explain the benefits of having valve repair surgery. Additionally, the patient who was operated on in late May will share his experience about his diagnosis and recovery. Viewers also can choose to watch the procedure in Spanish.

SUPPLEMENTAL CONTENT — VOX ORLive
This procedure is also featured in an episode of VOX ORLive, an audio podcast featuring the latest advancements in medicine, surgery, and medical technology.

About ORLive
ORLive is the leading provider of video communication channels to the healthcare community. Working collaboratively with hospitals and device manufacturers, ORLive produces and distributes customized, interactive, video programs that demonstrate the latest advances in medicine, surgical techniques and product innovations. The ORLive broadcasting network provides an intimate look at over 650 live and on-demand surgeries to a global audience, streaming over 50,000 hours of programming each month. The ORLive network can be found on-line at www.ORLive.com.

id=”nav_links”>

ORLANDO, FL–(Marketwire – June 29, 2010) –  Five-year results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study confirm that neither more intensive lowering of blood glucose (sugar) levels, more intensive lowering of blood pressure, nor treatment of blood lipids with a fibrate and a statin drug reduce cardiovascular risk in people with established type 2 diabetes who are at severely high risk for cardiovascular events. However, the study did find improvements to microvascular conditions, such as progression of diabetic eye disease (retinopathy), visual acuity, and renal and nerve function. The landmark study is sponsored by the federal government through the National Institutes of Health (NIH).

Speaking at the American Diabetes Association’s 70th Scientific Sessions^®, the ACCORD Study Group cautioned that any potential benefits must be weighed against the increased risk of mortality and episodes of seriously low blood glucose that were seen to accompany intensive lowering of blood glucose levels — which in ACCORD was focused on achieving normal A1C levels in the study population. They emphasized that both the positive and negative results of the study apply only to this population of middle-aged or older people with type 2 diabetes for an average of 10 years, who also had a history of cardiovascular disease (CVD) or at least two risk factors for CVD.

“These results underscore the importance of patient-centered care that stresses individual treatment choices made in consultation with a physician,” said Denise Simons-Morton, MD, Ph.D, Director of the Division for the Application of Research Discoveries at the NIH’s National Heart, Lung and Blood Institute (NHLBI), the primary sponsor of the study. “Within this group, it’s important for patients and doctors to decide the highest priority for the patient,” she said. “Is improved eye health worth a higher risk of death and low blood sugar episodes? That’s a question only a fully informed patient can answer.”

The ACCORD researchers set out to investigate whether cardiovascular risk in people with type 2 diabetes could be reduced using one of the following strategies, each compared with standard treatment: intensive lowering of blood glucose to near-normal levels (target A1C less than 6%), intensive lowering of blood pressure to near-normal levels, or treatment of blood lipids with a combination of fibrate and statin drugs. It also looked at how each of these treatments would affect other outcomes such as mortality and microvascular outcomes (e.g., eye, kidney and nerve complications). 

NHLBI prematurely halted the intensive blood-glucose lowering strategy after 3.5 years, in February 2008, due to safety concerns caused by an unexpected higher incidence of death in the intensive glucose lowering treatment group compared with the standard treatment group. Patients in the intensive treatment arm of the study were transitioned into the standard treatment arm for the remainder of the trial’s five years, which has now concluded.

Intensively Lowering Blood Glucose: Increased Mortality and No Cardio Benefit, But Possible Benefits to Eyes, Kidneys and Nerves

Results of intensive glucose lowering on microvascular outcomes were published today in the Lancet and presented at a symposium at the American Diabetes Association’s 70^th Scientific Sessions in Orlando.

The study examined patients who underwent intensive glucose-lowering treatment for 3.5 years (increased medication aimed at lowering A1C levels to less than 6 percent) and were then given standard treatments (aimed at achieving A1C levels of 7.0-7.9%) for the remaining 1.5 years, compared with standard treatment for the duration of the study. The intensively treated patients did not see a reduced incidence of cardiovascular disease.

In addition, the groups did not differ in overall measures of microvascular health, for example, in the progression rates to kidney failure, major vision loss, or advanced peripheral neuropathy, a common nerve problem in diabetes that usually begins as tingling or numbness in the feet. However, there were some microvascular improvements noted, such as a reduced incidence of albuminuria (protein in the urine, a marker of kidney disease) in the intensive group, compared to those receiving standard treatment, along with fewer cataract extractions during the study period. Visual acuity (sharpness of vision) and nerve function scores were also better for the intensive group than for the standard-treatment group, suggesting that intensive lowering of blood glucose may also help prevent eye and nerve damage.

“Patients who develop macroalbuminuria are prone to renal failure and cardiovascular events,” said Faramarz Ismail-Beigi, MD, Ph.D, of Case Western Reserve University and the lead researcher on this portion of the study. “Less protein in the urine is a very good sign.”

Though the visual acuity tests were somewhat subjective, Ismail-Beigi said, they could indicate that intensive glucose lowering helps to prevent eye damage.

Intensively Lowering Blood Glucose, Treating Lipids: Slows Retinopathy Progression

That finding is further supported by a substudy of ACCORD chaired by Emily Chew, MD, chief of the Clinical Trials Branch of the Division of Epidemiology and Clinical Applications at the NIH’s National Eye Institute (NEI). Results of the study were published online in the New England Journal of Medicine today. Chew and her colleagues investigated whether each treatment arm of the ACCORD trial — blood glucose, blood pressure, and blood lipids — would reduce the progression of diabetic eye disease (or retinopathy) in a subset of about 3,000 ACCORD study participants, compared to that treatment’s standard approach. Disease progression was identified through retinal photographs that indicated blood vessel changes or by the need for laser or vitrectomy surgery to treat abnormal blood vessels.

The study found that people in the intensive blood glucose lowering arm, as well as those who received a combination of a fibrate and a statin for blood lipids, experienced slower progression in diabetic retinopathy than those in each standard treatment arm. Those who were in the intensive blood pressure lowering arm did not see a reduction in eye disease progression when compared to people receiving standard blood pressure control.

Compared with standard blood glucose control, intensive control decreased the progression of diabetic retinopathy by about one-third, from 10.4 percent to 7.3 percent, over four years. Participants in the intensive control group had a median blood glucose level of 6.4 percent hemoglobin A1C — a level close to values in people without diabetes. The standard blood glucose control group maintained a median level of 7.5 percent.

In addition, compared with simvastatin treatment alone, combination lipid therapy with fenofibrate plus simvastatin also reduced disease progression by about one-third, from 10.2 percent to 6.5 percent, over four years. No prior clinical trial has shown that the combination of fenofibrate and simvastatin reduces diabetic eye disease progression.

Contrary to predictions, there was no difference in diabetic retinopathy progression among participants treated to an intensive systolic blood pressure (the top number in a blood pressure reading) target of less than 120 mm Hg, compared with those treated to a standard target of less than 140 mm Hg.

“The results of the ACCORD Eye Study indicate that intensive blood sugar control and combination fibrate plus statin treatment of lipids independently reduce diabetic retinopathy progression,” Chew said. “However, patients and their doctors should work together to develop an individual treatment plan, taking into account the potential risks of intensive glucose treatment.”

Combination Lipid Treatment: No Cardio Benefits Overall, But Subgroup May See Reduced Risk

Combination lipid therapy with a statin plus a fibrate did not help lower cardiovascular risks overall, but the results did suggest that a subgroup of the study — those with high triglycerides and low HDL (the so-called “good” cholesterol) — may benefit by such treatment.

In this subpopulation of the investigation, which included about 15 percent of the 5,518 people studied in the ACCORD Lipid Trial, those who had triglyceride levels of more than 200 and HDL levels below 34 saw a reduced incidence of cardiovascular events of 30 percent. These findings are supported by similar findings of subgroup populations in several large previously published clinical studies.

“If it were an isolated finding in our study I’d be less enthusiastic,” said Henry Ginsberg, MD, Irving Professor of Medicine and Director of the Irving Institute for Clinical and Translational Research at Columbia University. “But this finding is in line with subgroup analyses in several other trials.”

A second subgroup analysis of this arm of the study found that women and men respond differently to combination lipid therapy, Ginsberg said. Though overall the study found no cardiovascular benefits for the study population, when broken down by gender, the results showed men experienced a 20 percent reduction in cardiovascular events, while women experienced a 38 percent increase in cardiovascular events.

However, when examined for statistical significance, “the data for men showed a strong indication that they benefitted, while the data for women were not as conclusive,” Ginsberg said. “This raises possibilities that need to be further examined.”

These results were published in the April 29, 2010, issue of the New England Journal of Medicine.

Intensively Lowering Blood Pressure: No Cardio Benefits, But Suggested Reduction in Stroke

Results from the intensive blood pressure control arm of the study were also published in April in the New England Journal of Medicine. In this treatment arm, participants lowered blood pressure levels to “normal” levels of less than 120 mm Hg, to see if doing so would reduce major cardiovascular events, compared with standard treatment of levels less than 140 mm Hg. No significant reduction in overall CVD events was found.

The study did find a significant (41 percent) reduction in stroke, which was consistent with other BP-lowering clinical trials. However, because this was not the primary focus of the study, and because the overall rate of stroke was low, the researchers are hesitant to recommend a strategy of lowering blood pressure to this degree without further study.

“Older patients with known cardiovascular disease, higher blood pressure to begin with, and African Americans may benefit from such a treatment plan,” said William Cushman, MD, of the Memphis Veterans Affairs Medical Center, “but we’re going to have to do further analyses.”

The NHLBI is the primary sponsor of ACCORD, with additional funding and scientific expertise contributed by the National Institute of Diabetes and Digestive and Kidney Diseases. Other components of the NIH — including the National Institute of Aging — as well as the Centers for Disease Control and Prevention, support substudies. The following companies provided study medications, equipment, or supplies: Abbott Laboratories, Amylin Pharmaceutical, AstraZeneca Pharmaceuticals LP, Bayer HealthCare LLC, Closer Healthcare Inc., GlaxoSmithKline Pharmaceuticals, King Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Pharmaceuticals, Inc., Novo Nordisk, Inc., Omron Healthcare, Inc., Sanofi-Aventis U.S., and Takeda Pharmaceuticals, Inc.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

Symposium, June 29, 10:15 a.m.

id=”nav_links”>

NEW YORK, NY–(Marketwire – June 29, 2010) –  Interactivation Health Networks, parent company of the Newborn Channel and Patient Channel, the nation’s most comprehensive in-hospital TV networks, today announced the appointment of Chana Stern as Account Executive, Ad Sales, for both channels.

Formerly with Everwell TV, Chana joins Interactivation with over 10 years experience in the Out-of-Home media space. A seasoned executive, Chana will provide agencies with an additional point of contact for advertisers seeking expertise in point of care, place based media, as demand for both networks continues to grow.

“Demand for digital out-of-home video advertising, particularly as it relates to hospitals as a fourth screen location, has grown significantly over the past year,” said Suzanne Fleming SVP of Sales at Interactivation Health Networks. “Chana’s familiarity with both place based media advertising and the health industry at large will be key assets for us as we continue to meet the needs of our growing list of advertisers.”

Newborn Channel and Patient Channel provide marketers with unparalleled access to their target consumers in a highly trusted environment. 

About Interactivation Health Networks
The Patient Channel and The Newborn Channel are the most comprehensive in-hospital TV networks. Delivered directly to patient rooms and waiting areas, the Channels provide viewers with original, award-winning health programs and advertisers with the unique ability to integrate brand messaging with content that is compelling and endorsed by healthcare professionals. The Newborn Channel broadcasts baby care and postpartum programming for new parents, reaching 60% of new moms. The Patient Channel features both condition-specific and preventative health programming to empower and inform patients. The channels are currently available in over 2,700 hospitals nationwide.

ROCKVILLE, MD–(Marketwire – June 29, 2010) –  MarketResearch.com has announced the addition of Kalorama Information’s new report “Long Term Care Market: Nursing Homes, Home Care, Hospice Care, and Assisted Living,” to their collection of Home Healthcare market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2578516

Kalorama Information publishes its third edition of this detailed report on the long term care industry at a time of growth but also change and concern for the long term care industry. The economy has challenged the business strategies of key players, while the recent healthcare legislation introduces changes that may affect revenues. These twin challenges are addressed in The Long-Term Care Market: Nursing Homes, Home Care, Hospice Care, and Assisted Living The report provides an in-depth examination of the market for long-term care today. The following segments are broken out in detail: This report covers the most important segments of the long term care industry, each of which provide medical care and/or assistance with the activities of daily living (ADLs) on an ongoing basis:

• Nursing care;
• Home Care;
• Hospice Care;
• Assisted Living.

Excluded are markets that address temporary care needs such as physical or mental rehabilitation. Residential living programs and facilities that do not generally provide care such as retirement communities.

For each of the segments of long term care the report provides:

• Market Size and Forecast
• Number of Facilities/Providers and Growth Trends
• Patient Statistics
• Forms of Payment and Reimbursement Levels
• Trends Affecting the Marketplace
• Competitors and Competitive Analysis

Sales estimates for each market segment represent U.S. revenues and are expressed in current dollars. Estimates are provided for the historic 2005 to 2009 period and forecasts are provided through 2015.

As part of the report’s analysis of the state of the industry, the report covers the Recent Healthcare Reform and its Impact on Nursing Homes and the Effects of the Economy. Other issues and trends discussed in the report include:

• Medicare & Health Care Reform
• Patient Dumping
• Quality of Care
• Federal Quality Improvement Initiatives
• State Quality Improvement Initiatives
• Legal Actions
• Safety
• Aging of the Population
• Marital and Living Arrangements
• Geographic Concentrations
• Certification and Accreditation
• Fees and Payment
• Long Term Care Insurance
• Cost of Coverage and Affordability
• Staffing and Human Resources
• Building of New Facilities 

Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives were conducted to capture the perspectives from industry participants’ point of view and assess trends, and form the basis of the forecasting and competitive analysis.

As part of its coverage of the industry, the following long term care companies were profiled in this report:

• Apria Healthcare Group Inc./ Blackstone Group
• Brookdale Senior Living
• Emeritus Corporation
• Extendicare, Inc.
• Genesis Healthcare
• Golden Living
• Manor Care, Inc.
• Sun Healthcare Group Inc.
• Sunrise Senior Living Inc.

For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2578516.

Click here to see all recent news from this company

BOCA RATON, FL–(Marketwire – June 29, 2010) – Banyan Corporation (PINKSHEETS: BNYN) announced that its board of directors has agreed to the formation of a new operating unit of the company called “America’s Dentist.”

This operating division will focus on the multi-billion dollar dental industry and is establishing itself to provide marketing, finance, practice management and branding to the dental community. The company feels that it will be able to bring significant value added to a broad array of dental practices.

Banyan Corporation believes it can leverage off its significant experience with Chiropractic USA, as well as with its existing operations in its diagnostic imaging business, to move into the dental arena.

About Banyan Corporation:

Banyan Corporation is a publicly traded holding company focused on investing in and building a network of operating subsidiaries engaged in various innovative businesses. Currently the company’s subsidiaries, Premier Medical Group, Inc. and affiliated companies, provide diagnostic testing services to physicians nationwide.

This Press Release contains or incorporates by reference forward-looking statements including certain information with respect to plans and strategies of Banyan Corporation. For this purpose, any statements contained herein or incorporated herein by references that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “suggests,” “anticipates,” “plans,” “expects,” and similar expressions are intended to identify forward-looking statements. There are a number of events or actual results of Banyan Corporation operations that could differ materially from those indicated by such forward-looking statements.

DALLAS, TX–(Marketwire – June 29, 2010) – As a result of the health care reform law that was recently passed, organizations that process health care claims must take action to comply with the new regulation. To assist organizations, SOURCECORP, Incorporated, a premier business process outsourcing company, has released a new white paper, “Is Your Claims Processing Destined for Success in the Face of Government-Driven Change?” This complimentary document explains some of the law’s requirements and demonstrates why outsourcing is an efficient and cost-savvy way for organizations to adhere to the new standards.

The Patient Protection and Affordable Care Act is expected to cause an increase in enrollments, which will lead to growth in claims processing and customer service assistance. Payer companies and organizations must also convert to HIPAA 5010 standards and enact changes in medical coding from ICD-9 to ICD-10 as of October 1, 2013. In order to meet these mandates, these organizations will need to upgrade their software systems and implement other new processes.

There are many benefits of outsourcing the administrative burden that will come with the predicted surge in enrollment. Utilizing a subcontracting model will lower the operational cost of processing claims and responding to customer needs, and reduce the cost associated with the technology that must be used in order to comply with the law. It also helps ensure that organizations will meet the terms of the legislation, giving companies expert advice on this new platform.

Outsourcing will help organizations meet the demands of the rapid increase in enrollment, as well as the costs to manage additional insured customers. While HIPAA implementation and migration to ICD-10 codes are not required until 2013, the Department of Health and Human Services is expecting providers to complete testing by the end of this year.

To execute new HIPAA standards and code changes, most companies will have to update their infrastructure and expend the resources to evaluate and test new software systems. By subcontracting, organizations can eliminate the need for an additional capital expense and make sure the systems are implemented correctly.

Another benefit of outsourcing is that organizations will not need additional space to house equipment or provide additional staff to run the systems. Instead, health care payer companies can optimize their space for revenue-generating activities instead of storing bulky equipment and hosting mailroom operations.

Outsourcing will enable companies to speed up and efficiently process new enrollments and serve customers. Staff members will be able to focus more on customer care rather than tedious administrative tasks. In addition, employees of companies that subcontract can maintain accuracy despite spikes in enrollment and claim processing. Administrative expenses and time can be reduced by nearly 50 percent as a result of hiring a company that specializes in claims processing to meet the new health care reform guidelines.

John Nixon, Senior Vice President of Business Development for SOURCECORP’s BPS division, stated, “Outsourcing to SOURCECORP has helped many companies save on per claim capture costs by an average of $1.2 million to $4.5 million annually. Best of all, we can help ensure that a company will avoid penalties that can be issued from not implementing systems correctly, and from not deploying a new system on time.”

For a complimentary white paper on migrating to the new health care reform standards, visit www.sourcecorp.com/newsroom/white-papers.aspx

About SOURCECORP®
SOURCECORP, Incorporated provides business process outsourcing solutions and specialized high value consulting services to clients throughout the United Sates. SOURCECORP focuses on business processes in information-intensive industries including commercial, financial, government, healthcare, and legal. Headquartered in Dallas, the company serves clients throughout the United States through a network of locations in the U.S., Mexico, Philippines and India.

Click here to see all recent news from this company

CHARLOTTE, NC–(Marketwire – June 29, 2010) –  Patient Care Technology Systems (PCTS), a subsidiary of Consulier Engineering, Inc. (NASDAQ: CSLR), today announced the availability of an upgrade to its software for tracking patients, staff and equipment. The new release of Amelior Tracker 2.8 features multiple improved user interfaces with enhanced search and identification tools to help healthcare staff locate resources as efficiently as possible.

Some key software enhancements include advanced “Map View” configuration options such as popup balloons that enable users to customize the contents and the number of items displayed for each entity when in hover-mode. This allows for a quick view of the details of each entity in its location including: name, serial number, workflow status (clean, in use, dirty), asset type and hospital ID to name a few. Users will also be able to view the actual number of entities in a specific location, rather than just a dot indicating that there is a piece of equipment nearby. Another key feature is a new RTLS Component Health Monitoring module that will enable the user to more effectively and efficiently monitor the status and functionality of the RTLS equipment deployed. Other enhancements include improved zone tree displays, application to use globalization settings to configure date formatting, a textbox available for quick tag id search, and a powerful new keyword search feature that dynamically searches over all attributes of an entity.

Amelior Tracker 2.8 advanced utilization reports help drive purchasing, rental and allocation decisions by analyzing whether the facility is making the best use of the assets it has. The PCTS workflow engine receives and interprets data from the RTLS system applying client-specific business rules to assess status and provide feedback that is critical to drive business processes and asset workflow. These reports provide managers, administrators and process improvement teams with movement, interaction and flow data that assists in spotting trends and identifying situations that may require corrective action, thus providing real-time business intelligence to our clients.

The Amelior Tracker® solution is part of the Amelior Enterprise Visibility and Workflow Automation Suite™ which comprises department to facility-wide software solutions and services designed to more efficiently and safely orchestrate patient care through the real-time visualization of patient flow. Hospitals can scale their implementations by the entities they wish to track (movable medical equipment, patients, staff), purpose (temperature monitoring, asset management, patient flow, infection control) and by the scope of hospital workflow (acute care, inpatient floors, outpatient services, enterprise-wide). 

Amelior Tracker is interoperable with all major locating technologies including active-RFID, infrared, ultrasound, ultra-wideband, Wi-Fi and ZigBee. PCTS also works closely with a network of successful locating hardware partners and provides consulting services so the best locating technology or technologies are chosen to match the client’s particular needs. In addition, the Amelior Interface Gateway™ supports the exchange of data between an Amelior tracking or documentation solution and virtually any hospital information system. Key functions include sending/receiving, data transformation, transaction logging, administration/monitoring and notifications. These platforms work together to offer extensive performance and workflow advantages to the healthcare industry.

“Recent enhancements to our Amelior Tracker software allows us to continue to provide an improved system that requires less time spent locating resources needed to support patient flow and improve staff workflow,” says Chad Sallee, vice president of information technology at PCTS. “The real-time identification and visualization of asset location can help eliminate redundant equipment purchases and leases, improve equipment utilization and preventative maintenance, and track assets as part of infection control protocols.”

About Patient Care Technology Systems

Patient Care Technology Systems, a subsidiary of Consulier Engineering, Inc. (NASDAQ: CSLR), helps health care providers to improve patient flow, increase capacity and improve patient and staff safety by visualizing the real-time location and status of people and equipment throughout their facility. PCTS solutions have supported over 2 million patient visits annually and have shown a proven return on investment in high turnover, high-acuity units such as the emergency department and perioperative suites. The Amelior Enterprise Visibility and Workflow Automation Suite™ is interoperable with all leading locating technologies, including active-RFID, infrared, ultrasound, ultra-wideband, Wi-Fi and ZigBee. PCTS customers have been recognized nationally for improvements in efficiency and clinical excellence. For more information, visit www.pcts.com. 

This press release contains forward-looking statements within the meaning of federal securities laws. PCTS and CSLR caution you that any statements contained in this press release which are not strictly historical statements constitute forward-looking statements. Such forward-looking statements include, but are not limited to, those related to PCTS’s and CSLR’s expectations regarding continued business growth. These statements are neither promises nor guarantees, and involve risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, (copies of which may be obtained at the SEC’s website at: http://www.sec.gov) — could impact the forward-looking statements contained in this press release. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made. PCTS and CSLR disclaim any obligation to publicly update or revise any such statements to reflect any change in PCTS and CSLR’s expectations, or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – June 29, 2010) –  Healthnostics, Inc. (PINKSHEETS: HNSS), a medical and biotechnology analytics company, has initiated its acquisition strategy with cash investments in a medical manufacturing company.

The Company will continue to provide additional details as its acquisition strategy continues to unfold.

“We have now moved from the planning stage to the implementation stage of our acquisition strategy, which means that the positive impact on our sales and earnings will come sooner than originally planned,” said Alan Grofe, President.

About Healthnostics

Healthnostics, Inc. is a medical and biotechnology analytics company that provides comprehensive patient clinical monitoring and risk management systems to acute care hospitals and utilizes its Internet portals to deliver medical and biotechnology resource information to industry professionals as well as to the general public. Healthnostics’ major products include: MedGuardian, a patient care monitoring and risk management system for hospitals that is fully Web-based; and through the MedBioWeb subsidiary, MedBioWorld™, one of the largest professional medical and biotechnology directory resource and reference portal sites on the Internet, and FamilyMedicalNet, a companion consumer healthcare information portal.

For further information please visit Healthnostics www.healthnostics.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com.

And visit us on Facebook at www.facebook.com/Healthnostics.

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

FAIRFAX, VA–(Marketwire – June 29, 2010) –  Avaya Government Solutions, a wholly owned subsidiary of Avaya, today announced the company’s participation in the recently-released study to modernize the healthcare system used by the Department of Veterans Affairs (V.A.). The V.A. relies heavily on this system to ensure America’s Veterans receive the treatment they require. Called the “VistA Modernization Report – Legacy to Leadership,” it is focused on improving the V.A.’s VistA (V.A. Health Information Systems and Technology Architecture) healthcare network.

The V.A. has seen an uptake in the demands of its healthcare system; which must serve nearly eight million veterans, 153 V.A. hospitals and 768 outpatient clinics. VistA is the integrated health information system — recognized as one of the best in the nation — that supports the V.A. in its work.

“The V.A. relies on the best doctors and medical technology,” said Joel Hackney, president, Avaya Government Solutions. “We are honored to be chosen to contribute to the success of this study and help the V.A. make its next-generation, information network the best available. We support the work of the VistA study participants and thank them for their unique contributions in helping define the next-generation Healthcare IT vision.”

“Providing for those who have served this great nation is more than our mandate, it is our passion,” said the Honorable Roger Baker, assistant secretary for Information and Technology and Chief Information Officer, Veterans Affairs. “The VistA study provides critical insight from the leaders in industry as to how we can do this better, more effectively and more comprehensively. This is planned to enable us to employ our resources with laser precision, eliminating waste in terms of time to service and completely eliminating every unused or underused resource.”

Included in the recommendations of the VistA study is the need to migrate the design of the information system of the Veterans Affairs to an open, plug-and-play architecture so that the most modern and “built for purpose” components that enhance functionality can be incorporated. In addition, by moving to an open-standards approach, the VistA system can utilize the best technology from standards-compliant vendors as well as other open source communities that will provide the best, most innovative products in the future.

The VistA study was spearheaded by the American Council for Technology (ACT) – Industry Advisory Council (IAC), which promotes government and industry collaboration. It was managed by the V.A. and Andy Robinson, IAC executive vice chair, for the IAC Executive Committee. Ed Meagher, chair of the IAC VistA Modernization Working Group, led the working group of healthcare and IT professionals from 34 companies for the six-month study, which included co-chair of the VistA Modernization & Architecture subcommittee, Srinath Godavarthi, technical director, Avaya Government Solutions.

Enterprise network modernization is critical for all healthcare entities. HIPPA compliance has mandated that all such systems be ultra-secure in their totality with no margin for error. Avaya is focused on serving the needs of both the Civil Government and Federal Government as well as the Healthcare industry.

About Avaya Government Solutions
Avaya Government Solutions is a network-centric integrator, providing the services expertise, mission-critical systems and secure communications that empower government to ensure the security, livelihood, and well being of its citizens. Headquartered in Fairfax, Va., Avaya Government Solutions offers a one-stop shop for solutions designed to improve workforce productivity, reduce operating costs, and streamline inter-agency communications. Please visit www.Avayagov.com for more information.

About Avaya
Avaya is a global leader in enterprise communications systems. The company provides unified communications, contact centers, data solutions, and related services directly and through its channel partners to leading businesses and organizations around the world. Enterprises of all sizes depend on Avaya for state-of-the-art communications that improve efficiency, collaboration, customer service and competitiveness. For more information please visit www.avaya.com.

ORLANDO, FL–(Marketwire – June 29, 2010) –  A community-based lifestyle intervention program, modeled after one used in a landmark government funded diabetes-prevention study, can help participants in a group setting achieve weight loss and blood glucose reductions comparable to those achieved with individual counseling from health professionals, according to data presented by researchers at the American Diabetes Association’s 70th Scientific Sessions®.

In the Healthy Living Partnerships to Prevent Diabetes (HELP PD) study, participants were divided into two groups: a lifestyle weight loss group, which received six months of weekly behavioral weight loss sessions in a group setting, followed by monthly follow-up meetings, at which they were encouraged to change eating behaviors and exercise up to 180 minutes per week; and a usual care group, which received two visits with a dietitian and a quarterly newsletter with tips for lifestyle changes. The group weight loss sessions were delivered by lay community health workers trained and supervised by dietitians at the Wake Forest Diabetes Care Center in Winston-Salem, North Carolina.

The study found that those in the lifestyle intervention group achieved and maintained significantly greater weight loss (an average of 7.3 percent of body weight) than those in the regular care group (who achieved an average loss of just 1.3 percent of body weight) after 12 months. The lifestyle intervention group also reduced blood glucose levels by an average of over 4 mg/dl, from 105.8 mg/dl to 101.2 mg/dl, after 12 months, compared to an average drop of less than 2 mg/dl (to 104 mg/dl) for the regular care group. The results for the lifestyle group mirrored those achieved over three years by participants in the landmark National Institutes of Health-sponsored Diabetes Prevention Program, in which individuals with glucose levels in the pre-diabetic range were able to reverse the course of their disease by losing 5-7% of body weight and exercising 150 minutes per week, in addition to receiving individual counseling sessions with trained behavioralists. In the Diabetes Prevention Program, the weight loss program led to a 58% reduction in the development of diabetes, from about 11% a year to about 5% a year.

“In the Diabetes Prevention Program, professional behavioral specialists worked with participants with pre-diabetes in one-on-one sessions. We trained some of our patients with diabetes to work as lay community health workers with groups of participants with pre-diabetes, so we really didn’t expect to see quite as good a weight loss result as we did, but we were very pleased to see it,” said David Goff, MD, Chair of the Department of Epidemiology and Prevention at Wake Forest University School of Medicine, and lead researcher on the study. “Given that our weight loss results look as good as the DPP, this approach shows great promise for preventing diabetes. It’s a very translatable intervention to deliver in public health settings. We think this approach could be replicated at Diabetes Care Centers across the country.”

There are more than 3,000 such centers in the United States, with on-site physicians, diabetes educators and facilities that can be used for delivering the type of group intervention employed in this study. However, the intervention can be delivered in any setting where community health workers have access to a room large enough for about a dozen people to meet, a television, a DVD player, and a scale, Dr. Goff said.

The HELP PD model relies upon DVDs developed by the research team that give participants information about healthy eating, proper stretching and exercise tips, how to eat “mindfully” (i.e. not out of boredom or habitually in front of the television) and other lifestyle-related topics. Dr. Goff said that training community health workers to coach participants on how to set goals, solve problems and use the information in the DVDs could be accomplished by others interested in starting such a program in their own community. Reimbursement for these programs is a barrier.

Study participants will be followed for an additional five years to see whether individuals can maintain weight loss and blood glucose reductions independently, or if they need continued group counseling to do so. The study is being funded by the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health.

HELP PD is one of numerous community-centered intervention models being developed based upon a program used during the DPP. Several different programs, tested in a variety of community settings, will be discussed and presented during the Association’s 70^th Scientific Sessions, including the Group Lifestyle Balance Program, which helped significantly reduce diabetes risk factors through group settings at a primary care practice in California and also through DVDs that could be viewed at home (105-OR). This program was also successful when delivered by diabetes educators (417-PP). Another focused on Arab Americans in the Detroit, Michigan area, who successfully reached weight loss and physical activity goals through a program culturally modified to suit Middle Eastern diet and values (110-OR). And African Americans recruited during Sunday services at 42 churches in Georgia and Connecticut showed promising initial weight loss and a high willingness to participate in a church-based, culturally adapted lifestyle change program, according to preliminary data (109-OR).

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

Oral Presentation, Tuesday, June 29, 8:25 a.m.

id=”nav_links”>

KANSAS CITY, MO–(Marketwire – June 29, 2010) –  U.S. Secretary of Health and Human Services Kathleen Sebelius and other national leaders are coming together on July 6, 2010 for a first-of-its-kind town hall-style meeting with the goal of accelerating the discovery and development of new cancer drugs.

The event will bring together other senior government officials and thought leaders from industry, venture capital, academia, venture philanthropy and non-profit sectors to spur innovation and move discoveries more quickly from the laboratory to the clinic, where they can benefit patients battling cancer. Francis Collins, director of the National Institutes of Health, Margaret Hamburg, commissioner of the U.S. Food and Drug Administration, and Richard Gephardt, former U.S. House Majority Leader and Chairman of the Council for American Medical Innovation, are among those who will participate.

Reflecting the growing shift away from the model of large pharmaceutical companies developing drugs internally from start to finish, the town hall is titled, “The New Role of Academia in Drug Discovery and Development.” It is being sponsored by Friends of Cancer Research and the University of Kansas Cancer Center, with support from the Kansas Bioscience Authority, Ewing Marion Kauffman Foundation and Council for American Medical Innovation.

Where: The Kauffman Foundation Conference Center, 4801 Rockhill Road, Kansas City, Mo., 64110

When: July 6, 2010, 7:45 a.m. – 3:45 p.m. CDT

Many key participants and organizational leadership will be available for press prior to the conference.

Press Contacts:
Friends of Cancer Research: Ryan Hohman, [email protected] or 717-333-6248

The University of Kansas Cancer Center: Marci Nielsen, [email protected], 913-961-0759 or Stephanie Sharp, [email protected], 913-579-4376

Kansas Bioscience Authority: Chad Bettes, [email protected] or 913-397-8300

Kauffman Foundation: Barb Pruitt, [email protected] or 816-932-1288

Council for American Medical Innovation: Sean Donahue, [email protected] or 202-347-7947

About Friends of Cancer Research

Friends of Cancer Research (Friends) is a cancer research think tank based in the Washington, D.C. area. Working with the entire cancer research and advocacy community, Friends pioneers innovative public-private partnerships, organizes critical policy forums, educates the public, and brings together key stakeholders to overcome the barriers standing between patients and the most promising cancer treatments.

About The University of Kansas Cancer Center

At The University of Kansas Cancer Center, we are more than an academic cancer center; we are a unique community-based cancer research and care partnership focused on one mission: eliminating the burden of cancer. The University of Kansas Cancer Center is transforming cancer research and clinical care by linking our innovative approach to drug discovery, delivery and development to our nationally accredited patient care program.

About the Ewing Marion Kauffman Foundation

The Ewing Marion Kauffman Foundation is a private nonpartisan foundation that works to harness the power of entrepreneurship and innovation to grow economies and improve human welfare. 

About the Council for American Medical Innovation

The United States faces serious challenges to maintaining its leadership position in innovation. The Council for American Medical Innovation is bringing together leaders in research, medicine, public health, academia, education, labor, investment, and business, who are working in partnership toward a national policy agenda aimed at preserving U.S. leadership in medical innovation. American medical innovators create millions of high-paying jobs, and their discoveries are integral in the fight to cure cancer and other illnesses. The Council for American Medical Innovation views leadership in medical innovation as a key part of America’s economic recovery, future prosperity and health.

About the Kansas Bioscience Authority

The KBA is a $581 million initiative that is advancing Kansas’ national bioscience leadership by building world-class research capacity; fostering the formation and growth of bioscience startups; supporting expansion of the state’s bioscience clusters; and facilitating industrial expansion and attraction.

Click here to see all recent news from this company

NASHVILLE, TN–(Marketwire – June 29, 2010) –  Vanguard Health Systems, Inc. (“Vanguard”) announced today that its wholly-owned subsidiaries, Vanguard Health Holding Company II, LLC (“VHS Holdco II”), and Vanguard Holding Company II, Inc. (“VHS Holdco II Inc.” and, together with VHS Holdco II, the “Issuers”), plan to issue an aggregate principal amount of up to $225.0 million of 8% senior notes due 2018 (the “New Notes”) in a private placement. 

The Issuers intend to use the net proceeds from the offering of the New Notes, together with cash on hand, to finance Vanguard’s acquisition of substantially all of the assets of The Detroit Medical Center, a Michigan non-profit corporation, consisting primarily of eight acute care and specialty hospitals in the Detroit, Michigan metropolitan area and related healthcare facilities and to pay fees and expenses in connection with the foregoing. If the acquisition is not consummated, the proceeds of the offering of the New Notes will be used for general corporate purposes, including other acquisitions.

The New Notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). The New Notes may not be offered or sold within the United States or to U.S. persons, except to “qualified institutional buyers” in reliance on the exemption from registration provided by Rule 144A and to certain persons in offshore transactions in reliance on Regulation S. You are hereby notified that sellers of the New Notes may be relying on the exemption from the provisions of Section 5 of the Securities Act provided by Rule 144A. This announcement does not constitute an offer to sell or the solicitation of an offer to buy New Notes in any jurisdiction in which such an offer or sale would be unlawful.

Company Information and Forward Looking Statements

About Vanguard

Vanguard owns and operates 15 acute care hospitals with 4,135 licensed beds and complementary facilities and services in Chicago, Illinois; Phoenix, Arizona; San Antonio, Texas; and Massachusetts. Vanguard’s strategy is to develop locally branded, comprehensive healthcare delivery networks in urban markets. Vanguard will pursue acquisitions where there are opportunities to partner with leading delivery systems in new urban markets or to increase its presence in existing markets. Upon acquiring a facility or network of facilities, Vanguard implements strategic and operational improvement initiatives including expanding services, strengthening relationships with physicians and managed care organizations, recruiting new physicians and upgrading information systems and other capital equipment. These strategies improve quality and network coverage in a cost effective and accessible manner for the communities Vanguard serves.

This press release contains “forward-looking statements” within the meaning of the federal securities laws which are intended to be covered by the safe harbors created thereby. Forward-looking statements are those statements that are based upon management’s current plans and expectations as opposed to historical and current facts and are often identified in this report by use of words including but not limited to “may,” “believe,” “will,” “project,” “expect,” “estimate,” “anticipate,” and “plan.” These statements are based upon estimates and assumptions made by Vanguard’s management that, although believed to be reasonable, are subject to numerous factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those projected. These factors, risks and uncertainties include, among others, Vanguard’s high degree of leverage and interest rate risk; Vanguard’s ability to incur substantially more debt; operating and financial restrictions in Vanguard’s debt agreements; the enactment in March 2010 of major healthcare reform legislation and the future possible enactment of additional federal or state health care reform and changes in federal, state or local laws or regulations affecting the healthcare industry; Vanguard’s ability to generate cash necessary to service Vanguard’s debt; weakened economic conditions and volatile capital markets; post-payment claim reviews by governmental agencies could result in additional costs to us; Vanguard’s ability to successfully implement Vanguard’s business strategies; Vanguard’s ability to grow its business and successfully integrate future acquisitions, including the assets of The Detroit Medical Center; potential acquisitions, including the assets of The Detroit Medical Center, could be costly, unsuccessful or subject Vanguard to material unexpected liabilities; conflicts of interest that may arise as a result of Vanguard’s control by a small number of stockholders; the highly competitive nature of the healthcare industry; governmental regulation of the industry, including Medicare and Medicaid reimbursement levels; pressures to contain costs by managed care organizations and other insurers and Vanguard’s ability to negotiate acceptable terms with these third party payers; Vanguard’s ability to attract and retain qualified management and healthcare professionals, including physicians and nurses; future governmental investigations; the availability of capital to fund Vanguard’s corporate growth strategy; potential lawsuits or other claims asserted against Vanguard; Vanguard’s ability to maintain or increase patient membership and control costs of its managed healthcare plans; Vanguard’s exposure to the increased amounts of and collection risks associated with uninsured accounts and the co-pay and deductible portions of insured accounts; dependence on Vanguard’s senior management team and local management personnel; volatility of professional and general liability insurance for Vanguard and the physicians who practice at its hospitals and increases in the quantity and severity of professional liability claims; Vanguard’s ability to maintain and increase patient volumes and control the costs of providing services, including salaries and benefits, supplies and bad debts; increased costs from further regulation of healthcare and potential liability from Vanguard’s failure to comply, or allegations of Vanguard’s failure to comply, with applicable laws and regulations; the geographic concentration of Vanguard’s operations; Vanguard’s failure to adequately enhance Vanguard’s facilities with technologically advanced equipment; technological and pharmaceutical improvements that increase the cost of providing, or reduce the demand for, healthcare services and shift demand for inpatient services to outpatient settings; costs and compliance risks associated with Section 404 of the Sarbanes-Oxley Act; a failure of Vanguard’s information systems that would adversely impact its ability to manage its operations; material non-cash charges to earnings from impairment of goodwill associated with declines in the fair market values of Vanguard’s reporting units; and volatility of materials and labor costs for potential construction projects that may be necessary for future growth.

Although Vanguard believes that the assumptions underlying the forward-looking statements contained in this press release are reasonable, any of these assumptions could prove to be inaccurate, and, therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, you should not regard the inclusion of such information as a representation by Vanguard that its objectives and plans anticipated by the forward-looking statements will occur or be achieved, or if any of them do, what impact they will have on Vanguard’s results of operations and financial condition. Vanguard undertakes no obligation to publicly release any revisions to any forward-looking statements contained herein to reflect events and circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.

SALT LAKE CITY, UT–(Marketwire – June 29, 2010) –  Custom health communications company StayWell Custom Communications (SCC), a division of MediMedia USA, has announced an exclusive strategic alliance with SEO.com, a leading provider of search marketing strategies including search engine optimization, pay-per-click management, social media, and SEO Web design. 

Through this strategic alliance, StayWell Custom Communications will be offering a range of search marketing strategies designed to increase website traffic, build loyal customers and drive online transactions for its clients, which include health care providers, health plans, and retailers such as pharmacies and supermarket chains.

The increasing demand for online health information and services is fueling a growing need for health care organizations and health care retailers to focus on programs and tactics that make it easier for consumers to navigate the Internet and find information, which ultimately builds business for their organization. Search Engine Optimization and online advertising programs are becoming an increasingly important part of the mix when it comes to driving prospective patients and consumers to a health care site.

“As organizations continue to invest heavily in developing a robust online presence, ensuring that consumers can find them is critical to a successful e-business strategy,” said StayWell Custom Communications president and CEO Trent Sterling. “The need for such specialized search marketing strategies in order to optimize healthcare content and services have become ever more important.”

SCC established the alliance with SEO.com in order to meet this need and help its clients improve site performance. “We partner with our clients to deliver robust interactive health content solutions designed to achieve business results,” said Sterling. “The excellent search marketing strategies offered by SEO.com will enable our clients to maximize their ROI by helping them boost their Web traffic, and turn that traffic into revenue for their organization. With 80 percent of consumers going online to look for health information, the potential for our clients to use their content to attract visitors is unlimited.” 

SEO.com, an SEO company, is based just outside Salt Lake City, just minutes away from the headquarters of SCC’s Interactive Solutions. SEO.com’s clients include Dell, H&R Block, AlphaGraphics, Hugo Boss and Mrs. Field’s Cookies. Website Magazine ranked SEO.com the No. 2 SEO firm in the country in April 2010.

“Good content with the right keywords is critical for search engine optimization,” said Dave Bascom, CEO of SEO.com. “We’re excited to have joined forces with StayWell to help many respected organizations in the health industry achieve their goals.”

About StayWell Custom Communications (SCC)
StayWell Custom Communications is the leader in custom health content solutions delivered via a variety of sophisticated technology platforms. Our interactive offerings include robust web platforms, online health libraries, e-mail and SMS (or mobile) marketing programs, and an extensive range of multimedia tools including video, podcasts and animations. The company serves hundreds of clients representing several channels in the healthcare industry: hospitals and health systems; health plans; employers; and retail organizations. StayWell Custom Communications also offers a comprehensive range of print and print/interactive integrated solutions to meet a broad range of clients’ marketing and communication needs. 

SCC is a member of the StayWell family of companies, which includes Krames, StayWell Health Management, StayWell Consumer Health Publishing (A Harvard Medical School Strategic Alliance), Vitality Communications, StayWell Productions and StayWell Safety Solutions (a Red Cross Strategic Business Alliance). StayWell, which is a division of MediMedia USA, represents the largest patient education and consumer health information publisher in North America.

For more information, visit www.staywellcustom.com.

About MediMedia
Headquartered in Yardley, PA, with 1,700 employees in offices throughout the U.S., MediMedia changes consumer and professional behaviors through superior engagement, education and end-user preferences. Our health information services group creates, publishes, distributes, and syndicates on and off-line health information to help consumers make informed health decisions on behalf of a variety of sponsors, including providers — both hospitals and physicians, payers, and online media companies. Our health management services group provides population health management services which help consumers lower their health risk, enabling employers to lower their risks, utilization and ultimately their health care expenses. And finally, our professional segment derives its revenues from providing online/off-line professional promotion, engagement, and education services targeted to healthcare professionals and their patients.

MediMedia is a Vestar Capital Partners portfolio company.

About SEO.Com
SEO.com is a search marketing firm that makes its clients money by driving traffic to their websites through aggressive search engine optimization, pay per click management, and social media marketing. SEO.com then turns those visitors into sales through search-optimized Web design and conversion optimization. Clients range from small startups to Fortune 100 companies. For more information, visit http://www.seo.com/.

Click here to see all recent news from this company

KANKAKEE, IL–(Marketwire – June 29, 2010) –  Riverside Healthcare is proud to have their new website up and running. Current users of www.RiversideHealthcare.org will notice that the new website has maintained the overall look and feel of the original site and also offers new information in an easy to navigate format. As one of the top hospitals in Illinois, this website only makes Riverside’s services that much better.

With just a quick visit to this website you will see that they offer a wide range of services online. This Chicago south suburbs healthcare provider allows you to find a physician online with a basic search. Whether you need a dentist, family doctor, oncologist or even a plastic surgeon, this website can help you find one. If you need to schedule a mammogram or bone density scan, you can make this appointment directly online. There is no need to make telephone call and wait on hold anymore. Simply logon to get started today.

We all know that paying our medical bills can get hectic at times. Through Riverside Healthcare’s new website you can pay your medical bills with their bill payment center. This system makes paying your bills simple and convenient.

If you are not a patient at the hospital, but know someone staying at the southern Chicago healthcare center, there are services online that can help you as well. This website is great for those people who live out of town and can’t make it to the hospital to be there in person. You can go online and order flowers to be sent to your loved one. You can choose from a wide range of beautiful arrangements that will be delivered directly to their room. The website also offers access to The Market Place, where you can shop for all different types of medical goods. If you need books, gifts, strollers, or vitamins, this website has it all. One of the most popular features of the website is the online nursery. If someone you are close to just had a baby you can access the online nursery through their website as well.

Riverside Healthcare’s new website has something to offer everyone. You can visit the website every day to read up on the latest medical news. www.RiversideHealthcare.org is just what the doctor ordered!

Click here to see all recent news from this company

VANCOUVER, BRITISH COLUMBIA–(Marketwire – June 28, 2010) – Funding for maternal health care must stay front and centre as the G8 and G20 summits conclude. Approximately 500,000 women around the globe die each year from pregnancy related causes that are preventable. Another 70,000 die from complications of unsafe abortions. When their mothers die, 80% of children under age one will also die, usually within two years.

Prime Minister Stephen Harper demonstrated Canadian leadership when addressing the goal of improving maternal health and lowering maternal and child mortality. Women around the world need Canada’s commitment and that of the other G8 countries.

As physicians, we are committed to evidence based solutions and realize that to reach this goal the strategy must include access to a full range of reproductive health programs including access to safe abortion where legal. There must be development of strong health care systems, supported by trained health care providers and integrated into whichever local health systems already exist. There need to be community based programs for maternal and child health including preventative programs such as nutrition, public health and vaccination programs. There also need to be programs that continue to work on the big three diseases that ravage sub-Saharan Africa, namely TB, malaria and HIV/AIDS, as these diseases contribute significantly to maternal and child mortality.

As world leaders leave Canada and prepare for the upcoming meeting in South Korea, there needs to be a commitment from all G8 countries for $30 billion over five years to fund maternal health. Saving women makes economic sense. Women make up half of the world’s population, and as women, produce the other half.

The Medical Women’s International Association has been in existence since 1919 and is an organization of women physicians from around the world whose mandate is to improve the health of women and children. The national branch is the Federation of Medical Women of Canada.

ORLANDO, FL–(Marketwire – June 28, 2010) –  Rosiglitazone, a commonly used diabetes drug, poses no significant increased risk of death, stroke or heart attack, though it does increase the risk of fractures, according to a new analysis of thousands of patients with established cardiovascular disease and type 2 diabetes. The findings are being presented at the American Diabetes Association’s 70^th Scientific Sessions^®, and are part of the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D) study, a landmark multicenter trial focusing exclusively on patients with both diabetes and established heart disease.

The safety of rosiglitazone, marketed as Avandia, a medication in the class of thiazolidinedione (TZD) drugs, has been a controversial topic since a 2007 meta-analysis published in the New England Journal of Medicine concluded that rosiglitazone “was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes.” The strength of this study, which reviewed the results of 42 previously published investigations but did no independent testing of the drug, has been questioned by others in the field but ultimately led to a review of the drug’s safety by the U.S. Food and Drug Administration (FDA). In November 2007, the FDA added a warning label to the drug regarding potential heart risks.

The following year, however, researchers conducting the Veterans Affairs Diabetes Trial (VADT), a large-scale clinical trial in which 80 percent of patients were taking rosiglitazone, added further, while still inconclusive, information to this discussion. During the American Diabetes Association’s 68^th Scientific Sessions, the VADT researchers reported that a specific analysis of rosiglitazone found that it did not appear to cause excess cardiovascular events and may in fact provide protective benefits for cardiovascular health.

Now a post-hoc analysis of the BARI 2D findings also shows no increased risk of heart attack or cardiovascular death with rosiglitazone treatment. Analyzing 4.5 years of follow-up data for patients who were being treated with rosiglitazone, compared to those not taking any TZD drugs, the study found no increase in risk of death or heart attack from taking rosiglitazone. While no protective cardiovascular benefit was shown, the analysis found that the rate of death, heart attack and stroke tended to be lower — about 28 percent lower in fact — among patients taking rosiglitazone. As has been seen with other studies of TZDs, the rate of congestive heart failure was significantly higher among patients taking rosiglitazone, but this difference was not statistically significant. 

As seen in previous studies, the analysis of BARI 2D reported a 45 percent increase in fracture rates for those taking rosiglitazone, compared to those not taking any TZD medications.

“I think these data are important because they suggest there is no significant cardiovascular harm posed by taking rosiglitazone for patients with type 2 diabetes and coronary heart disease,” said lead researcher Richard Bach, M.D., Associate Professor of Medicine at the Washington University School of Medicine. “There is an increase in fractures, but when one considers the dramatic morbidity and mortality associated with ischemic cardiovascular events in patients with diabetes, these data are reassuring.”

The BARI 2D study, led by principal investigator Sheryl Kelsey, Ph.D, of the University of Pittsburgh Graduate School of Public Health, evaluated both a cardiovascular treatment approach as well as a diabetes control approach in 2,368 persons with type 2 diabetes and stable coronary artery disease (CAD) to reduce deaths or deaths and cardiovascular events (heart attacks and stroke) combined. The first component compared intensive medical treatment with prompt coronary revascularization by either bypass surgery or angioplasty (which opens blocked arteries by inserting metal stents or balloons through the arteries, without recourse to surgery) to intensive medical treatment alone. The second component compared whether controlling diabetes with drugs to make insulin work better (insulin sensitization) had an advantage for heart health or survival compared to using a strategy emphasizing drugs increasing insulin itself (insulin provision).

Nearly 24 million Americans have diabetes, a group of serious diseases characterized by high blood glucose levels that result from defects in the body’s ability to produce and/or use insulin. Diabetes can lead to severely debilitating or fatal complications, such as heart disease, stroke, blindness, kidney disease and amputation. It is a leading cause of death by disease in the United States. Type 2 diabetes involves insulin resistance — the body’s inability to properly use its own insulin — and occurs mainly in adults who are overweight and age 40 and older. More than 65 percent of people with diabetes die from heart disease or stroke. With diabetes, heart attacks occur earlier in life and often result in death.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

Oral presentation, Tuesday, 8:50 a.m.

id=”nav_links”>

TORONTO, ONTARIO–(Marketwire – June 28, 2010) – FMX Ventures Inc. (the “Company“) (TSX VENTURE:FXX.H)announced today that, subject to regulatory approval, it has appointed Mr. Carmelo Marrelli as its Chief Financial Officer. Mr. Marrelli replaces Jon Kelly who has resigned to pursue other interests. Mr. Kelly served as Chief Financial Officer of the Company prior to the sale of its orthotics business in 2007 and assisted with the Company’s transition from an operating company to its current form. The board of directors of the Company wishes to thank Mr. Kelly for his contributions.

Mr. Marrelli holds a Bachelor of Commerce degree from the University of Toronto and is a qualified Chartered Accountant and Certified General Accountant. Mr. Marrelli is currently President of Marrelli Support Services, a bookkeeping firm based in Toronto, Ontario.

Number of Common Shares Outstanding – 3,934,296

ORLANDO, FL–(Marketwire – June 28, 2010) –  The American Diabetes Association has announced a change in the embargo time of the rosiglitazone study being presented at the 70^th Scientific Session in Orlando, FL. This is part of the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D) study, a landmark multicenter trial focusing exclusively on patients with both diabetes and established heart disease. The new embargo time is 4:30 pm (EDT).

The American Diabetes Association thanks the BARI 2D investigators for their collaboration and appreciates their willingness to present this important scientific information to the diabetes community during the 70^th Scientific Sessions. The full scientific disclosure and discussion of these data will be featured at the Late Breaking Clinical Trials session on Tuesday, June 29, 2010 at 8:50 am.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

WASHINGTON, DC and WILLIAMSBURG, VA–(Marketwire – June 28, 2010) –  GuideStar, the leading source of nonprofit information, encourages any exempt organization whose fiscal year ends June 30 to verify that it is compliant with IRS reporting requirements in order to maintain its exemption.

Most tax-exempt organizations except churches are required to file an annual information return (IRS Form 990-N, 990-EZ, 990, or 990-PF). Organizations required to file that fail to do so for three consecutive years will automatically lose tax-exempt status, as mandated by a provision of the Pension Protection Act of 2006. 

The deadline for filing Form 990 and its variants is determined by the end of the filing organization’s fiscal year. The filing deadline for an organization whose fiscal year ends on June 30, 2010, is November 15, 2010. 

“The first time the revocation provision of the Pension Protection Act was put in effect was last May, when returns for organizations whose fiscal year ended December 31, 2009, were due,” said Bob Ottenhoff, GuideStar’s president and CEO. “We learned then that thousands of nonprofits, particularly smaller ones, did not realize they needed to file and were at risk of losing their exemptions. That’s why GuideStar created a nonprofit resource center about the revocations. Nonprofits can use the resource center to stay up to date on what they must do in terms of filing an annual information return.”

An organization’s annual gross revenue and assets determine which version of the 990 it must file. Filing extensions are available for Forms 990-EZ, 990, and 990-PF, but not for Form 990-N. (See the accompanying table.)

GuideStar’s nonprofit resource center provides an overview of the revocations issue and several quick links, including ones to a Form 990-N filing status database, the mechanics of filing Form 990-N, filing exceptions, filing thresholds, filing deadlines and extensions, and IRS and GuideStar revocation FAQs. The resource center is updated as new developments related to the revocations occur.

“We hope every exempt organization will use these resources to ensure that they are not at risk of losing their exemptions for failure to file an annual return,” Ottenhoff said. “Nonprofits play vital roles in our society, and losing tax-exempt status will hurt not only the organizations but also the causes and people they serve.” 

About GuideStar

GuideStar, www.guidestar.org, connects people and organizations with information on the programs and finances of more than 1.8 million IRS-recognized nonprofits. GuideStar serves a wide audience inside and outside the nonprofit sector, including individual donors, nonprofit leaders, grantmakers, government officials, academic researchers, and the media.

Click here to see all recent news from this company

POCATELLO, ID–(Marketwire – June 28, 2010) –  TetriDyn Solutions, Inc. (OTCBB: TDYS), a multi-channel technology innovator in the Information Technologies sector, announced today that it has delivered its latest revenue and business process improvements tool targeted specifically for hospital environments — Charge Catcher.

Charge Catcher enables hospitals to improve their revenue generation by identifying lost charges in an accurate and timely manner. Hospitals can improve their revenue by reviewing and correcting the identified and missed charges quickly and accurately. Charge Catcher uses a combination of rule-based logic and artificial intelligence techniques to detect potential missing charges before the patient bill is generated. 

Bear Lake Memorial Hospital increased its earnings by more than one percent of gross revenues in its first full year of using Charge Catcher. Bear Lake Memorial Hospital also found additional benefits of using Charge Catcher included lower administrative costs due to fewer re-billings, improvements in departments’ billings and procedures, and enhanced levels of compliance. TetriDyn has also recently signed a contract with Steele Memorial Medical Center to implement the latest version of Charge Catcher in their facility so that they can begin to appreciate increased revenues as well.

In addition, past charges can be reviewed in the initial stages of deployment to recoup lost revenue from previous billing cycles as much as one year later. Charge Catcher has been proven to incrementally increase revenue reimbursement, improve billing accuracy, and reduce business office expenses.

Dave Hempstead, CEO of TetriDyn Solutions, commented, “We are excited to be delivering to our customers a product that generates added revenue on a daily basis. The Charge Catcher tool creates revenue improvements for hospitals and reduces accounts receivable days throughout the revenue cycle.” 

For more information about Charge Catcher, visit www.chargecatcher.com.

About TetriDyn Solutions, Inc.
TetriDyn Solutions, Inc. (OTCBB: TDYS) specializes in providing business information technology (IT) solutions to its customers. TetriDyn Solutions optimizes business and IT processes by utilizing systems engineering methodologies, strategic planning, and system integration to add efficiencies and value to its customers’ business processes and to help its customers identify critical success factors in their business. For more information about the company, visit www.tetridyn.com.

ATLANTA, GA–(Marketwire – June 28, 2010) –  Armando L. Vilches, CPCU, a sales executive with 25 years of experience in property/casualty insurance, has joined Uni-Ter Underwriting Management Corporation as Vice President-Marketing, Nadeene Wood-Clater, Senior Vice President-Marketing, announced.

Vilches spent 20 years with the Willis Insurance Group and its subsidiary Stewart Smith where he was named the Company’s Most Valuable Producer in 2000. As Nashville Marketing Manager, he led a team that placed $250 million in commercial premium.

“Armando has an outstanding track record marketing and underwriting all lines of liability insurance. He will be a valuable addition to the Uni-Ter team as the Company grows,” Wood-Clater said.

Vilches will work in marketing and new business development for Lewis & Clark LTC RRG, Inc., provider of liability insurance to long-term care facilities and nurses nationwide and Ponce de Leon LTC RRG, Inc. that writes liability insurance for long-term care facilities in Florida. He will work also on new business development for J.M. Woodworth Risk Retention Group, Inc., medical malpractice insurance writer in New York, Connecticut, New Jersey, and Pennsylvania.

Vilches is a graduate of DePaul University. He holds the CPCU (Chartered Property Casualty Underwriter) Designation and is a recognized speaker on risk management and liability insurance.

Learn more about Uni-Ter at www.uni-ter.com.

MUNDELEIN, IL–(Marketwire – June 28, 2010) –  Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of medical supplies, today announced the launch of a new, completely redesigned and expanded company website that vastly improves the user experience for its healthcare customers. The newly revamped medline.com features improved navigation enabling direct access to key information regarding Medline products, programs and education.

“While we’ve refined the design, we’ve also improved the use of technology so users can engage directly with our content, products and services faster than ever,” said Jignesh Thakkar, Medline’s Director of E-Business Marketing. “The redesigned website vastly improves the customer experience. Visitors can now get much more information quickly and easily through expanded content, videos, product search capabilities and more.”

With users accessing medline.com content more than two million times a month, a critical outcome for the redesign was to not only create an updated interactive environment for customers, but to help them find what they are looking for easier and faster. The new site achieves this by not only increasing product search performance by more than 50 percent, but by also adding more features such as:

• 200-plus pages of fresh content that provides valuable information and resources to customers.
• Thousands of additional product images and updated descriptions
• New detailed product specification pages — in full page format
• Ability to select preferred product page views in thumbnail, column or table formats
• Filtered product category functionality to reduce product search results
• Selection categories of top products and manufacturers from the products results page.

“It is so much more user friendly. I like the options at the top (thumbnails) as to how you can view the items,” said Cali Yocom of Bethany Hospice in Valdosta, GA. “I also love the pictures. It is so nice to have that when you want to get a better view of the item.”

The medline.com redesign is the second major upgrade the company has made to its core group of websites. Last month significant enhancements were added to Medline University (MU), its online resource for clinical education and product training for healthcare providers. That site (www.medlineuniversity.com) now includes free unlimited access to CE credit courses, live webinars, downloadable podcasts, real-time news feeds and innovative interactive competency tools. Additionally, the company also recently added a free CE iPhone^® and iPod Touch^® app, now available for download from Apple’s iTunes store.

“Medline is committed to helping customers make profitable, educated decisions through engaging, interactive experiences,” said Mike Penny, Medline Chief Information Officer. “Our focus on innovation in online interaction will continue to increase over time as we see strong results from our efforts to date.”

About Medline Industries, Inc.

Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

BETHESDA, MD–(Marketwire – June 28, 2010) –  GetWellNetwork, Inc. will host a webinar on Tuesday, June 29th to demonstrate how children’s hospitals can improve patient satisfaction and enhance patients’ and families’ experience through using GetWell Town™, an interactive patient care solution.

GetWell Town was developed in collaboration with GetWellNetwork’s National Children’s Hospital Task Force, comprised of 15 pediatric facilities across the U.S., and direct input from pediatric patients and their families. GetWell Town is designed to complement the kid-friendly spaces that children’s hospitals have worked hard to create and features exclusive content in partnership with KidsHealth®, part of The Nemours Foundation’s Center for Children’s Health Media.

“Since the launch of GetWell Town, we’ve been honored to help many pediatric facilities improve patient care processes and drive better outcomes as a result,” said Shannon O’Neil, MSW, Director of Pediatrics at GetWellNetwork, Inc. “This webinar is designed to share with other children’s hospitals how they can realize the same benefits for their patients and gain efficiencies in core nursing activities such as education, patient documentation, and patient safety.”

To register for this webinar please visit http://www.getwellnetwork.com/webinar.asp.

When: June 29, 2010.
Time: 12:00-1:00 PM, EDT.
Who: Chief Nursing Officers, Child Life Specialists, Discharge Planners, Environmental Services, and Safety Services.

More information about GetWell Town is available at http://www.getwellnetwork.com/pdfs/getwell_town.pdf.

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

Click here to see all recent news from this company

ATLANTA, GA–(Marketwire – June 28, 2010) – ALR Technologies Inc. (OTCBB: ALRT) announces the appointment of Lawrence (Larry) Weinstein to be President and Chief Operating Officer effective July 1, 2010, replacing Sidney Chan who will become Chairman and Chief Executive Officer. Stan Cruitt is retiring as Chairman of the Company.

Larry has extensive experience in the development and launch of medical products. His experience includes 11 years with Cordis Corporation (a Johnson & Johnson company), 6 years with DHD Healthcare Corporation and most recently, 9 years with Pari Respiratory Equipment. He is leaving Pari as Senior Vice President of Operations at PRE Holding, Inc. and as President, Hydrate, Inc.

Mr. Chan says that, “Larry Weinstein brings a skill set and experience that will be invaluable as the company introduces the ALRT Health-e-Connect (HeC) monitoring system. Our product will be invaluable for the healthcare industry to achieve better health outcomes and contain costs.”

About ALR Technologies Inc.
ALRT Health-e-Connect (HeC) System is the principal product of the Company. HeC is a web-based application for medical professionals to improve compliance and adherence of care plans of patients in their homes. HeC is programmed to assist healthcare providers caring for diabetes patients. The platform will be expanded to cover patients with other chronic diseases. More information on ALR Technologies and its products can be found at http://www.alrt.com. 

This release contains certain “forward-looking statements” relating to ALR Technologies’ business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words “estimate,” “expect,” “anticipate,” “believe” and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company’s quarterly filings with the Securities Exchange Commission.

DEERFIELD BEACH, FL–(Marketwire – June 28, 2010) –  MedChoice Financial, a national medical financial company, announces new functionality for healthcare and medical providers to truly leverage its Platinum Provider Portal and go paperless. The secure, web-based provider portal enables a medical practice or clinic to dynamically manage its financing programs through automated processes, application submissions and reporting.

The portal now allows for more visibility into the current state of a patient’s account by showing in real time availability of funds. Healthcare providers can service patients faster when they know what funds can be applied to their patients’ procedures, whether it be medical, cosmetic, dental, laser hair removal or restoration. Additionally, MedChoice’s enhanced reporting benefits practices by allowing them to export data to an Excel spreadsheet and allows for the integration with other business applications.

“The enhancements we have made to our portal support our mission for a customer driven, flexible and responsive support system for a practice’s needs. Our investment in automation will benefit practices nationwide by not having to delay performing procedures and will give them an instant overview of a patient’s financing options,” said Valerie Harding, MedChoice Financial Marketing Spokesperson.

Healthcare practices today find physicians and their staff juggling more patients and paperwork, with fewer resources. MedChoice’s Platinum Provider Portal simplifies, accelerates and automates administrative tasks that drain precious resources. It allows staff and physicians to focus their energies on better serving their patients and brings the practice one step closer to achieving a paperless environment. Other benefits include increased efficiencies and accuracies, improved access to information, better collaboration and communication between colleagues and patients.

About MedChoice Financial

MedChoice Financial, headquartered in Deerfield Beach, FL, is a national medical financial institution that services the medical community (medical, dental, cosmetic) and its patients with flexible, convenient financing solutions. Dedicated foremost to superior customer service and partnered with World Financial Network National Bank (WFNNB), MedChoice Financial has become one of the largest and fastest growing elective medical financing companies in the nation. For more information, visit www.medchoicefinancial.com

Click here to see all recent news from this company

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – June 28, 2010) – www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today announced that new preclinical
results for NCX 434 were presented at the Retina International World
Congress in Stresa, Italy. NCX 434 is a nitric oxide (NO)-donating new
molecular entity (NME) and a potential preclinical candidate in Diabetic
Macular Edema (DME). It was shown to reduce retinal damage due to ischemia
(restriction of blood flow) and reperfusion (return of blood supply
following ischemia) in a preclinical model without inducing a significant
increase of intraocular pressure (IOP), in contrast to a reference steroid.

DME is a form of diabetic retinopathy, which results from high blood sugar
causing progressive damage to retinal cells and can lead to blindness. In
addition to laser surgery, DME is often treated with injections of steroids
inside the eye (intravitreal injections), which tend to increase IOP,
presenting a significant safety concern. Additionally, local ischemia
resulting from an imbalance between NO, known for its vasodilation
properties, and a vasoconstrictor substance called endothelin-1 (ET-1)
appears to play a pivotal role in DME progression.

This presentation showed that NCX 434 was efficient in reducing several
biochemical and functional aspects of retinal damage in a preclinical model
of ischemia/reperfusion induced by the injection of ET-1. NCX 434 did not
significantly change IOP in this model, while triamcinolone acetonide, a
reference steroid, resulted in significant increase in IOP.

Previous preclinical results showing that NCX 434 enhanced oxygen
saturation in various optic nerve head structures in contrast to a
reference steroid were presented recently at the Ocular Diseases & Drug
Discovery conference in Boston (NicOx press release dated June 1, 2010).

Risks factors which are likely to have a material effect on NicOx’s
business are presented in the 4th chapter of the ” Document de
référence, rapport financier annuel et rapport de gestion 2009 ”
filed with the French Autorité des Marchés Financiers (AMF) on
March 5, 2010 and available on NicOx’s website (www.nicox.com) and on the
AMF’s website (www.amf-france.org).

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA), which is currently under review by
regulatory authorities, following the submission and filing of a New Drug
Application (NDA) to the US Food and Drug Administration (FDA) and a
Marketing Authorization Application (MAA) to the European Medicines Agency
(EMA). The FDA and the EMA are evaluating the data submitted. The FDA has
set an action date of July 24, 2010, under the Prescription Drug User Fee
Act (PDUFA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although
the Company believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of NicOx S.A. to
differ from those contained in the forward-looking statements, please refer
to the Risk Factors (“Facteurs de Risque”) section of the Document de
Reference filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on NicOx S.A.’s website
(http://www.nicox.com).

CONTACTS

www.nicox.com

NicOx

Gavin Spencer – Vice President Business Development

Tel +33 (0)4 97 24 53 00 – [email protected]

Media Relations

Financial Dynamics

Europe

Guillaume Granier (France) – Tel: +33 (0)1 47 03 68 10 –
[email protected]

Stéphanie Bia (France) – Tel: +33 (0)1 47 03 68 10 –
[email protected]

Jonathan Birt (UK) – Tel +44 (0)20 7269 7205 – [email protected]

United States

Robert Stanislaro – Tel +1 212 850 5657 – [email protected]

Irma Gomez-Dib – Tel +1 212 850 5761 – [email protected]

NicOx S.A.,

Les Taissounières – Bât HB4 – 1681 route des Dolines – BP313,
06906 Sophia Antipolis cedex, France. Tel. +33 (0)4 97 24 53 00 – Fax +33
(0)4 97 24 53 99

This information is provided by HUGIN

ORLANDO, FL–(Marketwire – June 27, 2010) –  Research into whether an “artificial pancreas” can effectively control blood glucose levels in children and adults with type 1 diabetes continues to make rapid advances, leading those in the field to predict that technology could become commercially available within the next few years, according to speakers at a joint American Diabetes Association — Juvenile Diabetes Research Foundation (JDRF) symposium at the Association’s 70^th Scientific Sessions^®.

Results, presented for the first time at today’s symposium, show that adults with type 1 diabetes can use the artificial pancreas technology to significantly improve overnight blood glucose control without increasing the risk for hypoglycemia, across a range of real-life situations — even after eating a large meal and drinking a glass of white wine. Lead researcher Roman Hovorka, Ph.D, Principal Research Associate at the University of Cambridge Metabolic Research Laboratories, noted that such a system could greatly improve the lives of those who are insulin-dependent.

A second study, also presented for the first time at the Association’s 70^th Scientific Sessions, helped to identify the psychosocial characteristics of people with type 1 diabetes most likely to successfully utilize continuous glucose monitoring (CGM) devices, an important component of an artificial pancreas system. This data, presented by Marilyn Ritholz, Ph.D, Senior Psychologist at the Joslin Diabetes Center and Assistant Professor at Harvard Medical School, should help physicians and other diabetes care providers to identify patients for whom the new devices are most likely to be beneficial.

Both studies are part of the JDRF’S Artificial Pancreas Project, a partnership that brings together diabetes researchers and businesses focused on making the artificial pancreas a reality. The American Diabetes Association joined forces with JDRF at its Scientific Sessions to promote the research behind this project and to raise awareness of efforts underway to improve the lives of people with diabetes who are insulin-dependent.

“This joint symposium highlights how major organizations working together can move these technologies forward,” said Richard Bergenstal, MD, Executive Director of the International Diabetes Center and American Diabetes Association’s President, Medicine & Science. “It’s going to require collaboration between many different organizations to come together to tackle this problem.”

“It’s very exciting to work together to help people with diabetes achieve their outcomes,” said Aaron Kowalski, Ph.D, Research Director of the Artificial Pancreas Project. “We’re all interested in people with diabetes achieving better glucose control. The community needs to hear what’s happening and where we are headed.”

The JDRF research involving artificial pancreas technology combines CGM with an insulin pump and a sophisticated computer program (called an algorithm) that can automate when and how much insulin to deliver. All but the computer program are technologies already commercially available to people with diabetes. Research trials performed so far within the JDRF Artificial Pancreas Project have tested various levels of automation, multiple computer programs, and a range of in-clinic situations, including large and small meals, nighttime control, and exercise.

However, “a fully automated system that administers insulin as needed during the night without human intervention is planned to be tested on children in their homes in the United Kingdom. Nobody has done such a study before,” Hovorka said.

“I think artificial pancreas systems are going to turn out to be among the most promising short-term clinical benefits of diabetes research,” said Richard Insel, Executive Vice President of Research at JDRF. “They are going to obviously allow individuals to more effectively manage their blood glucose levels, especially after eating, when exercising, and during the night while they sleep. Not only will that help prevent long-term complications of the disease, but low blood sugars will be prevented, and living with diabetes will be easier. Just preventing the swings in glucose levels will help. The benefits are countless.”

Partially Automated Systems in Development

Hovorka and his team from the University of Cambridge have completed several recent studies of the artificial pancreas that hold promise for both children and adults with type 1 diabetes. Earlier this year, The Lancet published their landmark study of children and teenagers with type 1 diabetes who experienced better control of blood glucose levels and lower incidence of hypoglycemia while sleeping, using a closed loop artificial pancreas system.

Today, during the joint American Diabetes Association-JDRF symposium, Hovorka outlined results of his most recent study, which showed these benefits remain consistent even after adults with type 1 eat a large meal and drink a glass of white wine before bedtime. The study found that using the artificial pancreas system, these adults spent 70 percent of their time within their target blood glucose range, up from 47 percent of the time they spend within target overnight without use of the artificial pancreas system. As in the other studies, time spent in hypoglycemia tended to be reduced, even though alcohol is known to increase the risk of nocturnal/next morning hypoglycemia for people with type 1 diabetes. Full results will be presented on Monday.

The Cambridge team has also begun preliminary research into how such a system might work for pregnant women with type 1 diabetes. Early results have examined overnight glucose control in this population to establish a baseline against which they can measure effectiveness using the closed loop artificial pancreas system. These preliminary results were discussed in a poster presentation here on Saturday.

Barriers to Continuous Glucose Monitoring (CGM)

A major component of the technology needed to produce an artificial pancreas is a continuous glucose monitoring (CGM) system, which relates blood glucose levels and the direction they are trending throughout the day and night, compared to the “snapshots” that are currently taken by pricking the skin and using test strips on a periodic basis. CGM involves inserting a glucose-sensing device called a “sensor” under the skin of the abdomen, where it takes a glucose reading from the tissue every few seconds and relays it to a handheld device or insulin pump.

“CGM has the potential to be one of the most important breakthroughs in diabetes management in many years, especially for type 1, probably since pump therapies were developed in the 1980s,” said William Tamborlane, MD, of Yale University, and co-chair of JDRF’s Continuous Glucose Monitoring Group. Holding back more wide scale adoption of the technology at present, he said, are technical imperfections that make the devices cumbersome to use and require frequent calibrations and manual confirmations to ensure accuracy. “What we have now are imperfect simulations of the perfect system,” he said. But the technology holds great promise because even while not yet perfected, research has shown that using it regularly can significantly reduce A1C levels without increasing severe hypoglycemia in those who used it as directed.

JDRF-funded studies have shown that adults over the age of 25 were able to reduce their A1C levels from 7.6 to 7.1, using CGM in conjunction with an insulin pump, he said. In children ages 8-14, A1C levels dropped from 8.0 to 7.6 using CGM. Teenagers did not see a benefit, but that is likely because they were less likely to comply with using the technology than the other two groups, Tamborlane said. Participants in the trials who used the technology regularly — more than six days per week — saw similar improvement regardless of age.

“To get a benefit from a device, you actually have to use it,” he said.

Most importantly, when using CGM, A1C levels were reduced half a percentage point without increasing the risk of severe hypoglycemia, Tamborlane said. Hypoglycemia is perhaps the biggest concern for people with diabetes looking to significantly lower blood glucose levels and can have serious negative consequences, such as loss of consciousness.

The Joslin Center’s Ritholz said her team studied the psycho-social barriers that can prevent people from successful use of a CGM system and found that those who used problem-solving skills for coping with frustration and anger; who saw CGM as a mechanism for better understanding glucose patterns; and who had good support from a spouse or significant other were most likely to achieve good results with using this technology. Conversely, those who had anger and impulse control issues, who failed to synthesize the data from CGM and who didn’t have good emotional support were less likely to benefit from CGM use.

Success was defined, in this study, as lowering A1C levels by at least half a percentage point (if levels were above 7 percent at baseline) or decreasing the amount of hypoglycemia (if levels were below 7 percent at baseline), Ritholz said.

“There needs to be attention paid to the people using CGM,” she said. “We can’t just focus on the technology. In determining individualized patient care, it’s important to pay attention to who is most likely to succeed with this technology. It’s not for everybody.”

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

About JDRF
JDRF is the leader in research leading to a cure for type 1 diabetes in the world. It sets the global agenda for diabetes research, and is the largest charitable funder and advocate of diabetes science worldwide.

The mission of JDRF is to find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump — each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its eventual and devastating complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. The goal of the JDRF Artificial Pancreas Project is to speed the development of automated diabetes management systems. Since its founding in 1970 by parents of children with type 1 diabetes, JDRF has awarded more than $1.4 billion to diabetes research, including more than $100 million in 20 countries last year alone.

Symposium, Sunday June 27, 2 P.M.

id=”nav_links”>

TORONTO, ONTARIO–(Marketwire – June 26, 2010) – The Ministry of Health and Long-Term Care has deployed Ontario’s Emergency Medical Assistance Team (EMAT) to support capacity at the Huntsville District Memorial Hospital site of Muskoka Algonquin Healthcare. In anticipation of the many visitors expected in the region, the ministry has been working with the North Simcoe Muskoka Local Health Integration Network (LHIN) and local health service providers in the Simcoe-Muskoka region for over a year to develop plans to ensure there are minimal disruptions during the G8 summit.

The EMAT is funded by the ministry and is operated by the Sunnybrook-Osler Centre for Prehospital Care (SOCPC), a division of Sunnybrook Health Sciences Centre.

“The EMAT is providing additional critical care capacity in the region as part of a comprehensive health care plan to support the needs of this community”, said Robert Burgess, SOCPC Senior Director.

The EMAT mobile field hospital has been erected directly adjacent to the Huntsville District Memorial Hospital.

The Emergency Medical Assistance Team (EMAT)

Backgrounder

Q1. What is the Emergency Medical Assistance Team (EMAT)?

The EMAT is a part of the Ministry of Health and Long-Term Care’s (the ministry) health emergency response program and is an important component of Ontario’s overall emergency response capacity. The EMAT is funded by the ministry and is operated by Sunnybrook Health Sciences Centre. The EMAT is a 56-bed mobile field hospital that may be deployed by the ministry within 24-hours to any road-accessible community in Ontario. The unit provides the capacity to provide ongoing treatment for up to 20 acute care and 36 intermediate care patients and/or a staging and triage base for patients prior to transporting them to acute care hospitals and is medically self-sustainable (supplies, equipment, power, and personnel) for 72 hours.

Q2. What kind of health emergency response services does the EMAT provide?

The EMAT has the capacity to provide ongoing treatment for up to 20 acute care and 36 intermediate care patients and/or triage. The EMAT has expertise in: patient isolation in the case of an infectious disease outbreak; the provision of medical support and first receiver cold zone decontamination in the case of a chemical, biological, radiological or nuclear (CBRN) incidents; and assisting with managing patients in a mass casualty situation. If any jurisdiction in Ontario finds that it does not have the capacity to respond effectively to a health incident or emergency, the EMAT may be deployed to support the local health system.

Q3. How is the EMAT staffed?

The EMAT uses on-call professional health care providers from across the province who volunteer to work on the EMAT. Team members come from a variety of locations so that no single area is without vital health human resources at any given time. There are approximately 90 members including physicians, nurses, critical and advanced care paramedics and social workers, who are specially trained through the EMAT in health emergency management and response. Once the EMAT is activated, on-call volunteer workers are alerted and transported to the emergency site.

Q4. Who determines when the EMAT is deployed?

Deployment is based on an established set of criteria, including an immediate assessment of the local health care system’s ability to respond to the incident/ emergency, the availability of accommodations, water and food supplies for the EMAT volunteer workers, and an assessment of the emergency site (e.g., safety assessment for the mobile unit and EMAT volunteer workers). To deploy the EMAT, the local hospital and/or health system contacts the ministry with the initial request for EMAT support. If the situation meets the criteria, the ministry activates the EMAT.

Q5. How is the EMAT trained?

The EMAT team has the appropriate training and skills to function as a team in a health emergency environment involving infectious diseases outbreaks, natural disasters, CBRN, and mass causality incidents. The EMAT team trains regularly through full-scale exercises, which involve the participation of local health care organizations, and may also include local police, fire and ambulance services, as well as local municipalities.

Q6. What is the EMAT’s role at the G8?

The EMAT is a mobile field hospital that has been deployed to the G8 in Huntsville, ON to support capacity for the Huntsville hospital. It is onsite as part of the Ontario Ministry of Health and Long-Term Care’s work to ensure there is capacity for care for all patients.

ORLANDO, FL–(Marketwire – June 25, 2010) –  Bret Michaels, lead vocalist of Poison and winner of this season of “Celebrity Apprentice,” has received the American Diabetes Association’s prestigious Chair’s Citation Award in Orlando, FL. Bret will be the first recipient of the Award, which recognizes the outstanding accomplishments of individuals, corporations, institutions or organizations who have demonstrated significant dedication and commitment in their local market and have had a positive impact in advancing the mission of the American Diabetes Association.

“We are proud of Bret’s passion and commitment to raising funds for the American Diabetes Association. His efforts this year will truly help us change the future of this deadly disease,” said Larry Hausner, CEO, American Diabetes Association. “We are also very excited to continue our relationship with Bret and, together, help Stop Diabetes^SM.”

Bret, who has type 1 diabetes, chose the American Diabetes Association as his charity during this season of “Celebrity Apprentice.” He raised $390,000 for the Association and has helped put a face to diabetes by raising critical awareness about the seriousness of diabetes and the importance of diabetes prevention and management.

The American Diabetes Association is the largest voluntary health organization committed to the fight to stop diabetes. Each year the Association honors volunteers who have made a significant contribution to this fight at its Community Volunteer Leadership Conference and National Board Meeting. Immediately following this conference, the Association hosts its Scientific Sessions with more than 13,000 top scientists, physicians and other health care professionals from around the world to share cutting edge research, treatment recommendations and advances toward a cure for diabetes.

Nearly 24 million children and adults in the United States have diabetes. Diabetes contributes to the deaths of more than 230,000 Americans each year. The American Diabetes Association estimates that the total cost of diagnosed diabetes in the United States is more than $174 billion; further published studies suggest that when additional costs for gestational diabetes, pre-diabetes and undiagnosed diabetes are included, the total diabetes-related costs in the United States could exceed $218 billion. 

About Bret Michaels
Bret Michaels, lead vocalist of Poison and winner of this season’s “Celebrity Apprentice,” has an album coming out on July 6, 2010 called “Custom Built.” Bret will also be producing and appearing in a new reality show on VH1 called “Bret Michaels: Life as You Know It.”

About the American Diabetes Association
The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure, and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>